

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 10, 2002, 13:51:02 ; Search time 14.5 Seconds
(without alignments)
798.519 Million cell updates/sec

Title: US-09-724-583-2
Perfect score: 818
Sequence: 1 MCSLPMARYIIKYADQKAL.....QLTKSEPSARTKFFQPSW 152

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 219241 seqs, 76174552 residues

Total number of hits satisfying chosen parameters: 219241

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_68.*
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	283	34.6	155	JC7104	interleukin-1 rece
2	260.5	31.8	178	C40956	interleukin-1 rece
3	257.5	31.5	178	A44610	interleukin-1 rece
4	241	29.5	177	A54377	interleukin-1 rece
5	238.5	29.2	177	A30368	interleukin-1 rece
6	238.5	29.2	180	A39386	interleukin-1 rece
7	137.5	16.8	267	S38373	interleukin-1 beta
8	134.5	16.4	267	JN0724	interleukin-1 beta
9	132	16.1	266	S23010	interleukin-1 beta
10	124.5	15.2	269	I35969	interleukin-1 beta
11	117	14.3	266	ICB01B	interleukin-1 beta
12	110.5	13.5	268	A30584	interleukin-1 beta
13	104.5	12.8	269	ICB01B	interleukin-1 beta
14	92	11.2	214	JC5646	interleukin-1 beta
15	89	10.9	3623	T09456	intrinsic factor-B
16	84.5	10.3	299	I49264	ubiquitinating enz
17	80	9.8	381	A75490	probable transamin
18	80	9.8	1092	S42798	fibronectin-bindin
19	76.5	9.4	520	A46661	leukotriene B4 ome
20	76	9.3	463	S44267	sulfate adenylyltr
21	76	9.3	1117	S33851	fibronectin-kidney
22	71.5	8.7	4302	A38971	polycystic kidney
23	71	8.7	599	I53395	antigen LEC-A - mo
24	71	8.7	7962	I38346	elastic titin - hu
25	70.5	8.6	927	F0M5TA	retrovirus-related
26	70	8.6	263	C83616	beta-ketoadipate e
27	70	8.6	331	E75067	aminopeptidase m42
28	70	8.6	348	C69399	N5,N10-methylenete
29	69.5	8.5	465	E71409	sulfate adenylyltr

30 69.5 8.5 532 2 B82354 deoxycytidylate de
31 69 8.4 339 2 S09264 ig alpha chain c r
32 69 8.4 355 2 T47147 hypothetical prote
33 69 8.4 520 2 S45702 leukotriene-B4 20-
34 69 8.4 700 2 A84243 phosphoribosylform
35 68.5 8.4 256 2 T12999 aquaporin homolog
36 68.5 8.4 450 2 T45573 anthranilate N-hyd
37 68.5 8.4 557 4 EBR7MS iGE-binding protei
38 68.5 8.4 656 2 E96713 hypothetical prote
39 68.5 8.4 729 2 JC5812 norbin - rat
40 68.5 8.4 892 1 S42228 replication licens
41 67.5 8.3 2403 2 T30875 pR8 protein homol
42 67 8.2 398 2 F75417 L-sorboseone dehyd
43 67 8.2 622 2 T51223 hypothetical prote
44 67 8.2 665 2 H69101 archaeosine tRNA-r
45 67 8.2 832 2 S41889 beta-galactosidase

ALIGNMENTS

RESULT 1
JC7104
interleukin-1 receptor antagonist - human
C:Species: Homo sapiens (man)
C:Date: 03-Dec-1999 #sequence_revision 03-Dec-1999 #text_change 21-Jul-2000
C:Accession: JC7104
R:Mulero, J.J.; Pace, A.M.; Nelken, S.T.; Loeb, D.B.; Correa, T.R.; Drmanac, R.; Ford
Biochem. Biophys. Res. Commun. 263, 702-706, 1999
A:Title: IL1HV1: A novel interleukin-1 receptor antagonist gene.
A:Reference number: JC7104; MUID:99443727
A:Accession: JC7104
A:Molecule type: mRNA
A:Residues: 1-155 <NUL>
A:Cross-references: GB:AF186094; NID:g6049804; PIDN:AAF02757.1; PID:g6049805
C:Genetics:
A:Gene: il1h1
A:Map position: 2q14
C:Keywords: macrophage

Query Match 34.6%; Score 283; DB 2; Length 155;
Best Local Similarity 45.7%; Pred. No. 8.3e-22;
Matches 63; Conservative 20; Mismatches 49; Indels 6; Gaps 3;
QY 18 KALYTRDGLLVGDPVADNCC-AEKICTLPNRGLDRTKVPFLGIQGGSRCLACVETEFG 76
DB 17 KVLVYLNHNNQLLAGLHAGKVIKGEISWPNRWLDASLSPVILGVQGSQCLSCGVQE- 75
QY 77 PSLOLEDVNEELYKGGEEATRTFFQSSGSFRLAANAAPWFLCGPAPQPQVLT 136
DB 76 PTUTLEPVMIMELYLGAKESKFTFYRDMGLTSSFSAAYPGWFLCTVPEADQPVRLTQ 135

QY 137 ESE-----PSARTKFFEQ 150
DB 136 LPENGGNAPITDFVFOQ 153

RESULT 2
C40956
interleukin-1 receptor antagonist precursor - rat
C:Species: Rattus norvegicus (Norway rat)
C:Date: 20-Mar-1992 #sequence_revision 20-Mar-1992 #text_change 16-Jul-1999
C:Accession: C40956
R:Eisenberg, S.P.; Brewer, M.T.; Verderber, E.; Heindal, P.; Brandhuber, B.J.; Thomps
Proc. Natl. Acad. Sci. U.S.A. 88, 5232-5236, 1991
A:Title: interleukin-1 receptor antagonist is a member of the interleukin 1 gene fami
A:Reference number: A40956; MUID:91271363
A:Accession: C40956
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-178 <EIS>
A:Cross-references: GB:M63101; NID:g204928; PIDN:AAA41434.1; PID:g204929

QY	16	DOKALYTREGQLLVGDPVADNC-CAEKICTLTPNRGLDRTKVPFIPIFGIOGGSRCLACVETE	74
		: : : : :	
Db	44	NOKTYLRNNQLVAGYLQGPNVNLEEIKIDVVPIE-----PHALFLTIGHGKMCLSCVKSG	98
		: : : : :	
QY	75	EGPSIQLEDVNIIELYKGGEATRFTEFQSSGSFAFRLEAAAWPGWFLCGPAEPQPVL	134
		: : : : :	
Db	99	DETRLQLEAVNITDLSENKKDKRFAIRSDSGPTTSFSAACPCGWFLCTAMEADQPVSL	158
		: : : : :	
QY	135	TKESEPSAR-TKFYFEQ	150
		: : : : :	
Db	159	TNMPDGCVWTKFYQE	175
		: : : : :	
RESULT	6		
A39386			
Interleukin-1 receptor antagonist, long intracellular splice form - human			
N:Contains: Interleukin-1 receptor antagonist, short intracellular splice form			
C:Species:	Homo sapiens (man)		
C>Date:	28-Feb-1992 #sequence_revision 11-Apr-1997 #text_change 26-May-2000		
C:Accession:	I37893; A39386		
R:Muzio, M.; Polentarutti, N.; Sironi, M.; Poli, G.; De Gioia, L.; Introna, M.; Mantovani, J.; Exp. Med.	182, 623-628, 1995		
A:Title:	Cloning and characterization of a new isoform of the interleukin 1 receptor		
A:Reference number:	I37893; MUID:95355865		
A:Accession:	I37893		
A>Status:	translated from GB/EMBL/DDBJ		
A:Molecule type:	mRNA		
A:Residues:	1-180 <RES>		
A:Cross-references:	EMBL:X84348; NID:g1008970; PIDN:CAA59087.1; PTD:g1008971		
R:Haskill, S.; Martin, G.; Van der, L.; Morris, J.; Pearce, A.; Bigler, C.F.; Jaffe, G.	Proc. Natl. Acad. Sci. U.S.A.	88, 3681-3685, 1991	
A:Title:	cDNA cloning of an intracellular form of the human interleukin 1 receptor an		
A:Reference number:	A39386; MUID:91219436		
A:Accession:	A39386		
A:Molecule type:	mRNA		
A:Residues:	1-3,25-180 <HAS>		
A:Cross-references:	GB:M55646; NID:g186291; PIDN:AAA59138.1; PID:g186292		
C:Comment:	For an alternative splice form, see PIR:A30368		
C:Genetics:			
A:Gene:	GDB:ILLRN		
A:Cross-references:	GDB:I25897; OMIM:147679		
A:Map position:	Zq14.2-q14.2		
C:Superfamily:	interleukin-1		
C:Keywords:	alternative splicing; cytokine receptor		
F:1-180/Product:	Interleukin-1 receptor antagonist, long intracellular splice form #8		
F:1-3,25-180/Product:	Interleukin-1 receptor antagonist, short intracellular splice f		
Query Match	29.2%	Score 238.5; DB 2; Length 180;	
Best Local Similarity	40.9%;	Pred. No. 3.7e-17;	
Matches	56; Conservative 18; Mismatches 56; Indels 7; Gaps 3;		
QY	16	DOKALYTREGQLLVGDPVADNC-CAEKICTLTPNRGLDRTKVPFIPIFGIOGGSRCLACVETE	74
		: : : : :	
Db	47	NOKTYLRNNQLVAGYLQGPNVNLEEIKIDVVPIE-----PHALFLTIGHGKMCLSCVKSG	101
		: : : : :	
QY	75	EGPSIQLEDVNIIELYKGGEATRFTEFQSSGSFAFRLEAAAWPGWFLCGPAEPQPVL	134
		: : : : :	
Db	102	DETRLQLEAVNITDLSENKKDKRFAIRSDSGPTTSFSAACPCGWFLCTAMEADQPVSL	161
		: : : : :	
QY	135	TKESEPSAR-TKFYFEQ	150
		: : : : :	
Db	162	TNMPDGCVWTKFYQE	178
		: : : : :	
RESULT	7		
S38373			
Interleukin-1 beta precursor - pig			
C:Species: Sus scrofa domestica (domestic pig)			
C>Date:	20-May-1994 #sequence_revision 01-Dec-1995 #text_change 16-Jul-1999		
C:Accession:	S38373		
R:Van den Broeck, K.; Fiten, P.; Beuken, E.; Martens, E.; Janssen, A.; van Damme, J.;			

C:\Species: homo sapiens (man)
C:\Date: 28-Feb-1986 #sequence_revision 15-May-1998 #text_change 15-Sep-2000

A:Reference number: A48293; MUID:93348250
A:Contents: annotation; myristylation of lysines
R:Randuri, V.B.; Hulmes, J.D.; Pan, Y.C.E.; Kilian, P.L.; Stern, A.S.
Biochim. Biophys. Acta 1118, 25-35, 1991
A:Title: The role of arginine residues in interleukin 1 receptor binding.
A:Reference number: SI9608; MUID:92110334
A:Contents: annotation; type 1 IL-1 receptor interaction site
A:Note: modification of Arg-120 by phenylglyoxal blocks receptor binding
R:Clore, G.M.; Gronenborn, A.M.
submitted to the Brookhaven Protein Data Bank, January 1991
A:Reference number: A50049; PDB:611B
A:Contents: annotation; conformation by (13)C- and (1)H-NMR, residues 117-269
R:Clore, G.M.; Windfield, P.T.; Gronenborn, A.M.
Biochemistry 30, 2315-2323, 1991
A:Title: High-resolution three-dimensional structure of interleukin beta in solution
A:Reference number: A44675; MUID:91159409
A:Contents: annotation; (1)H-NMR structural determination
R:Hazuda, D.J.; Strickler, J.; Simon, P.; Young, P.R.
J. Biol. Chem. 266, 7081-7086, 1991
A:Title: Structure-function mapping of interleukin 1 precursors. Cleavage leads to a
A:Reference number: A39774; MUID:91201363
A:Contents: annotation
R:Finzel, B.C.; Watenpaugh, K.D.; Einspahr, H.M.
submitted to the Brookhaven Protein Data Bank, December 1989
A:Reference number: A50016; PDB:11B
A:Contents: annotation; X-ray crystallography, 2.0 angstroms, residues 119-269
R:Finzel, B.C.; Clancy, L.L.; Holland, D.R.; Muchmore, S.W.; Watenpaugh, K.D.; Einspahr, B.C.
J. Mol. Biol. 209, 779-791, 1989
A:Title: Crystal structure of recombinant human interleukin-beta at 2.0 angstrom resolution
A:Reference number: A44666; MUID:90064532
A:Contents: annotation; X-ray crystallography, 2.0 angstroms
C:Comment: This protein lacks a conventional signal sequence for protein export. Cleaved form of interleukin-beta, unlike interleukin 1-alpha, is inactive.
C:Comment: Interleukin-beta precursor is less heavily myristoylated than interleukin 1
C:Genetics:
A:Gene: GDB:IL1B
A:Cross-references: GDB:120094; OMIM:147720
A:Map position: 2q13-2q21
A:Introns: 16/2; 33/3; 101/1; 156/1; 199/3
C:Superfamily: Interleukin-1
C:Keywords: cytokine; immunoregulation; inflammation; lipoprotein; lymphokine; macrophage product; interleukin-1 beta #status experimental <IL1>
F:117-269/product: interleukin-1 beta #status experimental
F:75/Binding site: myristate (Lys) (covalent) (partial) #status experimental
F:123/Binding site: carbohydrate (Asn) (covalent) #status absent

Query Match 12.8%; Score 104.5; DB 1; Length 269;
Best Local Similarity 29.6%; Pred. No. 0.0035;
Matches 24; Conservative 18; Mismatches 38; Indels 1; Gaps 1;

Qy 54 KVPFLIGGSGRCLACVETEGPSLQEDYNIELYKGGEATRTFFQSSSGSAFRL 113
Db 171 KIPVALGKKNLYLSCVLKDDKPTQLQESVDPKN-YPKKKMKRKFVNKIENKLEFE 229
Qy 114 AAAPGWFLCGPAEPQPVOL 134
Db 230 SAQFPNNYISTQAENMPVL 250

RESULT 14
JC5646
interleukin-1 beta - horse
C:Species: Equus caballus (domestic horse)
C:Date: 28-Oct-1997 #sequence_revision 28-Oct-1997 #text_change 20-Jun-2000
C:Accession: JC5646
R:Kato, H.; Yoon, H.Y.; Ohashi, T.; Watari, T.; Goitsuka, R.; Tsujimoto, H.; Hasegawa, A.
Gene 177, 11-16, 1996
A:Title: Identification of an alternatively spliced transcript of equine interleukin-1
A:Reference number: JC5646; MUID:97080493
A:Accession: JC5646
A:Molecule type: mRNA
A:Residues: 1-214 <RAT>
A:Cross-references: DDBJ:D42165; NID:q2463549; PIDN:BAA22528.1; PID:q2463550

C:Comment: This protein mediates a variety of physiological response to infections and synthesis by hepatocytes, and stimulation of chondrocytes and synovial cells to produce C:Superfamily: Interleukin-1

Query Match 11.2%; Score 92; DB 2; Length 214;
Best Local Similarity 28.4%; Pred. No. 0.052;
Matches 25; Conservative 18; Mismatches 43; Indels 2; Gaps 2;
QY 48 RGLDRT-KYPIELGOGSRLACVETEEGPSLOLEDVNIIELYKGGGEATRTFTFQSSS 106
Db 109 QGEETDKIPVALGKERNLYLSCGMKGRPTQLQETVD-PNTYPRKMKRFRVFNKMEI 167
QY 107 GSAFRLEAAWPGWFLCGPAEPQPVOL 134
Db 168 KGNVEFESAMYPNWTISTSOAEKSPVFL 195

RESULT 15
T09456
intrinsic factor-B12 receptor Cubilin precursor - human
Species: Homo sapiens (man)
Date: 16-Jul-1999 #sequence_revision 16-Jul-1999 #text_change 21-Jul-2000
C:Accession: T09456
R:Kozyraki, R.; Kristiansen, M.; Silahtaroglu, A.; Hansen, C.; Jacobsen, C.; Tommerup, N.
Blood 91, 3593-3600, 1998
A:Title: The human intrinsic factor-vitamin B12 receptor, cubilin: Molecular characterization.
A:Reference number: Z16677; MUID:98241400
A:Accession: T09456
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-3623 <KOZ>
A:Cross-references: EMBL:AF034611; NID:g3929528; PIDN:AAC82612.1; PID:g3929529
C:Genetics:
A:Map position: 10p12
C:Superfamily: unassigned EGF-related proteins; EGF homology
C:Keywords: receptor; vitamin B12 uptake
F:1-24/Domain: signal sequence #status predicted <SIG>
F:25-3623/Product: intrinsic factor-B12 receptor #status predicted <MAT>
F:436-467/Domain: EGF homology <EGF>

Query Match 10.9%; Score 89; DB 2; Length 3623;
Best Local Similarity 27.3%; Pred. No. 2.6;
Matches 33; Conservative 19; Mismatches 57; Indels 12; Gaps 5;
QY 18 KALYTRDGLLVGDPVADNCCAE-KIC--TLPNRGLDRTKVPILFIQGGSRCLACVETE 74
2544 KVIFFDGSRPYGGFTASYTSSEDAVCGSLPNTPEGNFTSPGYDGVNYSRNLANCEWTL 2603
75 EGPSLOLEDVNI--EELYKGGGEATRTFTFQSSGSFAFLEAAWP-GWFLCGPAEPQOP 131
Db 2604 SNPQGNSSISIHFDYLFESHQDQFDVLE-----FRVGADGPLMWRLCGPSKPTLP 2657
QY 132 V 132
Db 2658 L 2658

Search completed: May 10, 2002, 13:53:15
Job time: 133 sec

Db 76 PTLTLEPVNIMELYLGAKESKFTFYRRDMGLTSSFESAAYPGWFLCTVPEADQPVLRTQ 135

Qy 137 ESE-----PSARTKFFFEQ 150

Db 136 LPENGWGNAPITDFFYFQ 153

RESULT 2

US-09-000-630C-23

; Sequence 23, Application US/09000630C

; Patent No. 6018029

; GENERAL INFORMATION:

; APPLICANT: Fuentes, Gerald M.

; TITLE OF INVENTION: DNA Encoding Canine Interleukin-1 Receptor

; NUMBER OF SEQUENCES: 27

; CORRESPONDENCE ADDRESS:

ADDRESSEE: Douglas C Murdock/Bradley, Arant, Rose & White

STREET: 2001 Park Place, Suite 1400

CITY: Birmingham

STATE: Alabama

COUNTRY: USA

ZIP: 35203-2736

; COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette, 3.50 inch,

COMPUTER: IBM compatible

OPERATING SYSTEM: Microsoft Windows

SOFTWARE: WordPerfect 6.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/000,630C

FILING DATE:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/862,730

FILING DATE:

INFORMATION FOR SEQ ID NO: 23:

SEQUENCE CHARACTERISTICS:

LENGTH: 178 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: rat IL-1ra sequence

US-09-000-630C-23

Query Match

Best Local Similarity 31.8%; Score 260.5; DB 3; Length 178;

Mismatches 61; Conservative 16; Mismatches 53; Indels 7; Gaps 4;

Qy 16 DQKALYTRDGLLVGDPVADNC-CAEKICTLPNRLDRTKVPFIFUGIOGGSRLCLACVETE 74

Db 45 NQTFYLRNQLIAGYLOGPNTKLEKIDMVP---IDFRNV--FLIGHGKLCCLSCVKS 99

Qy 75 EGPISQLEDVNIIELYKGGERTFTFFQSSGSAFRLEAAAWPFLCGPAEPQPVOL 134

Db 100 DDTKLQLEEVNITDLNKNKEEDKRTFTIRSETGPTTSFESLACPGWFLCTLEADHPVSL 159

Qy 135 TK-ESEPSARTKFFFEQ 150

Db 160 TNTPEKPCVTTRKFFOE 176

RESULT 3

US-08-862-730C-23

; Sequence 23, Application US/08862730C

; Patent No. 6063600

; GENERAL INFORMATION:

; APPLICANT: Fuentes, Gerald M.

; TITLE OF INVENTION: DNA Encoding Canine Interleukin-1 Receptor

; NUMBER OF SEQUENCES: 27

; CORRESPONDENCE ADDRESS:

ADDRESSEE: Douglas C Murdock/Bradley, Arant, Rose & White

STREET: 2001 Park Place, Suite 1400

CITY: Birmingham

STATE: Alabama

COUNTRY: USA

ZIP: 35203-2736

; COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette, 3.50 inch,

COMPUTER: IBM compatible

OPERATING SYSTEM: Microsoft Windows

SOFTWARE: WordPerfect 6.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/862,730C

FILING DATE: 5/23/97

INFORMATION FOR SEQ ID NO: 23:

SEQUENCE CHARACTERISTICS:

LENGTH: 178 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: rat IL-1ra sequence

US-08-862-730C-23

Query Match 31.8%; Score 260.5; DB 3; Length 178;

Best Local Similarity 44.5%; Pred. No. 1.1e-23;

Mismatches 61; Conservative 16; Mismatches 53; Indels 7; Gaps 4;

Qy 16 DQKALYTRDGLLVGDPVADNC-CAEKICTLPNRLDRTKVPFIFUGIOGGSRLCLACVETE 74

Db 45 NQTFYLRNQLIAGYLOGPNTKLEKIDMVP---IDFRNV--FLIGHGKLCCLSCVKS 99

Qy 75 EGPISQLEDVNIIELYKGGERTFTFFQSSGSAFRLEAAAWPFLCGPAEPQPVOL 134

Db 100 DDTKLQLEEVNITDLNKNKEEDKRTFTIRSETGPTTSFESLACPGWFLCTLEADHPVSL 159

Qy 135 TK-ESEPSARTKFFFEQ 150

Db 160 TNTPEKPCVTTRKFFOE 176

RESULT 4

US-09-417-455-10

; Sequence 10, Application US/09417455

; Patent No. 6294655

; GENERAL INFORMATION:

; APPLICANT: Ford, John

; TITLE OF INVENTION: A NOVEL INTERLEUKIN-1 RECEPTOR ANTAGONIST AND USES THEREOF

FILE REFERENCE: 28110/36328

CURRENT APPLICATION NUMBER: US/09/417,455

CURRENT FILING DATE: 1999-10-13

PRIOR APPLICATION NUMBER: US 09/348,942

PRIOR FILING DATE: 1999-07-07

PRIOR APPLICATION NUMBER: PCT/US99/04291

PRIOR FILING DATE: 1999-04-05

PRIOR APPLICATION NUMBER: US 09/287,210

PRIOR FILING DATE: 1999-04-05

PRIOR APPLICATION NUMBER: US 09/251,370

PRIOR FILING DATE: 1999-02-17

PRIOR APPLICATION NUMBER: US 09/229,591

PRIOR FILING DATE: 1999-01-13

PRIOR APPLICATION NUMBER: US 09/127,698

PRIOR FILING DATE: 1998-07-31

PRIOR APPLICATION NUMBER: US 09/099,818

PRIOR FILING DATE: 1998-06-19

PRIOR APPLICATION NUMBER: US 09/082,364

PRIOR FILING DATE: 1998-05-20

PRIOR APPLICATION NUMBER: US 09/079,909

PRIOR FILING DATE: 1998-05-15

PRIOR APPLICATION NUMBER: US 09/055,010

PRIOR FILING DATE: 1998-04-03

NUMBER OF SEQ ID NOS: 30

;; SOFTWARE: FastSeq for Windows Version 3.0
;; SEQ ID NO 10
;; LENGTH: 178
;; TYPE: PRT
;; ORGANISM: Rattus norvegicus
us-09-417-455-10

Query Match 31.8%; Score 260.5; DB 4; Length 178;
Best Local Similarity 44.5%; Pred. No. 1.1e-23;
Matches 61; Conservative 16; Mismatches 53; Indels 7; Gaps 4;

Qy 16 DQALYTRDGLLVGDPVADNC-CAEKICTLPNRGLDRKVPFLGIGGSRCLACVETE 74
Db 45 NQTFYLRNQLIAGYLOGPNKLEKIDMVP---IDFRNV--FLGIGGKLCCLSCVKS 99
Qy 75 EGPSLOLEDVNIIELYKGGBEATRTFFOSSGSAFRLEAAANPGWFLGPAEPQPVOL 134
Db 100 DDTKLOLEEVNITDLNKNKEEDKRFTFIRSETGPTTSPESLACPGWFLCTTLEADHPVSL 159
Qy 135 TK-ESEPSARTKIFYEQ 150
Db 160 TNTPEEPCTVTKFYQE 176

RESULT 5
us-09-417-455-9
;; Sequence 9, Application US/09417455
;; Patent No. 6294655
;; GENERAL INFORMATION:
;; APPLICANT: Ford, Ann
;; TITLE OF INVENTION: A NOVEL INTERLEUKIN-1 RECEPTOR ANTAGONIST AND USES THEREOF
;; FILE REFERENCE: 28110/36328
;; CURRENT APPLICATION NUMBER: US/09/417,455
;; PRIOR FILING DATE: 1999-10-13
;; PRIOR APPLICATION NUMBER: US 09/348,942
;; PRIOR FILING DATE: 1999-07-07
;; PRIOR APPLICATION NUMBER: PCT/US99/04291
;; PRIOR FILING DATE: 1999-04-05
;; PRIOR APPLICATION NUMBER: US 09/287,210
;; PRIOR FILING DATE: 1999-04-05
;; PRIOR APPLICATION NUMBER: US 09/251,370
;; PRIOR FILING DATE: 1999-02-17
;; PRIOR APPLICATION NUMBER: US 09/229,591
;; PRIOR FILING DATE: 1999-01-13
;; PRIOR APPLICATION NUMBER: US 09/127,698
;; PRIOR FILING DATE: 1998-07-31
;; PRIOR APPLICATION NUMBER: US 09/099,818
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: US 09/082,364
;; PRIOR FILING DATE: 1998-05-20
;; PRIOR APPLICATION NUMBER: US 09/079,909
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: US 09/055,010
;; PRIOR FILING DATE: 1998-04-03
;; NUMBER OF SEQ ID NOS: 30
;; SOFTWARE: FastSeq for Windows Version 3.0
;; SEQ ID NO 9
;; LENGTH: 178
;; TYPE: PRT
;; ORGANISM: Mus musculus
us-09-417-455-9

Query Match 31.5%; Score 257.5; DB 4; Length 178;
Best Local Similarity 44.5%; Pred. No. 2.5e-23;
Matches 61; Conservative 16; Mismatches 53; Indels 7; Gaps 4;

Qy 16 DQALYTRDGLLVGDPVADNC-CAEKICTLPNRGLDRKVPFLGIGGSRCLACVETE 74
Db 45 NQTFYLRNQLIAGYLOGPNKLEKIDMVP---IDLSV--FLGIGGKLCCLSCAKSG 99

Qy 75 EGPSLOLEDVNIIELYKGGBEATRTFFOSSGSAFRLEAAANPGWFLGPAEPQPVOL 134
Db 100 DDTKLOLEEVNITDLNKNKEEDKRFTFIRSEKGTPTTSPESACPGWFLCTTLEADRPVSL 159
Qy 135 TK-ESEPSARTKIFYEQ 150
Db 160 TNTPEEPLIVTKFYQE 176

RESULT 6
us-09-000-630C-21
;; Sequence 21, Application US/09000630C
;; Patent No. 6018029
;; GENERAL INFORMATION:
;; APPLICANT: Fuller, Gerald M.
;; TITLE OF INVENTION: DNA Encoding Canine Interleukin-1 Receptor
;; TITLE OF INVENTION: Antagonist
;; NUMBER OF SEQUENCES: 27
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Douglas C Murdock/ Bradley, Arant, Rose & White
;; STREET: 2001 Park Place, Suite 1400
;; CITY: Birmingham
;; STATE: Alabama
;; COUNTRY: USA
;; ZIP: 35203-2736
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Diskette, 3.50 inch,
;; COMPUTER: IBM compatible
;; OPERATING SYSTEM: Microsoft Windows
;; SOFTWARE: WordPerfect 6.0
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/000,630C
;; FILING DATE:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/862,730
;; FILING DATE:
;; INFORMATION FOR SEQ ID NO: 21:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 178 amino acids
;; TYPE: amino acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: mouse IL-1ra sequence
us-09-000-630C-21

Query Match 31.2%; Score 255.5; DB 3; Length 178;
Best Local Similarity 44.5%; Pred. No. 4.4e-23;
Matches 61; Conservative 16; Mismatches 53; Indels 7; Gaps 4;

Qy 16 DQALYTRDGLLVGDPVADNCAE-KICTLPNRGLDRKVPFLGIGGSRCLACVETE 74
Db 45 NQTFYLRNQLIAGYLOGPNKLEKIDMVP---IDLSV--FLGIGGKLCCLSCAKSG 99
Qy 75 EGPSLOLEDVNIIELYKGGBEATRTFFOSSGSAFRLEAAANPGWFLGPAEPQPVOL 134
Db 100 DDTKLOLEEVNITDLNKNKEEDKRFTFIRSEKGTPTTSPESACPGWFLCTTLEADRPVSL 159
Qy 135 TK-ESEPSARTKIFYEQ 150
Db 160 TNTPEEPLIVTKFYQE 176

RESULT 7
us-08-862-730C-21
;; Sequence 21, Application US/08862730C
;; Patent No. 6063600
;; GENERAL INFORMATION:
;; APPLICANT: Fuller, Gerald M.
;; TITLE OF INVENTION: DNA Encoding Canine Interleukin-1 Receptor
;; TITLE OF INVENTION: Antagonist

Query Match 30.3%; Score 248; DB 3; Length 176;
Best Local Similarity 39.7%; Pred. No. 3.5e-22;

```
Matches 60; Conservative 20; Mismatches 61; Indels 10; Gaps 4;
QY 2 CSLPMARYIIKYADQKALYTRDGLVGPVADNC-CAEIKICTLPNRLDRTKVPFLG 60
   | : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 33 CRMQAFRIWDV---NOKTFYLRNNQLVAGYLOGSNKLEEKLDVVPE-----PHAVFLG 84
   | : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 61 IQGSGRCLACVETEGPSLOLEDVNIIEELYKGGEATRTFFQSSSGSAFRLAAAPGW 120
   || || || || || : : || || || : : || || || : : || || || : : || || ||
Db 85 IHGKLCCLACVKGSDGTRIQLEAVNITDLSKNKDQDKRFTFLSDSGPTTSFESAACPGW 144
   || || || || || : : || || || : : || || || : : || || || : : || || ||
QY 121 FLCGPAEPQPOPVOLTKSEPSAR-TKTFYFEQ 150
   ||| | : : || || : : : : || || : : : : || || : : : : || || : :
Db 145 FLCTALEADRPVSLNRPPEAMVTKFYFQK 175
   ||| | : : || || : : : : || || : : : : || || : : : : || || : :

RESULT 13
US-08-862-730C-4
; Sequence 4, Application US/08862730C
; Patent No. 6063600
; GENERAL INFORMATION:
; APPLICANT: Fuentes, Nelson L.
; TITLE OF INVENTION: DNA Encoding Canine Interleukin-1 Receptor
; TITLE OF INVENTION: Antagonist
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Douglas C Murdock/ Bradley, Arant, Rose & White
; STREET: 2001 Park Place, Suite 1400
; CITY: Birmingham
; STATE: Alabama
; COUNTRY: USA
; ZIP: 35203-2736
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch,
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Microsoft Windows
; SOFTWARE: WordPerfect 6.0
; CURRENT APPLICATION DATA:
; FILING DATE: 5/23/97
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 176 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: IL-1ra full length peptide
; US-08-862-730C-4

Query Match 30.3%; Score 248; DB 3; Length 176;
Best Local Similarity 39.7%; Pred. No. 3.5e-22;
Matches 60; Conservative 20; Mismatches 61; Indels 10; Gaps 4;
QY 2 CSLPMARYIIKYADQKALYTRDGLVGPVADNC-CAEIKICTLPNRLDRTKVPFLG 60
   | : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 33 CRMQAFRIWDV---NOKTFYLRNNQLVAGYLOGSNKLEEKLDVVPE-----PHAVFLG 84
   | : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 61 IQGSGRCLACVETEGPSLOLEDVNIIEELYKGGEATRTFFQSSSGSAFRLAAAPGW 120
   || || || || || : : || || || : : || || || : : || || || : : || || ||
Db 85 IHGKLCCLACVKGSDGTRIQLEAVNITDLSKNKDQDKRFTFLSDSGPTTSFESAACPGW 144
   || || || || || : : || || || : : || || || : : || || || : : || || ||
QY 121 FLCGPAEPQPOPVOLTKSEPSAR-TKTFYFEQ 150
   ||| | : : || || : : : : || || : : : : || || : : : : || || : :
Db 145 FLCTALEADRPVSLNRPPEAMVTKFYFQK 175
   ||| | : : || || : : : : || || : : : : || || : : : : || || : :

RESULT 14
US-09-000-630C-22
; Sequence 22, Application US/09000630C
; Patent No. 6018029
; GENERAL INFORMATION:
; APPLICANT: Fuentes, Nelson L.
```

```
; TITLE OF INVENTION: DNA Encoding Canine Interleukin-1 Receptor
; TITLE OF INVENTION: Antagonist
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Douglas C Murdock/ Bradley, Arant, Rose & White
; STREET: 2001 Park Place, Suite 1400
; CITY: Birmingham
; STATE: Alabama
; COUNTRY: USA
; ZIP: 35203-2736
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch,
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Microsoft Windows
; SOFTWARE: WordPerfect 6.0
; CURRENT APPLICATION DATA:
; FILING DATE:
; APPLICATION NUMBER: US/09/000.630C
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/862.730
; FILING DATE:
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 177 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: rabbit IL-1ra sequence
; US-09-000-630C-22

Query Match 29.5%; Score 241; DB 3; Length 177;
Best Local Similarity 39.2%; Pred. No. 2.5e-21;
Matches 60; Conservative 22; Mismatches 57; Indels 14; Gaps 5;
QY 2 CSLPMARYIIKYADQKALYTRDGLVGPVADNC-CAEIKICTLPNRLDRTKVP--IF 58
   | : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 33 CRMQAFRIWDV---NOKTFYLRNNQLVAGYLOGSNKLEERIDVVPE-----PQLLF 82
   | : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 59 LGIQGSRCLACVETEGPSLOLEDVNIIEELYKGGEATRTFFQSSSGSAFRLAAAPW 118
   |||| | |||| : : |||| : : |||| : : |||| : : |||| : : |||| : :
Db 83 LGIQGSRCLACVKGSDGKMKLHLEAVNITDLGKNKQDKRFTFIRNSGPTTTFESASCP 142
   |||| | |||| : : |||| : : |||| : : |||| : : |||| : : |||| : :
QY 119 GWFCLGPAEPQPOPVOLTKSEPS-ARTKTFYFEQ 150
   |||| | |||| : : |||| : : |||| : : |||| : : |||| : : |||| : :
Db 143 GWFCLTALEADQPVSUTNTPTDDSIIVTKFYFQE 175
   |||| | |||| : : |||| : : |||| : : |||| : : |||| : : |||| : :

RESULT 15
US-08-862-730C-22
; Sequence 22, Application US/08862730C
; Patent No. 6063600
; GENERAL INFORMATION:
; APPLICANT: Fuentes, Nelson L.
; TITLE OF INVENTION: DNA Encoding Canine Interleukin-1 Receptor
; TITLE OF INVENTION: Antagonist
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Douglas C Murdock/ Bradley, Arant, Rose & White
; STREET: 2001 Park Place, Suite 1400
; CITY: Birmingham
; STATE: Alabama
; COUNTRY: USA
; ZIP: 35203-2736
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch,
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Microsoft Windows
; SOFTWARE: WordPerfect 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/862.730C
; FILING DATE: 5/23/97
```

```

; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 177 amino acids
;   TYPE: amino acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;   MOLECULE TYPE: rabbit IL-lra sequence
US-08-862-730C-22

Query Match      29.5%; Score 241; DB 3; Length 177;
Best Local Similarity 39.2%; Pred. No. 2.5e-21;
Matches 60; Conservative 22; Mismatches 57; Indels 14; Gaps 5;

QY      2 CSLPMARYIIRYADQKALYTRDGQLLVGDPVADNC-CAEKICTLPNRGLDRTKVP--IF 58
      | : : : ||| | : ||| : | : | : | : | : | : | : | : | : | : |
Db      33 CRMQAFRIWDV---NQKTFYLRNNQLVAGYLOGPNAKLEERIDVVPLE-----PQLLF 82

QY      59 LGIOGSRCLACVETEETEGFSLOLEDVNIIEELYKGGEATRTFTFOSSGSAFRLEAAAMP 118
      |||| | ||| : : | ||| : | ||| : | ||| : | ||| : | ||| : | ||| :
Db      83 LGIORGKLCUSCVKSGDKMKHLEAVNITDLGKNKEQDKRFTFIRNSGPTTTTESASCP 142

      119 GWFLCGPAEPQPPVQLTKSEPS-ARTKFFPEQ 150
      |||| | ||| | : | |||| :
Db      143 GWFCLTALEADQPVSUTNTPDDSIIVVTKFFQE 175

Search completed: May 10, 2002, 13:52:52
Job time: 125 sec
```


GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 10, 2002, 13:50:17 ; Search time 23.86 Seconds
(without alignments)
471.883 Million cell updates/sec

Title: US-09-724-583-2

Perfect score: 818

Sequence: 1 MCSLPMARYIIRYADQKAL.....QLTKSEPSARTKVFQSW 152

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 522463 seqs, 74073290 residues

Total number of hits satisfying chosen parameters: 522463

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_1101.*
1: /SIDS8/gcgdata/geneseq/geneseq/AA1980.DAT.*
2: /SIDS8/gcgdata/geneseq/geneseq/AA1981.DAT.*
3: /SIDS8/gcgdata/geneseq/geneseq/AA1982.DAT.*
4: /SIDS8/gcgdata/geneseq/geneseq/AA1983.DAT.*
5: /SIDS8/gcgdata/geneseq/geneseq/AA1984.DAT.*
6: /SIDS8/gcgdata/geneseq/geneseq/AA1985.DAT.*
7: /SIDS8/gcgdata/geneseq/geneseq/AA1986.DAT.*
8: /SIDS8/gcgdata/geneseq/geneseq/AA1987.DAT.*
9: /SIDS8/gcgdata/geneseq/geneseq/AA1988.DAT.*
10: /SIDS8/gcgdata/geneseq/geneseq/AA1989.DAT.*
11: /SIDS8/gcgdata/geneseq/geneseq/AA1990.DAT.*
12: /SIDS8/gcgdata/geneseq/geneseq/AA1991.DAT.*
13: /SIDS8/gcgdata/geneseq/geneseq/AA1992.DAT.*
14: /SIDS8/gcgdata/geneseq/geneseq/AA1993.DAT.*
15: /SIDS8/gcgdata/geneseq/geneseq/AA1994.DAT.*
16: /SIDS8/gcgdata/geneseq/geneseq/AA1995.DAT.*
17: /SIDS8/gcgdata/geneseq/geneseq/AA1996.DAT.*
18: /SIDS8/gcgdata/geneseq/geneseq/AA1997.DAT.*
19: /SIDS8/gcgdata/geneseq/geneseq/AA1998.DAT.*
20: /SIDS8/gcgdata/geneseq/geneseq/AA1999.DAT.*
21: /SIDS8/gcgdata/geneseq/geneseq/AA2000.DAT.*
22: /SIDS8/gcgdata/geneseq/geneseq/AA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	818	100.0	152	AAE05840	Human FIL-1 theta
2	818	100.0	152	AAE05840	Human interlukin-
3	818	100.0	169	AAE05840	Human interlukin-
4	818	100.0	200	AAE05840	Human interlukin-
5	729.5	89.2	154	AAE05840	Human interlukin-
6	657	80.3	152	AAE05840	Human interlukin-
7	657	80.3	152	AAE05840	Human interlukin-
8	587	71.8	112	AAE05839	Human interlukin-
9	309	37.8	156	AAE05839	Human interlukin-
10	309	37.8	156	AAE05839	Human interlukin-
11	309	37.8	156	AAE05839	Human interlukin-

12	309	37.8	156	21	AAE05840	Murine TANGO-93 pr
13	307	37.5	154	22	AAE05840	Mouse interlukin-
14	307	37.5	155	21	AAE05840	Murine IL-1 recept
15	307	37.5	155	22	AAE05840	Murine IL-1L1. Mu
16	307	37.5	155	22	AAE05840	Invention related
17	307	37.5	155	22	AAE05840	Murine interlukin
18	289	35.3	155	21	AAE05840	Human IL-1 homolog
19	283	34.6	154	22	AAE05840	Interleukin-1L1 re
20	283	34.6	155	20	AAE05840	Human interlukin
21	283	34.6	155	21	AAE05840	Human IL-1 recepto
22	283	34.6	155	21	AAE05840	Human IL-1 homolog
23	283	34.6	155	21	AAE05840	Human TANGO-93 pro
24	283	34.6	155	22	AAE05840	Human interlukin-
25	283	34.6	155	22	AAE05840	Human PR04342. Ho
26	283	34.6	155	22	AAE05840	Human IL-1L1. Hom
27	283	34.6	155	22	AAE05840	Interleukin-1L1 re
28	283	34.6	155	22	AAE05840	Protein encoded by
29	283	34.6	157	22	AAE05840	Interleukin-1L1 re
30	282	34.5	155	21	AAE05840	Generic human IL-1
31	280	34.2	155	20	AAE05840	A human interlukin
32	276	33.7	155	21	AAE05840	Generic human IL-1
33	276	33.7	155	21	AAE05840	Human IL-1 homolo
34	260.5	31.8	178	20	AAE05840	Rat interlukin-1
35	260.5	31.8	178	20	AAE05840	Rat interlukin-1
36	260.5	31.8	178	20	AAE05840	Rat interlukin-1
37	260	31.8	178	20	AAE05840	Mouse interlukin-
38	257.5	31.5	178	20	AAE05840	Mouse interlukin-
39	257.5	31.5	178	20	AAE05840	Mouse interlukin-
40	248	30.3	151	20	AAE05840	Amino acid sequenc
41	248	30.3	154	20	AAE05840	fusion protein of
42	248	30.3	176	20	AAE05840	Amino acid sequenc
43	241	29.5	177	20	AAE05840	Rabbit interlukin
44	241	29.5	177	22	AAE05840	Rabbit interlukin
45	240.5	29.4	159	16	AAE05840	ICIL-1ra. Homo sa

ALIGNMENTS

RESULT 1
AAE05840
ID AAE05840 standard; Protein; 152 AA.
XX AC AAE05840;
XX XX
DT 24-SEP-2001 (first entry)
XX XX
DE Human FIL-1 theta full-length protein.
XX XX
KW Interleukin-1 family ligand; FIL-1 theta; IL-1; glaucoma; leukaemia;
KW insulin dependent diabetes mellitus; lymphoma; microbial infection;
KW ectodermal dysplasia; wrinkly skin syndrome; antisense therapy;
KW tibial muscular dystrophy; inflammation; gene therapy; human.
XX OS Homo sapiens.
XX XX
PN WC200155211-A2.
XX XX
PD 02-AUG-2001.
XX XX
PF 25-JAN-2001; 2001WO-US02514.
XX XX
PR 27-JAN-2000; 2000US-0178389.
PR 11-APR-2000; 2000US-0195962.
XX XX
PA (IMV) IMMUNEX CORP.
XX XX
PI Sims JE;
XX XX
DR WPI; 2001-457718/49.
DR N-PSDB; AAD11148.
XX XX
PT Isolated FIL-1 theta polypeptide to induce or inhibit the induction of

PT fever and to stimulate the immune system for the treatment of microbial
 PT infections -
 XX
 PS Claim 14; Page 5; 65pp; English.
 XX
 CC The invention relates to interleukin-1 (IL-1) family ligand designated
 CC as FIL-1 theta polypeptides and nucleic acid molecules encoding such
 CC polypeptides. FIL-1 theta DNA is used to identify glaucoma, insulin
 CC dependent diabetes mellitus, ectodermal dysplasia, T-cell leukaemia/
 CC lymphoma, wrinkle skin syndrome and tibial muscular dystrophy. FIL-1
 CC theta polypeptides are used to activate and/or inhibit the activation
 CC of vascular endothelial cells and lymphocytes; the induction of local
 CC tissue destruction and fever; the stimulation of macrophages and
 CC vascular endothelial cells to produce IL-6 and the induction of
 CC prostaglandins. They are also used to treat inflammation and microbial
 CC infections. FIL-1 theta DNA is useful in antisense therapy and gene
 CC therapy. The present sequence is human FIL-1 theta full-length protein.
 CC
 CC Sequence 152 AA;

Query Match 100.0%; Score 818; DB 22; Length 152;
 Best Local Similarity 100.0%; Pred. No. 2.4e-86;
 Matches 152; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MCSLPMARYIIKYADOKALYTRDGLLVGDPVADNCCAEKICTLPNRGLDRTKVPFIIG 60
 DB 1 mcslpmaryiikyaqkalytrdgqllvgdpvadnccaekictlpnrgldrtkvpfig 60
 QY 61 TGGSRCLACVETERGPSIQLEDVNIIEELYKGGEATRTFFQSSGSAFRLEAAAWPGW 120
 DB 61 iqggsrclacveteegpslqledvniieelykggeatrtffqssgsafrleaaawpgw 120
 QY 121 FLCGPAEPQPVQLTKSEPSARTKFFEQSW 152
 DB 121 flcgpaeppqvqltkesepartkfyfegsw 152

RESULT 2

ID AAB19922
 ID AAB19922 standard; Protein; 152 AA.

AC AAB19922;

DT 19-MAR-2001 (first entry)

XX Human interleukin-1 Hy2 (short version).

KW Interleukin-2 Hy2; IL-1 Hy2; human; interleukin-1 receptor;
 KW antagonist; cancer; breast adenocarcinoma; brain tumour; melanoma;
 KW myeloma; giant cell tumour of bone; acute myelogenous leukaemia;
 KW oral epidermoid carcinoma; squamous cell carcinoma; inflammation;
 KW antitumour; antiinflammatory; diagnosis; therapy.

OS Homo sapiens.

XX Key Location/Qualifiers

FT Misc-difference 44
 FT /note= "polymorphism in nucleotide sequence, alters
 Thr-44 to Ile"

FT Misc-difference 51
 FT /note= "polymorphism in nucleotide sequence, alters
 Asp-51 to Ala"

XX WO200071719-A1.

PN 30-NOV-2000.

XX 22-MAY-2000; 2000WO-US14144.

XX 20-MAY-1999; 99US-0316086.

PR 10-MAR-2000; 2000US-0522964.

XX

PA (HYSE-) HYSEQ INC.
 XX Ballinger DG, Ford J, Ho AS, Lin HS, Pace AM;
 XX
 XX WPI; 2001-016409/02.
 DR N-PSDB; AAA89175, AAA89176.
 XX
 XX New isolated polynucleotide encoding interleukin-1 Hy2 for diagnosing,
 PT preventing and treating disorders, such as cancers and inflammatory
 PT diseases -
 XX
 XX Example 5; Page 130-132; 158pp; English.
 PS
 XX The present sequence is that of human interleukin-1 Hy2 (IL-1 Hy2),
 CC a novel member of the interleukin-1 receptor antagonist family.
 CC The sequence is predicted from isolated cDNA clones (see AAA89175 and
 CC AAA89176). Potential polymorphisms in the coding region may alter
 CC the sequence, specifically changing Thr-44 to Ile and Asp-51 to
 CC Ala, which may affect the biological activity of the molecule.
 CC An alternative, extended open reading frame encodes a 200-amino
 CC acid protein (see AAB19924). IL-1 Hy2 polypeptides and polynucleotides
 CC are used to treat cancers involving elevated levels of IL-1, such as
 CC breast adenocarcinoma, brain tumours, melanoma, giant cell tumours
 CC of bone, acute myelogenous leukaemia, oral epidermoid carcinoma or
 CC squamous cell carcinoma, and inflammatory disease mediated by
 CC interleukin-18 (all claimed). They can also be used to diagnose,
 CC prevent or treat shock, thrombosis, acute pancreatitis, arthritis,
 CC vasculitis, lupus, immune complex glomerulonephritis, pancreatic
 CC cell damage, allograft and xenograft transplantation, graft versus
 CC host disease, inflammatory bowel disease, bone degenerative
 CC diseases, diabetes and neurodegenerative disorders.
 XX
 XX Sequence 152 AA;

Query Match 100.0%; Score 818; DB 22; Length 152;
 Best Local Similarity 100.0%; Pred. No. 2.4e-86;
 Matches 152; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MCSLPMARYIIKYADOKALYTRDGLLVGDPVADNCCAEKICTLPNRGLDRTKVPFIIG 60
 DB 1 mcslpmaryiikyaqkalytrdgqllvgdpvadnccaekictlpnrgldrtkvpfig 60
 QY 61 TGGSRCLACVETERGPSIQLEDVNIIEELYKGGEATRTFFQSSGSAFRLEAAAWPGW 120
 DB 61 iqggsrclacveteegpslqledvniieelykggeatrtffqssgsafrleaaawpgw 120
 QY 121 FLCGPAEPQPVQLTKSEPSARTKFFEQSW 152
 DB 121 flcgpaeppqvqltkesepartkfyfegsw 152

RESULT 3

AAB19923
 ID AAB19923 standard; Protein; 169 AA.

XX AAB19923;

DT 19-MAR-2001 (first entry)

XX Human interleukin-1 Hy2 (extended form, partial sequence).

KW Interleukin-2 Hy2; IL-1 Hy2; human; interleukin-1 receptor;
 KW antagonist; cancer; breast adenocarcinoma; brain tumour; melanoma;
 KW myeloma; giant cell tumour of bone; acute myelogenous leukaemia;
 KW oral epidermoid carcinoma; squamous cell carcinoma; inflammation;
 KW antitumour; antiinflammatory; diagnosis; therapy.

OS Homo sapiens.

PN WO200071719-A1.

XX 30-NOV-2000.

XX 22-MAY-2000; 2000NO-US14144.
XX 20-MAY-1999; 99US-0316086.
PR 10-MAR-2000; 2000US-0522964.
XX (HYSE-) HYSEQ INC.
PI Ballinger DG, Ford J, Ho AS, Lin HS, Pace AM;
XX WPI; 2001-016409/02.
DR N-PSDB; AAA89175.
XX
PT New isolated polynucleotide encoding interleukin-1 Hy2 for diagnosing,
PT preventing and treating disorders, such as cancers and inflammatory
PT diseases -
XX
XX Example 5; Page 134-145; 158pp; English.
XX The present sequence is that of a human interleukin-1 Hy2 (IL-1 Hy2)
CC non-full length polypeptide, as predicted from an isolated cDNA
CC clone (see AAA89175). A 200-amino acid full-length sequence is given
CC in AAB19924. IL-1 Hy2 is a novel member of the interleukin-1 receptor
CC antagonist family. IL-1 Hy2 polypeptides and polynucleotides are
CC used to treat cancers involving elevated levels of IL-1, such as
CC breast adenocarcinoma, brain tumours, melanoma, giant cell tumours
CC of bone, acute myelogenous leukaemia, oral epidermoid carcinoma or
CC squamous cell carcinoma, and inflammatory disease mediated by
CC interleukin-18 (all claimed). They can also be used to diagnose,
CC prevent or treat shock, thrombosis, acute pancreatitis, arthritis,
CC vasculitis, lupus, immune complex glomerulonephritis, pancreatic
CC cell damage, allograft and xenograft transplantation, graft versus
CC host disease, inflammatory bowel disease, bone degenerative
CC diseases, diabetes and neurodegenerative disorders.
XX
XX Sequence 169 AA;
SQ

Query Match 100.0%; Score 818; DB 22; Length 169;
Best Local Similarity 100.0%; Pred. No. 2.7e-86;
Matches 152; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MCSLPMARYIITKYADOKALYTRDGLLVGDPVADNCCAEKICTLPNGLDRTKVPFLG 60
Db 18 mcslpmaryylikyadqkalytrdggllvgdpvadnccaeikictlpnrgldrtkvpflg 77
QY 61 IQGSRCLACVETEEGPSLQLEDVNIIELYKGGEATRTFTFQSSGSFAFRLEAAAPGW 120
Db 78 iqgsrclacveteegpslqledvnieelykggeatrtftfqsngsafrleaaapgw 137
121 FLCGPAEPQVPQVLTKESEPSARTKFFEQSW 152
Db 138 flcgpaeppqpvtkesepsartkfyfegsw 169

RESULT 4
AAB19924
ID AAB19924 standard; Protein; 200 AA.
XX
AC AAB19924;
XX
DT 19-MAR-2001 (first entry)
XX
DE Human interleukin-1 Hy2 (long version).
XX
KW Interleukin-2 Hy2; IL-1 Hy2; human; interleukin-1 receptor;
KW antagonist; cancer; breast adenocarcinoma; brain tumour; melanoma;
KW myeloma; giant cell tumour of bone; acute myelogenous leukaemia;
KW oral epidermoid carcinoma; squamous cell carcinoma; inflammation;
KW antitumour; antiinflammatory; diagnosis; therapy.
XX
OS Homo sapiens.
XX

PN WO200071719-AL.
XX 30-NOV-2000.
XX 22-MAY-2000; 2000WO-US14144.
XX 20-MAY-1999; 99US-0316086.
PR 10-MAR-2000; 2000US-0522964.
XX (HYSE-) HYSEQ INC.
PI Ballinger DG, Ford J, Ho AS, Lin HS, Pace AM;
XX WPI; 2001-016409/02.
DR N-PSDB; AAA89177, AAA89178.
XX
PT New isolated polynucleotide encoding interleukin-1 Hy2 for diagnosing,
PT preventing and treating disorders, such as cancers and inflammatory
PT diseases -
XX
XX Example 5; Page 144-145; 158pp; English.
XX The present sequence is that of human interleukin-1 Hy2 (IL-1 Hy2),
CC a novel member of the interleukin-1 receptor antagonist family.
CC The sequence is predicted from the genomic DNA sequence (see
CC AAA89177) and a predicted cDNA sequence (see AAA89178). An alternative
CC open reading frame (see AAA89176) encodes a 152 polypeptide (see
CC AAB19922). IL-1 Hy2 polypeptides and polynucleotides are used to
CC treat cancers involving elevated levels of IL-1, such as
CC breast adenocarcinoma, brain tumours, melanoma, giant cell tumours
CC of bone, acute myelogenous leukaemia, oral epidermoid carcinoma or
CC squamous cell carcinoma, and inflammatory disease mediated by
CC interleukin-18 (all claimed). They can also be used to diagnose,
CC prevent or treat shock, thrombosis, acute pancreatitis, arthritis,
CC vasculitis, lupus, immune complex glomerulonephritis, pancreatic
CC cell damage, allograft and xenograft transplantation, graft versus
CC host disease, inflammatory bowel disease, bone degenerative
CC diseases, diabetes and neurodegenerative disorders.
XX
XX Sequence 200 AA;
SQ

Query Match 100.0%; Score 818; DB 22; Length 200;
Best Local Similarity 100.0%; Pred. No. 3.4e-86;
Matches 152; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MCSLPMARYIITKYADOKALYTRDGLLVGDPVADNCCAEKICTLPNGLDRTKVPFLG 60
Db 49 mcslpmaryylikyadqkalytrdggllvgdpvadnccaeikictlpnrgldrtkvpflg 108
QY 61 IQGSRCLACVETEEGPSLQLEDVNIIELYKGGEATRTFTFQSSGSFAFRLEAAAPGW 120
Db 109 iqgsrclacveteegpslqledvnieelykggeatrtftfqsngsafrleaaapgw 168
121 FLCGPAEPQVPQVLTKESEPSARTKFFEQSW 152
Db 169 flcgpaeppqpvtkesepsartkfyfegsw 200

RESULT 5
AAB84999
ID AAB84999 standard; Protein; 154 AA.
XX
AC AAB84999;
XX
DT 06-AUG-2001 (first entry)
XX
DE Human interleukin-1 receptor antagonist (NOVINTRA A) polypeptide.
XX
KW NOVX; transmembrane protein; NOVTRAN; neuromedin peptide; NOVNEUR;
KW gonadotropin-like protein; NOVGN; interleukin-1; NOVINTRA; human;
KW cytostatic; neuroprotective; reproductive; antiinflammatory; cancer;
KW antibacterial; cerebroprotective; antidiabetic; antiarthritic;
KW

KW antiasthmatic; antiallergic.

OS Homo sapiens.

PN WO200140291-A2.

XX 07-JUN-2001.

PF 06-DEC-2000; 2000WO-US33029.

XX 06-DEC-1999; 99US-0169056.

PR 09-DEC-1999; 99US-0169866.

PR 09-DEC-1999; 99US-0169886.

PR 10-DEC-1999; 99US-0170252.

PR 12-JAN-2000; 2000US-0175740.

PR 05-DEC-2000; 2000US-0170252.

XX (CURA-) CURAGEN CORP.

PI Burgess CE, Prayaga SK, Shinkels RA, Rastelli L, Zerhusen BD;

XX Mezes PS;

DR WPI; 2001-374790/39.

DR N-PSDB; AAF83868.

XX Novel isolated human transmembrane, neuromedin peptide

PT gonadotropin-like protein and interleukin-1 receptor antagonist

PT proteins, useful for treating cancer, immune response disorder,

PT metabolic function disorders -

XX Claim 1; Fig 9B; 138pp; English.

XX The invention provides novel polypeptides (NOVX) selected from human
CC transmembrane protein (NOVTRAN), neuromedin peptide (NOVNEUR),
CC gonadotropin-like protein (NOVGON) and two interleukin-1 receptor
CC antagonist proteins (NOVINTRA A and B). The invention also provides
CC methods in which a NOVX polypeptide, polynucleotide and antibody are
CC used in the detection, prevention and treatment of a broad range of
CC pathological states. NOVTRAN can be used to treat a cell signaling
CC disorder such as cancer, immune response disorder, hematopoietic
CC disorder, neurodegenerative disorder. NOVNEUR can be used to treat
CC endocrine disorder, muscle disorder, neurologic disorder, cancers of
CC central nervous system, breast, colon, ovary, kidney, prostate and
CC thyroid. NOVGON can be used to treat reproductive development disorder,
CC metabolic function disorder and melanoma. NOVINTRA A and B can be used
CC to treat bone metabolism or structure disorder, inflammatory response
CC disorder, immune regulation disorder, septic shock, stroke, diabetes,
CC arthritis and cancer. The present sequence represents the NOVINTRA A
CC polypeptide.

XX Sequence 154 AA;

Query Match 89.2%; Score 729 5; DB 22; Length 154;
Best Local Similarity 93.9%; Pred. No. 3.8e-76;
Matches 139; Conservative 0; Mismatches 2; Indels 7; Gaps 1;

QY 12 IKYADQKALYTRDQQLLVGDPVADNCCAEKICTLPNRGLDRTKVPFLGIQGSRLACY 71

DB 7 IKYADQKALYTRDQQLLVGDPVADNCCAEKICTLPNRGLDRTKVPFLGIQGSRLACY 66

QY 72 ETEEGPSLQLE-----DVNTEELYKGEEATRTFFQSSSGSAFRLEAAAPGWFLCG 124

DB 67 ETEEGPSLQLETPPPQDVNTEELYKGEEATRTFFQSSSGSAFRLEAAAPGWFLCG 126

QY 125 PAEPQPPVQLTKSEPSARTKFFQSW 152

DB 127 PAEPQPPVQLTKSEPSARTKFFQSW 154

RESULT 6

ID AAE05841 standard; Protein; 152 AA.

XX

AC AAE05841;

DT 24-SEP-2001 (first entry)

XX Mouse FIL-1 theta protein.

DE Interleukin-1 family ligand; FIL-1 theta; IL-1; glaucoma; leukaemia;

XX Insulin dependent diabetes mellitus; lymphoma; microbial infection;

KW ectodermal dysplasia; wrinkly skin syndrome; antisense therapy;

KW tibial muscular dystrophy; inflammation; gene therapy; mouse.

XX Mus musculus.

XX WO20015211-A2.

XX 02-AUG-2001.

XX 25-JAN-2001; 2001WO-US02514.

XX 27-JAN-2000; 2000US-0178389.

PR 11-APR-2000; 2000US-0195962.

XX (IMMV) IMMUNEX CORP.

XX Silms JE;

XX WPI; 2001-457718/49.

DR N-PSDB; AAD11158.

XX Isolated FIL-1 theta polypeptide to induce or inhibit the induction of

PT fever and to stimulate the immune system for the treatment of microbial

PT infections -

XX Claim 17; Page 6; 65pp; English.

XX The invention relates to interleukin-1 (IL-1) family ligand designated

CC as FIL-1 theta polypeptides and nucleic acid molecules encoding such

CC polypeptides FIL-1 theta DNA is used to identify glaucoma, insulin

CC dependent diabetes mellitus, ectodermal dysplasia, T-cell leukaemia/

CC lymphoma, wrinkly skin syndrome and tibial muscular dystrophy. FIL-1

CC theta polypeptides are used to activate and/or inhibit the activation

CC of vascular endothelial cells and lymphocytes; the induction of local

CC tissue destruction and fever; the stimulation of macrophages and

CC vascular endothelial cells to produce IL-6 and the induction of

CC prostaglandins. They are also used to treat inflammation and microbial

CC infections. FIL-1 theta DNA is useful in antisense therapy and gene

CC therapy. The present sequence is mouse FIL-1 theta protein.

XX Sequence 152 AA;

QY Query Match 80.3%; Score 657; DB 22; Length 152;

Best Local Similarity 82.1%; Pred. No. 8.5e-68;

Matches 124; Conservative 10; Mismatches 17; Indels 0; Gaps 0;

QY 1 MCSLPMARYIIKIVADOKALYTRDQQLLVGDPVADNCCAEKICTLPNRGLDRTKVPFLG 60

DB 1 mcslpmaryiikidahgkalytrngqlllgdpdsdmsyepkvcilpnrgldrskvpflg 60

QY 61 IQGGSRLACVTEGPGSLQLEDVNTEELYKGEEATRTFFQSSSGSAFRLEAAAPGW 120

DB 61 mqqgscclacvktregplqledvniedlykggeqtrtffqslgsafrleaaapgw 120

QY 121 FLCGPAEPQPPVQLTKSEPSARTKFFQSW 151

DB 121 flcgpaepqppvqltkesepsthtefyems 151

RESULT 7

ID AAB19925 standard; Protein; 152 AA.

XX Interleukin; IL-1 delta: polyclonal antibody; IL-1 epsilon; cytokine;
 KW inflammatory response; immune system; diagnosis; agonist; antagonist;
 KW chemokine.
 XX
 OS Mus sp.
 XX
 PN W09847921-A1.
 XX
 PD 29-OCT-1998.
 XX
 PF 17-APR-1998; 98WO-US06879.
 XX
 PR 06-AUG-1997; 97US-0055111.
 XX
 PR 21-APR-1997; 97US-0837627.
 XX
 PA (SCHE) SCHERING CORP.
 XX
 BAZAN JF, Hedrick JA, Kastelein RA, Sana TR;
 WPI; 1998-609976/51.
 DR N-PSDB; AAV71958.
 XX
 PT Mammalian interleukin 1-delta and 1-epsilon - useful for, e.g.
 PT regulating the immune system and inflammatory responses
 XX
 PS Claim 1; Pages 89-90; 113pp; English.
 XX
 CC This represents a rodent interleukin (IL)-1 delta polypeptide. The
 CC invention relates to a recombinant polypeptide that specifically binds
 CC polyclonal antibodies (Abs) generated against a 12 consecutive amino acid
 CC segment of IL-1 delta or IL-1 epsilon. Agonists or antagonists of these
 CC IL polypeptides are used to regulate a cell involved in an inflammatory
 CC response. The IL-1 delta or IL-1 epsilon polypeptides and peptides are
 CC used to produce Abs and antigen-Abs complexes. The polypeptides, Abs and
 CC the corresponding nucleic acids regulate development and/or the immune
 CC system, and can be used to diagnose and treat conditions associated with
 CC abnormal expression of IL. Agonists or antagonists of IL-1 delta or IL-1
 CC epsilon polypeptides are used with agonists or antagonists of IL-1 alpha,
 CC IL-1RA, IL-1 beta, IL-1 gamma, IL-2 and/or IL-12. The IL-1 delta or IL-1
 CC epsilon polypeptides may be used as a soluble polypeptide or as a fusion
 CC protein with another cytokine or chemokine.
 XX
 SQ Sequence 156 AA;

Query Match 37.8%; Score 309; DB 19; Length 156;
 Best Local Similarity 45.2%; Pred. No. 1.le-27;
 Matches 70; Conservative 23; Mismatches 56; Indels 6; Gaps 3;

QY 1 MCSLPMARYIYIKVADOKALYTRDGLLVGDPVADNCC-AEKICTLPNRLDRTKVPFL 59
 Db 1 mmvlsqalcfrmkdsalkvlylhnnqllagglaekvikgeesvvpnralspsvll 60
 QY 60 GIGGSRCLACVETEGPSIQLEDVNIIELYKGGEEATRTFFQSSGSAFRLAAAWPG 119
 Db 61 gvqgsgqlsc-gtekgplkplepvnimelylgakeskftfyrddmgltssfsaaypg 119
 QY 120 WFLCSPAPPOQPVOLTKESPSA----RTKVFPEQ 150
 Db 120 wfictspadqpvriltqipedawdaptidfyfqq 154

RESULT 10
 AAY28407
 ID AAY28407 standard; Protein: 156 AA.
 XX
 AC AAY28407;
 XX
 DT 28-SEP-1999 (first entry)
 XX
 DE Mouse interleukin 1 delta.
 XX

KW Interleukin 1 delta; IL-1 delta; glaucoma; ectodermal dysplasia;
 KW insulin-dependent diabetes mellitus; wrinkly skin syndrome;
 KW T-cell leukemia; lymphoma; tibial muscular dystrophy.
 XX
 OS Mus musculus.
 XX
 PN W09935268-A1.
 XX
 PD 15-JUL-1999.
 XX
 PF 08-JAN-1999; 99WO-US00514.
 XX
 PR 01-JUN-1998; 98US-0087393.
 XX
 PR 09-JAN-1998; 98US-0071074.
 XX
 PA (IMMV) IMMUNEX CORP.
 XX
 XX Sims JE;
 XX
 XX WPI; 1999-458310/38.
 DR N-PSDB; AAX89431.
 XX
 PT Murine and Human interleukin 1 delta DNA, polypeptides and its
 PT fragments, useful as molecular weight markers
 XX
 PS Claim 1; Page 67; 72pp; English.
 XX
 CC The present sequence represents mouse interleukin 1 delta (IL-1 delta).
 CC IL-1 delta proteins are useful for the determination of the molecular
 CC weight of a sample protein. The protein and its fragments are useful as
 CC controls for peptide fragmentation. This is useful for determining the
 CC isoelectric point of a sample protein. Antibodies generated against
 CC IL-1 delta and its fragmented peptides can be used to enhance the
 CC accuracy of these molecular weight markers to determine the apparent
 CC molecular eight and isoelectric point of a sample protein. IL-1 delta
 CC can be used to screen for potential inhibitors of activity associated
 CC with IL-1 delta counter-structure molecules. IL-1 delta can also be used
 CC as therapeutic agents for the treatment of diseases mediated by IL-1
 CC delta. IL-1 delta may be used as a reagent in studying the interleukin 1
 CC (IL-1) signalling pathway, or as a reagent to block IL-1 signalling. The
 CC IL-1 delta coding sequences can be used to identify human chromosome 2,
 CC and to identify genes associated with certain diseases, especially with
 CC region 2q11-12, including glaucoma, ectodermal dysplasia, insulin-
 CC dependent diabetes mellitus, wrinkly skin syndrome, T-cell leukemia/
 CC lymphoma and tibial muscular dystrophy.
 XX
 SQ Sequence 156 AA;

Query Match 37.8%; Score 309; DB 20; Length 156;
 Best Local Similarity 45.2%; Pred. No. 1.le-27;
 Matches 70; Conservative 23; Mismatches 56; Indels 6; Gaps 3;

QY 1 MCSLPMARYIYIKVADOKALYTRDGLLVGDPVADNCC-AEKICTLPNRLDRTKVPFL 59
 Db 1 mmvlsqalcfrmkdsalkvlylhnnqllagglaekvikgeesvvpnralspsvll 60
 QY 60 GIGGSRCLACVETEGPSIQLEDVNIIELYKGGEEATRTFFQSSGSAFRLAAAWPG 119
 Db 61 gvqgsgqlsc-gtekgplkplepvnimelylgakeskftfyrddmgltssfsaaypg 119
 QY 120 WFLCSPAPPOQPVOLTKESPSA----RTKVFPEQ 150
 Db 120 wfictspadqpvriltqipedawdaptidfyfqq 154

RESULT 11
 AAY92260
 ID AAY92260 standard; Protein: 156 AA.
 XX
 AC AAY92260;
 XX
 DT 10-AUG-2000 (first entry)

```

XX DE Murine IL-1 homologue, zilla3.
XX AC
XX KW Generic; interleukin-1; IL-1; homologue; zilla3; anti-inflammatory;
XX KW antagonist; pro-inflammatory; agonist; immunomodulator; antiarthritic;
XX KW antirheumatic; osteopathic; antipsoriatic; antibacterial; cytostatic;
XX KW immunosuppressive; antiulcer; antidiabetic; nephrotropic; vasotropic;
XX KW vulnerary; 2ql4.
XX OS Mus musculus.
XX PN WO200020595-A1.
XX PD 13-APR-2000.
XX PF 08-OCT-1999; 99WO-US23533.
XX PR 08-OCT-1998; 98US-0169745.
XX PA (ZYMO ) ZYMOGENETICS INC.
XX PS Sheppard PO, West RR, Clegg CH;
XX N-PSDB; AAA09198.
XX DR WPI; 2000-303780/26.
XX PT Proteins useful for treatment of inflammatory conditions such as
XX PT rheumatoid arthritis and psoriasis are agonists or antagonists forms of
XX PT new interleukin-1 homologue
XX PS Example 7; Page 59-60; 64pp; English.
XX CC This shows an interleukin-1 (IL-1) homologue, designated zilla3, A 350
XX CC bp probe generated from the DNA sequence by PCR using AAA09199-200 was
XX CC used to analyze human northern blots.
XX CC It is believed that zilla3 acts through IL-1 receptors. In general,
XX CC zilla3 proteins having a Lys residue at position 148 will have
XX CC (anti-inflammatory activity (e.g. AAY92256), whilst those having Asp
XX CC (see AAY92254) or Glu at this position will have pro-inflammatory
XX CC action. Zilla3 is used to modulate an immune response in an animal
XX CC (claimed). Antagonists zilla3 forms may be used to treat or prevent
XX CC chronic inflammatory diseases such as rheumatoid arthritis,
XX CC osteoarthritis and Lyme arthritis, psoriasis, to reduce tissue damage
XX CC after ischemia, to treat septic shock, graft-versus-host disease and
XX CC leukemia. The antagonists may also alleviate inflammatory bowel disease
XX CC including Crohn's disease and ulcerative colitis, insulin-dependent
XX CC diabetes mellitus, acute pancreatitis, glomerulonephritis and cerebral
XX CC ischemia. Agonist forms of zilla3 may promote wound healing by IL-1
XX CC effects on growth factor secretion and cell proliferation. They may also
XX CC treat infections, especially gastrointestinal infections.
XX CC Sequence 156 AA;
XX CC
XX CC Query Match 37.8%; Score 309; DB 21; Length 156;
XX CC Best Local Similarity 45.2%; Pred. No. 1.1e-27;
XX CC Matches 70; Conservative 23; Mismatches 56; Indels 6; Gaps 3;
XX CC
XX QY 1 MCSLPMARYIYIKYADQKALYTRDQGLLVGDPVADNCC-AEKICTLPNRLDRTKVPFL 59
XX Db 1 mmvlsqalcfrmkdsalkvlyhnnqllagglhaekvikgeesvvpnrldaslspsvll 60
XX QY 60 GIOGSRCLACVETEGPSLQLEDVNIIEELKGGEEATRTFFQSSSGSAFRLEAAWPG 119
XX Db 61 gvqgsgqlsc-gtekpgilkpvnimelylgakesksftfyrrdmgltsfesaaypg 119
XX QY 120 WFLCGPAEPQPPVOLTKESEPSA---RTKEYFEQ 150
XX Db 120 wflctspadqpvrltqipedpawdapitcdfyrdq 154
XX RESULT 12
XX AAY45061

```

```

ID XX AAY45061 standard; Protein; 156 AA.
AC XX AAY45061;
DT 31-MAY-2000 (first entry)
DE Murine TANGO-93 protein.
XX KW TANGO-93; cytokine; mouse; secreted protein; IL-1 expression; cancer;
XX KW Interleukin-1 receptor antagonist; IL-1ra; inflammation; antiasthmatic;
XX KW immunosuppressive; antirheumatic; antiarthritic; antipsoriatic; asthma;
XX KW antiinflammatory; antibacterial; antiulcer; cytostatic; immunomodulator;
XX KW osteopathic; dermatological; antidiabetic; psoriasis; ulcerative colitis;
XX KW graft vs-host disease; rheumatoid arthritis; inflammatory bowel disease;
XX KW septic shock; cachexia; Crohn's disease; chronic myelogenous leukaemia;
XX KW liver disease; diabetes; osteoarthritis; Hodgkin's disease; Lyme disease;
XX KW autoimmune disease; myasthenia gravis; pharmacogenomic; diagnosis;
XX KW systemic lupus erythematosus; forensic; transgenic animal.
OS Mus sp.
XX PN WO200008045-A2.
XX PD 17-FEB-2000.
XX PF 06-AUG-1999; 99WO-US17886.
XX PR 07-AUG-1998; 98US-0131263.
XX PA (MILL-) MILLENNIUM BIOTHERAPEUTICS INC.
XX PI Pan Y;
XX DR WPI; 2000-205669/18.
XX DR N-PSDB; AAZ50811.
XX PT Isolated nucleic acid sequences encoding TANGO-93 polypeptide useful
XX PT for treating a variety of cellular processes e.g. asthma, rheumatoid
XX PT arthritis, psoriasis and autoimmune diseases
XX PS Claim 9; Fig 1; 113pp; English.
XX CC The present sequence is the murine TANGO-93, a secreted protein, that
XX CC belongs to the cytokine superfamily. It plays a role similar to secreted
XX CC Interleukin-1 receptor antagonist (IL-1ra) and its expression is
XX CC developmentally regulated in liver, heart and bone marrow. TANGO-93
XX CC modulates immune mediated inflammation and IL-1 gene or protein
XX CC expression. TANGO-93 is useful as a modulating agent for regulating
XX CC cellular processes like asthma, graft vs-host disease, rheumatoid
XX CC arthritis, psoriasis, inflammatory bowel disease, septic shock,
XX CC ulcerative colitis, Crohn's disease, chronic myelogenous leukaemia,
XX CC cancer, liver disease, Hodgkin's disease, osteoarthritis, Lyme disease,
XX CC cachexia, and autoimmune diseases e.g. myasthenia gravis, autoimmune
XX CC diabetes and systemic lupus erythematosus. Partial TANGO-93 sequences
XX CC are useful in forensic biology, for diagnostic and prognostic assays,
XX CC prophylactic and therapeutic treatment and pharmacogenomics. The DNA
XX CC sequences are useful as hybridisation probes and primers, for isolation
XX CC of TANGO-93 sequence and for the creation of transgenic animals.
XX CC Sequence 156 AA;
XX CC
XX CC Query Match 37.8%; Score 309; DB 21; Length 156;
XX CC Best Local Similarity 45.2%; Pred. No. 1.1e-27;
XX CC Matches 70; Conservative 23; Mismatches 56; Indels 6; Gaps 3;
XX CC
XX QY 1 MCSLPMARYIYIKYADQKALYTRDQGLLVGDPVADNCC-AEKICTLPNRLDRTKVPFL 59
XX Db 1 mmvlsqalcfrmkdsalkvlyhnnqllagglhaekvikgeesvvpnrldaslspsvll 60
XX QY 60 GIOGSRCLACVETEGPSLQLEDVNIIEELKGGEEATRTFFQSSSGSAFRLEAAWPG 119
XX Db 61 gvqgsgqlsc-gtekpgilkpvnimelylgakesksftfyrrdmgltsfesaaypg 119

```

QY	120	WFLCCPAPQPQPVQLTKSEPSA----	RTKYPFEQ	150
Db	120	wflccpdpvrltqipedapwdpdtfdyfq		154
RESULT	13			
AAE06663				
ID	AAE06663	standard; Protein; 154 AA.		
AC	AAE06663;			
DT	16-OCT-2001	(first entry)		
DE	Mouse interleukin-1delta (IL-1delta) protein.			
XX				
XX	Mouse; interleukin-1delta; IL-1delta; virucide; hepatotropic; fever;			
XX	immunological disorder; tumour; inflammatory disorder; hypoglycaemia;			
XX	autoimmune disease; pulmonary tuberculosis; fulminant hepatitis; leprosy;			
XX	psoriasis; viral infection; allergy; cytokine; HIV; drug screening.			
OS	Mus sp.			
PN	WO200157219-A2.			
PD	09-AUG-2001.			
PF	01-FEB-2001; 2001WO-US03285.			
XX				
PR	02-FEB-2000; 2000US-0179638.			
XX				
PA	(SCHE) SCHERING CORP.			
PI	Debets JEMA, Timans JC, Bazan JF, Kastelein RA;			
DR	WPI; 2001-488886/53.			
XX				
PT	Novel isolated or recombinant antigenic interleukin-1 delta or epsilon			
PT	polypeptide useful for treating conditions exhibiting abnormal			
PT	expression of interleukin such as immunological disorders, tumor and			
XX	allergy			
PS	Disclosure; Fig 1; 103pp; English.			
XX				
CC	The invention relates to recombinant antigenic interleukin-1 like			
CC	molecules and their corresponding nucleic acid sequences, designated			
CC	as interleukin-1delta (IL-1delta) and interleukin-1epsilon (IL-1epsilon),			
CC	IL-1delta and IL-1epsilon are useful for treating conditions exhibiting			
CC	abnormal expression of the interleukin such as immunological disorders,			
CC	tumours, inflammatory disorders, fever, hypoglycaemia, psoriasis,			
CC	allergy, autoimmune diseases and infectious diseases (e.g., pulmonary			
CC	tuberculosis, leprosy, fulminant hepatitis, and viral infections such as			
CC	HIV). The invention also relates to methods of using the composition			
CC	containing IL-1delta or IL-1epsilon for both diagnostic and therapeutic			
CC	utilities. IL-1delta is used as an immunogen for the production of			
CC	antisera or antibodies specific, e.g., capable of distinguishing between			
CC	IL-1 family members and an IL-1delta, for the interleukin or its			
CC	fragment. The purified interleukin is used as a reagent to detect any			
CC	antibodies generated in response to the presence of elevated levels of			
CC	expression, or immunological disorders which lead to antibody production			
CC	to the endogenous cytokine. The invention also contemplates the use of			
CC	competitive drug screening assays. The present sequence is mouse			
CC	interleukin-1delta (IL-1delta) protein related to the invention.			
XX				
SQ	Sequence	154 AA;		

Query Match	37.58;	Score	307;	DB	22;	Length	154;
Best Local Similarity	47.88;	Pred. No.	1.9e-27;				
Matches	66;	Conservative	20;	Mismatches	46;	Indels	6;
Gaps							

QY	18	KALYTRDGLGVADNCC-AEKICTLPNRLDTRKVP	IFLIGQSGRLACVTEER	76

BASE COUNT	212 a	232 c	247 g	209 t	
ORIGIN	RLFAAAMPWFILCGPAEPQDPVQLTKESPSARTKYPFEQSW"				
Query Match	70.1%;	Score 714.8;	DB 11;	Length 900;	
Best Local Similarity	99.7%;	Pred. No. 1.1e-166;			
Matches 716;	Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;
Qy	180	agagaagatctgcacactcttaacagaggttgaccgcacacaaagttccatttct	239		
Db	183	AGAGAAGATCTGCATACTCTTCAACAGAGGCTTGCCCCGGACCAAGSTCCCCATTTTCCT	242		
Qy	240	ggggatccagagagggagcgctgcctggcatgtgtgagacagagaggggcttcct	299		
Db	243	GGGGATCAGGAGGAGGAGCGCTGCTGGCATGTGTGAGACAGAAAGGGGCTTTCCCT	302		
Qy	300	acagctggagatgtgaacattgaggaactgtacaaagggtgtgaagaggccacacgctt	359		
Db	303	ACAGCTGGAGGATGTGAACATTGAGGAAGTGTACAAAGGGTGTGAAGAGGCCACACGCTT	362		
Qy	360	cacctctccagagcagctccagctccgctctcaggcttgaggtctgctgcctggcctgg	419		
Db	363	CACCTTCCTCCAGAGCAGCTCAGGCTCCGCTTCAGGCTTGAGGCTGCTGGCCCTGG	422		
Qy	420	ctgggtctctgtggtccgcagagcccgacgagccagctacagctcaccagagagtgga	479		
Db	423	CTGGTTCCTGTGTGGCCCCGGCAGAGCCCGACGACCCAGTACAGCTCACCACAGAGATGA	482		
Qy	480	gcctccagccgtaccagtttactttgaacagagctggttagggagacaggaactgcg	539		
Db	483	GCCCTCAGCCCGTACCAAGTTTACTTTTGAACAGAGCTGTGTAGGGAGACAGGAAATGCG	542		
Qy	540	ttttagccttgcgccccaacaaagctatctctcaggtctatgttagtcgagaata	599		
Db	543	TTTTAGCCTTGTGCCCCCAAAAGCTCATCTCTCAGGGTCTATGCTAGGCAGAATA	602		
Qy	600	atgtcccccgaatatgtccacatcctaataccagatctgtgcatattaccatacat	659		
Db	603	ATGTCCCCCGGAATATGTCCACATCTTAATCCACAGATCTGTGCATATGTTACCATATCAT	662		
Qy	660	gtccaaagaggtttgcaaatgtattgtttaaggatcttgaataggagacaaactct	719		
Db	663	GTCCAAAGAGGTTTTGCAAAATGTGATTATCTTAAGGATCTTGAATCAGGAGACAAATCCT	722		
Qy	720	gggttatctctgtgggtcagtttaataccagaagagggcaggaagggagagtcagaga	779		
Db	723	GGGTATCTCTGTGGCTCAGTTTATCACAGAAGGAGGAGGAGGAGGAGTACAGAGA	782		
Qy	780	gagaatggaatataccatgcttctaatttgaagatggagtgggggcttgagccaaca	839		
Db	783	GAGAAATGGAAGATACCATGCTTCTTAATTTTGAAGATGAGTGAAGGGGCTTGAGCCAACA	842		
Qy	840	aatcagagtggttttagaagtggaagaaagcgaaggtatctcctctagagct	897		
Db	843	AATGCAGTGTTTTTAGAAGTGGAAAGCCCAAGGAACGGATTCTCCTCTAGAGTCT	900		
RESULT 2					
BI051175/c					
LOCUS					
DEFINITION	CM2-GN0289-100101-685-c09 GN0289 Homo sapiens cDNA, mRNA sequence.				
ACCESSION	BI051175				
VERSION	BI051175.1				
KEYWORDS	EST.				
SOURCE	human.				
ORGANISM	Homo sapiens				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.				
	1 (bases 1 to 285)				
	Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,				
	Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F.,				
	Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H.,				

SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 574)
AUTHORS Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R., Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F., Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H., Brunstein,A., deoliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and Simpson,A.J.
TITLE Shotgun sequencing of the human transcriptome with ORF expressed sequence tags
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
MEDLINE 20202663
COMMENT Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP, Brazil
Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL
(<http://www.ludwig.org.br/scripts/gethtml2.pl?tl=kt2=PMO-BT0340-170>)
100-004-b01kt3-2000-01-17kt4-1)
Seq primer: puc 18 forward
High quality sequence stop: 573.
FEATURES Location/Qualifiers
source 1..574
 `/organism="Homo sapiens"`
 `/db_xref="taxon:9606"`
 `/clone_lib="BT0340"`
 `/dev_stage="Adult"`
 Note="Organ: breast; Vector: puc18; Site_1: SmaI; Site_2: SmaI; A mini-library was made by cloning products derived from ORESTES PCR (U.S. Letters Patent application No. 196,716 - Ludwig Institute for Cancer Research) profiles into the puc 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions." 144 a 111 c 154 g 165 t
BASE COUNT 144 a 111 c 154 g 165 t
ORIGIN
Query Match 16.5%; Score 168.6; DB 9; Length 574;
Best Local Similarity 68.1%; Pred. No. 2.9e-31;
Matches 280; Conservative 0; Mismatches 124; Indels 7; Gaps 3;

QY 603 tcccccaaatatgtccacatcctacttaatcccaagatctgtgcatagtttaccatacatgctc 662
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 55 TACCCCCAAGAGGTTCGATGTCCTTAATCTTGGAACCTGTGGATATGTACATATTGTGGC 114

QY 663 caaagaggttttgcgaatgtgattatgtaagatcttgaatgaggagagacaatcctggg 722
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 115 AAAGGAGATTTTCATGTGTGATTAAAGGAAAGATCTTGAGATGGGAGATTCTCTGCA 174

QY 723 ttatcctgtggctcagttttaatcacaaagaa-----ggaggcagaagaaggagatcagag 778
 ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 175 TGACCCAGGTAGGCCCAATGTAAATTCAAAGGATCTTTAAAGAGGAGAGGTAGGAGGTAC 234

QY 779 agagaatggaagataccatgctctctaattttgaagatggagtgaggccttgagccaac 838
 ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 235 ACTCAGGAGAGAGACGAGGATTCCTGGCTTTGAAGGTGGAGCAAGGCCCAAGCAAG 294

QY 839 aaatgcagggtgttttagaaggtgaaagcaaggaagattctctctctctctctctctctc 898
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 295 AAATGTCAGGTGGGCTCTAGAGCTGGGAAGGCAATGG-GTGGATTCCCTCTGGAGCCTC 353

QY 899 cggaaagaaacacagctct--tgacacatggtatttcagctcagtgacacccatttcagact 956

Db 354 CAGAAGAACACAGCCCTGCTACCTCTTGCTTTAGCCACGAGACCCGTTTTCGAAA 413

JOURNAL scanning the human genome
MEDLINE Proc. Natl. Acad. Sci. U. S. A. 96 (17), 9739-9744 (1999)
COMMENT 99380589
Contact: Mahairas GG, Wallace JC, Hood L
High throughput Sequencing Center
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618
Fax: (206) 616-3887
Email: jwallace@u.washington.edu
Clones are derived from the human BAC library RPCI-11. For BAC
library availability, please contact Pieter de Jong
(pieter@dejong.med.buffalo.edu). Clones may be purchased from
BACPAC Resources (http://bacpac.med.buffalo.edu/ordering_bac.htm)
or from Research Genetics (info@resgen.com). BAC end Web Server:
http://www.htsc.washington.edu
Plate: 692 row: N column: 8
Seq primer: T7
Class: BAC ends
High quality sequence stop: 533.

FEATURES
source
1..533
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="Plate=692 Col=8 Row=N"
/clone_lib="RPCI-11 Human Male BAC Library"
/sex="male"
/note="Vector: pBACE3.6; Site_1: EcoRI; Site_2: EcoRI;
Male blood DNA was isolated from one randomly chosen donor
and partially digested with a combination of EcoRI and
EcoRI Methylase. Size selected DNA was cloned into the
pBACE3.6 vector at EcoRI sites"
BASE COUNT 178 a 98 c 115 g 135 t 7 others
ORIGIN

Query Match 12.0%; Score 122.2; DB 12; Length 533;
Best Local Similarity 64.4%; Pred. No. 9.3e-20;
Matches 269; Conservative 0; Mismatches 129; Indels 20; Gaps 5;
Db 561 ccaagctcctcgtcagggctctgtgtaggcagaataatgtcccccgaatatgtcca 620
Db 117 CAAGACTCCTTGCTCTATCTTTTGGTGAGAGAGATATGATTTCTCAAGTAT-CCAT 175
Qy 621 catcctaatacccaagatctgtgcatatgtaccatacatgtccaaagaggttttgcacaa 680
Db 176 GACCGAATACCCAGAGCCTGTGAATATATTACCTTCCATGGCAAAAGGGACACTTTACAGAT 235
Qy 681 gtgattatgttaaggtcttgaaatgaggagacaatcctgggttatccttggggtcag 740
236 GTGATTAACTTAAGGATCTTGACATGAGG-GATTAACTGGATTTGCCAGGTGGCCCCAG 294
Qy 741 ttaataccaagaaggaggcag-----gaaggagagtcagagagaatgg 787
Db 295 TATAATCACAGAAATCTTAAAGATCGAAGAGCGCAGACAGAGTCAGAGAAAGATTG 354
Qy 788 agatataccatgctcttaatttgaagatggagtgaggggccttgagccacaataatgca-g 846
Db 355 AAGGTGCTACACACTCGCTTGTAATAAGAGGAAGGGCTGTGAGCCCAAGGAGTGCACA 414
Qy 847 gtgtttttagaaggtgaaagccaaggaacggtatctctctagatctccgaa--- 903
Db 415 CTGCTTTATGAGCTGGCAAAACAAGAAACAATAATCTCCTATAGTTTCCAGAAAC 474
Qy 904 -ggaacacagctcttgcacatggatttcagctcagtcagtcacaccattcagactctg 960
Db 475 GAACACAAACCCCTCTGACACCTTGATTTAGCCCAAGTGAATAATCTTTTGCATCTTG 532

RESULT 11
A0318555
LOCUS A0318555 526 bp DNA linear GSS 04-MAY-1999
DEFINITION RPCI11-90J12.TJ RPCI-11 Homo sapiens genomic clone RPCI-11-90J12,

DNA sequence.
ACCESSION A0318555
VERSION A0318555.1 GI:4051597
KEYWORDS GSS.
SOURCE human.
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 526)
AUTHORS Adams M.D., Rounsley S.D., Zhao S., Bass S., Linher K., Golden K.,
Berry K., Granger D., Suh E., Wible C., de Jong P. and Venter J.C.
Use of human BAC End Sequences for Sequence-Ready Map Building
JOURNAL Unpublished (1998), 90J12.TJ
COMMENT Other_GSSs: RPCI11-90J12.TJ
Contact: Shaying Zhao, William Nierman, Mark Adams
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850
Tel: 301 838 0200
Fax: 301 838 0208
Email: hbe@tigr.org
Clones are derived from the human BAC library RPCI-11. For BAC
library availability, please contact Pieter de Jong
(pieter@dejong.med.buffalo.edu). Clones may be purchased from
BACPAC Resources (http://bacpac.med.buffalo.edu/ordering) or from
Research Genetics (info@resgen.com). BAC end search page:
http://www.tigr.org/tldb/hungen/bac_end_search/bac_end_search.html
Seq primer: SP6
Class: BAC ends.
FEATURES
Location/Qualifiers
source
1..526
/organism="Homo sapiens"
/db_xref="GDB:7534403"
/db_xref="taxon:9606"
/clone="RPCI-11-90J12"
/clone_lib="RPCI-11"
/sex="Male"
/cell_type="Lymphocytes"
/note="Vector: pBACE3.6; Site_1: EcoRI; Site_2: EcoRI;
RPCI11 Human Male BAC Library"
BASE COUNT 158 a 86 c 122 g 160 t
ORIGIN

Query Match 11.9%; Score 121; DB 12; Length 526;
Best Local Similarity 59.3%; Pred. No. 1.8e-19;
Matches 246; Conservative 0; Mismatches 160; Indels 9; Gaps 2;
Qy 583 ctatgtgagcagaataatgtccccggaataatgtccacatcctcaatcccaag-atctgt 641
Db 56 CTATGTAAGCGGAATAATGGACTTCCCAAAAGGTCTCTCATCTCTCCTCGAATCTGT 115
Qy 642 gcatatgttaccatacatgtccaaagaggttttgcacatgtgattgttaagatcttg 701
Db 116 GAATATGTTACTTACATGTAAGAGGACTTTACAGATGTGATTAAGTTAGGATCTTG 175
Qy 702 aaatgagagacacactcctgggttatccttgggtcagtttaatacacagaagaggaca 761
Db 176 AGATGTGGAGATTTCTTCTGGATTATTTGCATACAGAAATAACACAGAGTCATGATA 235
Qy 762 ggaaggagagtcagagagaagaatggaataccatgctctcaattttgaagatggagtg 821
Db 236 GAGATAGGTACTAGGATTAAAGTCGCTAGTACGAATAATGATATATAGAGA-----TT 287
Qy 822 aggggcttgagccacaataatgcagggtgtttttagaaggtggaagcaaggggaacgga 881
Db 288 GGTGTAATGAGAGCTGTGGAGTGTGCGAGCTTTCAGAGCTTTAGAGCTGAGAGCGCAGAGAACAGG 347
Qy 882 ttctctctctagatctcgcgaaggaacacagctcttgcacatggttttcagctcagtg 941
Db 348 TTTTCCCTTGAATCTCTGAAAGGAACACAGCTCGCTGACATCTTTGATTTTGCCCCCATAA 407
Qy 942 caccatttcagactcttgacctcccaactataataataaacttggttatt 996

Qy	623	tcctaaatcccaag-----actgtgcatactgtaccatacatatgtcccaagaggtttg	675
Db	519	tcctaaatccctaaatccccacagatctatcaatattgtgtgccttgcattgtgtaaaagaacctttg	460
Qy	676	caaatgtattatgtttaaggalcttgaatgaggagagacaactcctgggttatcctctgtggg	735
Db	459	caaatgtgattaaagtcaaaagatctttgagataggagattattcttggattatccaagtctg	400
Qy	736	ctcagtttaatacaag-----aaggagg	759
Db	399	cccaattatatacaagggtcctttataggagacagaggagctcacagaggaattcgaagg	340
Qy	760	caggaaaggagagtcagagagagaagtgaagataccatgctctctaatttgaagatgag	819
Db	339	acagaaccacaaagtcagaggggtgtaaaaatgctctacactgctactctttgaggatgaa	280

Db	279	AAAGGACCATGAGCCAGGACCTAGGTGGCTCTAGGAGCTGGAGAGCATGTCACCC	220
QY	880	gattctctctagagtctccggaaggacacagctcttgcacatggtattcagctcagtt	939
Db	219	AACCTCCCTT-GAGAAATCTCCAGAGGAAAGACACTTCCCG-CACTTTGATTTTAGCTCAGC	162
QY	940	gcaccatttcagactctcgaacctccacacataataaataat	982
db	161	GAAACTGATTTTGGACCTTCTCACCTCTTGAACCTGAAAAATAAT	119

RESULT	15
AQ405885/c	
LOCUS	
DEFINITION	AQ405885 525 bp DNA linear GSS 13-MAR-
	HS_5043_B2_F07_T7 POCI-11 Human Male ERAC Library Homo sapiens
	genomic clone Plate-619 Col-14 Row-L, DNA sequence.
ACCESSION	AQ405885
VERSION	AQ405885 1 CT-AJ415973

KEYWORDS	GSS.
SOURCE	human.
ORGANISM	Homo sapiens
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi
	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE	1 (bases 1 to 525)
AUTHORS	Maheiras,G.G., Wallace,J.C., Smith,K., Swartzell,S., Holzman,T. Keller,A., Shaker,R., Furlong,J., Young,J., Zhao,S., Adams,M.D. Hood,L.
TITLE	Sequence-tagged connectors: A sequence approach to mapping and scanning the human genome
JOURNAL	Proc. Natl. Acad. Sci. U. S. A. 96 (17), 9739-9744 (1999)
MEDLINE	93380589

High Throughput Sequencing Center
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618
Fax: (206) 616-3887
Email: jwallace@u.washington.edu
Clones are derived from the human BAC library RPC1-11. For BAC library availability, please contact Pieter de Jong (pieter@dejong.med.buffalo.edu). Clones may be purchased from BACPAC Resources (<http://bacpac.med.buffalo.edu/ordering.bac.htm>) or from Research Genetics (info@resgen.com). BAC end Web Server: <http://www.bsc.washington.edu>

```

FEATURES
  source
    Plate: 619 row: L column: 14
    Seq primer: T7
    Class: BAC ends
    High quality sequence stop: 525.
      Location/Qualifiers
        l..525
        /organism="Homo sapiens"
        /db_xref="taxon:9606"
        /clone="plate=619 Col=14 Row=L"
        /clone.lib="Rpci-11 Human Male BAC Library"
        /sex="male"

```

/note=vector: pBACE3.6; Site.1: EcoRI; Site.2: EcoRI;
Male blood DNA was isolated from one randomly chosen donor
and partially digested with a combination of EcoRI and
EcoRI Methylase. Size selected DNA was cloned into the
pBACE3.6 vector at EcoRI sites"
111 a 139 c 109 g 160 t 6 others

BASE COUNT
ORIGIN

Query Match	11.28;	Score 114.6;	DB 12;	Length 525;
Best Local Similarity	70.08;	Pred. No. 7.1e-18;		
Matches 224;	Conservative 0;	Mismatches 90;	Indels 6;	Gaps 5;
Qy 636	atctgtgcatagtttaccatacatgtccaaagggttttgcaaatgtgattatgtttaagg	695		
Db 361	ACCTGTCAATATGTGACCTTTTCATGGCAAAAGAGACTTTGC-AGTGTGATTGGATTGAGG	303		
Qy 696	atcttgaatgaggagacaatccctgggttatcctt-gtgggctcagtttaatacacagaa	754		
Db 302	ATCTTGAGATGAGGAGATTATCTGGTGGCCCTAAAGTAATCACAGGGGTCCCTATGAGAC	243		
Qy 755	ggaggcaggaaggg-agagtcagagagagaatggaagataccatgcttctaattttgaag	813		
Db 242	GGAGGCAGGAGGGTCAGAGTCACACAGAGACTGGAAGATGCCACGCTGTTGGCTTTGAAG	183		
Qy 814	atgagtgaggggccttagccaaatgcagg-tgtttttagaaggtagaaagccaa	872		
Db 182	GTGAAGAGAGGGGCCATGAGCCAGGCATGCCAGCAGCTTCCACAAGCTGGAAAAAGAAA	123		
Qy 873	gggaacggattctctcttagagtcctccggagggaacacacagctct--tgacacatggattt	930		
Db 122	GGAACAGACTCTCTCTGGAGCATCCAGAGGAGGACACAAACCCCTGCTAATACCTTGATNT	63		
Qy 931	cagctcagtgacacccattt	950		
Db 62	TAGCCACGTGAGATCCATTT	43		

Search completed: May 19, 2002, 08:44:01
Job time: 14234 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 10, 2002, 13:52:07 ; Search time 11.75 seconds
(without alignments)
474,302 Million cell updates/sec

Title: US-09-724-583-2
Perfect score: 818
Sequence: 1 MCSLPMARYIYIKYADOKAL.....QLTKSEPSARTKFFEQSW 152

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 100059 seqs, 36664827 residues
Total number of hits satisfying chosen parameters: 100059

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Swissprot_39:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	260.5	31.8	178	1 ILIX_RAT	P25086 rattus norv
2	257.5	31.5	178	1 ILIX_MOUSE	P25085 mus musculus
3	256	31.3	177	1 ILIX_PIG	Q29056 sus scrofa
4	241	29.5	177	1 ILIX_RABIT	P26890 oryctolagus
5	238.5	29.2	177	1 ILIX_HUMAN	P18510 homo sapien
6	238	29.1	177	1 ILIX_HORSE	Q18999 equus caball
7	232	28.4	174	1 ILIX_BOVIN	O77482 bos taurus
8	134.5	16.4	267	1 ILIB_PIG	P26889 sus scrofa
9	132	16.1	266	1 ILIB_SHEEP	P21621 ovis aries
10	124.5	15.2	269	1 ILIB_MOUSE	P10749 mus musculus
11	119.5	14.6	266	1 ILIB_CEREL	P51745 cervus elap
12	117	14.3	266	1 ILIB_BOVIN	P09428 bos taurus
13	112.5	13.8	268	1 ILIB_RAT	Q63264 rattus norv
14	111	13.6	266	1 ILIB_CAPHI	P79162 capra hircu
15	110.5	13.5	268	1 ILIB_RABIT	P14628 oryctolagus
16	106.5	13.0	268	1 ILIB_MACFA	P79182 macaca fasc
17	106.5	13.0	269	1 ILIB_CERTO	P46648 cercopithec
18	106.5	13.0	269	1 ILIB_MACMU	P48090 macaca mula
19	106.5	13.0	269	1 ILIB_MACNE	P51493 macaca neme
20	104.5	12.8	267	1 ILIB_HUMAN	P01584 homo sapien
21	94.5	11.6	267	1 ILIB_FELCA	P41687 felis silve
22	92	11.2	268	1 ILIB_HORSE	Q28386 equus caball
23	77	9.4	997	1 YPX2_CARFL	Q20256 caenorhabdi
24	76.5	9.4	520	1 CFP3_HUMAN	Q08477 homo sapien
25	71.5	8.7	4303	1 PKD1_HUMAN	P08161 homo sapien
26	71	8.7	2766	1 THYG_MOUSE	O08710 mus musculus
27	70.5	8.6	620	1 VLCS_MOUSE	Q35488 mus musculus
28	70.5	8.6	827	1 GAG_IPMA	P11365 mouse intra
29	69.5	8.5	214	1 GTH7_ARATH	Q96324 arabidopsis
30	69	8.4	355	1 KLC3_HUMAN	Q9nsko homo sapien
31	69	8.4	520	1 CFP2_HUMAN	P78329 homo sapien
32	69	8.4	700	1 PURL_HA1N1	Q9hr49 halobacteri
33	68.5	8.4	557	1 IGEB_MOUSE	P03975 mus musculus

34	67.5	8.3	271	1 ILIA_MACMU	P48089 macaca mula
35	67	8.2	665	1 V176_METTH	Q26278 methanobact
36	67	8.2	832	1 BGAL_ASPOF	P45592 asparagus o
37	66.5	8.1	271	1 ILIA_MACFA	P79340 macaca fasc
38	66.5	8.1	687	1 V541_GIALA	P32127 giardia lam
39	66	8.1	254	1 TPIS_BUCAP	Q59179 buchnera ap
40	66	8.1	290	1 MAB3_CABEL	O18214 caenorhabdi
41	66	8.1	438	1 GSA_STRCO	Q3f2s0 streptomyce
42	66	8.1	619	1 KLC3_MOUSE	Q9db55 mus musculu
43	65	7.9	531	1 G6PI_SYNY3	P52983 synecocyst
44	65	7.9	3206	1 POLG_PSBMV	P29152 p genome po
45	64.5	7.9	967	1 SVA_BOMMO	P21894 bombyx mori

ALIGNMENTS

RESULT 1					
ID ILIX_RAT					
AC P25086;	STANDARD;	PRT;	178 AA.		
DT 01-MAY-1992 (Rel. 22, Created)					
DT 01-MAY-1992 (Rel. 22, Last sequence update)					
DT 01-NOV-1995 (Rel. 32, Last annotation update)					
DE INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN PRECURSOR (IL-1RA) (IL-1RN)					
DE (IRAP).					
GN IL1RN OR IL-1RA.					
OS Rattus norvegicus (Rat).					
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;					
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Rattus.					
OX NCBI_TaxID=10116;					
RN [1]					
RP SEQUENCE FROM N.A.					
RX MEDLINE=91271363; PubMed=1828896;					
RA Eisenberg S.P., Brewer M.F., Verderber E., Heimdal P.,					
RA Brandhuber B.J., Thompson R.C.;					
RT "Interleukin 1 receptor antagonist is a member of the interleukin 1					
RT gene family: evolution of a cytokine control mechanism.";					
RL Proc. Natl. Acad. Sci. U.S.A. 88:5232-5236(1991).					
CC -!- RECEPTION: IL-1RA INHIBITS THE ACTIVITY OF IL-1 BY BINDING TO ITS					
CC -!- RECEPTOR. IL-1RA HAS NO IL-1 LIKE ACTIVITY.					
CC -!- SIMILARITY: BELONGS TO THE IL-1 FAMILY.					
CC This SWISS-PROT entry is copyright. It is produced through a collaboration					
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -					
CC the European Bioinformatics Institute. There are no restrictions on its					
CC use. by non-profit institutions as long as its content is in no way					
CC modified and this statement is not removed. Usage by and for commercial					
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/					
CC or send an email to license@isb-sib.ch).					
CC -----					
CC EMBL: M63101; AAA41434.1; .					
CC PIR: C40956; C40956.					
CC HSSP: P18510; ILIR.					
CC InterPro: IPR000975; Interleukin_1.					
CC Pfam: PF00340; IL1; 1.					
CC PRINTS: PR00264; INTERLEUKIN1.					
CC SMART: SM00125; IL1; 1.					
CC PROSITE: PS00253; INTERLEUKIN_1; 1.					
CC Glycoprotein; Signal.					
CC FT SIGNAL 1 26 BY SIMILARITY.					
CC FT CHAIN 27 178 INTERLEUKIN-1 RECEPTOR ANTAGONIST					
CC FT PROTEIN.					
CC FT DISULFID 92 142 BY SIMILARITY.					
CC FT CARBOHYD 110 110 N-LINKED (GLCNAC...) (POTENTIAL).					
CC SQ SEQUENCE 178 AA; 20282 MW; F3A5754FB6C51B03 CRC64;					

Query Match 31.8%; Score 260.5; DB 1; Length 178;
Best Local Similarity 44.5%; Pred. No. 2.7e-20;
Matches 61; Conservative 16; Mismatches 53; Indels 7; Gaps 4;
QY 16 DQKALYTRDGLLVGDPVADNC-CAEKICTLPNRGLDRTKVPFIIGGSRCLACVETE 74

```

Db 45 NQFTYLRNNQIAGYLOGPNTKLEKIDMVP---IDFRNV--FLIGHGKGLCLSCVKS 99
Qy 75 EGPSSQLQEDVNTIELYKGGEEATRTFFQSSGSAFRLEAAAWPGWFLCGPAPQPOFVOL 134
Db 100 DDTKLQLEEVNITDLNKKNEEDKRFTRISSETGPTTSFESLACPGWFLCTTLEADHPVSL 159
Qy 135 TK-ESEPSARTKFFYEQ 150
Db 160 TNPPEPCTVTRFYQE 176

RESULT 2
IL1X MOUSE STANDARD; PRT; 178 AA.
AC P25085;
DT 01-MAY-1992 (Rel. 22, Created)
DT 01-MAY-1992 (Rel. 22, Last sequence update)
DT 01-NOV-1997 (Rel. 35, Last annotation update)
DB INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN PRECURSOR (IL-1RA) (IL-1RN) (IRAP).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=91250712; PubMed=1828262;
RA Zahedi K., Seldin M.F., Rits M., Ezekowitz R.A., Whitehead A.S.;
RT "Mouse IL-1 receptor antagonist protein. Molecular characterization,
RT gene mapping, and expression of mRNA in vitro and in vivo."
RL J. Immunol. 146:4228-4233(1991).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=91316273; PubMed=1830498;
RA Matsushima H., Roussel M.F., Matsushima K., Hishinuma A., Sherr C.J.;
RT "Cloning and expression of murine interleukin-1 receptor antagonist
RT in macrophages stimulated by colony-stimulating factor 1."
RL Blood 78:616-623(1991).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=SWISS;
RX MEDLINE=94217131; PubMed=8003626;
RA Zahedi K.A., Uhlar C.M., Rits M., Prada A.E., Whitehead A.S.;
RT "The mouse interleukin 1 receptor antagonist protein: gene structure
RT and regulation in vitro."
RL Cytokine 6:1-9(1994).
RN [4]
RP SEQUENCE OF 7-178 FROM N.A.
RX MEDLINE=91271363; PubMed=1828896;
RA Eisenberg S.P., Brewer M.T., Verderber E., Heimdal P.,
RA Brandhuber B.J., Thompson R.C.;
RT "Interleukin 1 receptor antagonist is a member of the interleukin 1
RT gene family: evolution of a cytokine control mechanism."
RL Proc. Natl. Acad. Sci. U.S.A. 88:5232-5236(1991).
RN [5]
RP SEQUENCE OF 23-178 FROM N.A.
RX MEDLINE=92037824; PubMed=1834470;
RA Shuck M.E., Pessalu T.E., Tracey D.E., Bienkowski M.J.;
RT "Cloning, heterologous expression and characterization of murine
RT interleukin 1 receptor antagonist protein."
RL Eur. J. Immunol. 21:2775-2780(1991).
CC -!- FUNCTION: IL-1RA INHIBITS THE ACTIVITY OF IL-1 BY BINDING TO ITS
CC RECEPTOR. IL-1RA HAS NO IL-1 LIKE ACTIVITY.
CC -!- SIMILARITY: BELONGS TO THE IL-1 FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/

```

```

or send an email to license@isb-sib.ch).
CC -----
CC EMBL; M74294; AAA39309.1; -
CC EMBL; M64404; AAA39277.1; -
CC EMBL; L32838; AAA20576.1; -
CC EMBL; M57525; AAA39278.1; -
CC EMBL; M63100; AAA39310.1; -
CC EMBL; S64082; AAB20265.1; -
CC PIR; B40956; B40956.
CC PIR; A44610; A44610.
CC HSSP; P18510; IIRA.
CC MGD; MGI:96547; Il1rn.
CC InterPro; IPR000975; Interleukin_1.
CC Pfam; PF00340; IL1; 1.
CC PRINTS; PR00264; INTERLEUKIN1.
CC SMART; SM00125; IL1; 1.
CC PROSITE; PS00253; INTERLEUKIN_1; 1.
KW Glycoprotein; Signal.
FT SIGNAL 1 26 BY SIMILARITY.
FT CHAIN 27 178 INTERLEUKIN-1 RECEPTOR ANTAGONIST
FT PROTEIN.
FT DISULFID 92 142 BY SIMILARITY.
FT CARBOHYD 110 110 N-LINKED (GLCNAC... ) (POTENTIAL).
SQ SEQUENCE 178 AA; 20274 MW; 84AA002A3119C024 CRC64;

Query Match 31.5%; Score 257.5; DB 1; Length 178;
Best Local Similarity 44.5%; Pred. No. 5.5e-20;
Matches 61; Conservative 16; Mismatches 53; Indels 7; Gaps 4;

Qy 16 DOKALYTRDGLLVGDDVDVADNC-CARKICTLPNRCIDRTKVPFLGIGGSRCLACVETE 74
Db 45 NOKTYLANNOLIAGYLQGNKLEEKIDMVP---IDLHSV--FLIGHGKGLCLSCAKSG 99
Qy 75 EGPSSQLQEDVNVIELYKGGEEATRTFFQSSGSAFRLEAAAWPGWFLCGPAPQPOVOL 134
Db 100 DDTKLQLEEVNITDLNKKNEEDKRFTRISSETGPTTSFESACPGWFLCTTLEADRPVSL 159
Qy 135 TK-ESEPSARTKFFYEQ 150
Db 160 TNPPEPCTVTRFYQE 176

RESULT 3
IL1X PIG STANDARD; PRT; 177 AA.
AC Q29056;
DT 15-DEC-1998 (Rel. 37, Created)
DT 15-DEC-1998 (Rel. 37, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN PRECURSOR (IL-1RA) (IL-1RN) (IRAP).
GN IL1RN OR IRAP1.
OS Sus scrofa (Pig).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
OX NCBI_TaxID=9823;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CROSSBREED; TISSUE=Lung;
RA Yin J., Murtaugh M.P.;
RT "Characterization of IRAP in morphine treated pig."
RL Submitted (MAY-1996) to the EMBL/GenBank/DBJ databases.
CC -!- FUNCTION: IL-1RA INHIBITS THE ACTIVITY OF IL-1 BY BINDING TO ITS
CC RECEPTOR. IL-1RA HAS NO IL-1 LIKE ACTIVITY.
CC -!- SIMILARITY: BELONGS TO THE IL-1 FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/

```

<hr/>					
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).				
CC	<hr/>				
DR	EMBL:	S68977:	AAB30093.1;	-	
DR	EMBL:	M57526:	AAA31374.1;	-	
DR	EMBL:	D21832:	BAA04860.1;	-	
DR	PIR:	A54377:	A54377.		
DR	HSP:	PI8510:	IILR.		
DR	InterPro:	IPR000975:	Interleukin_1.		
DR	Fam:	PF00340:	ILI; 1.		
DR	PRINTS:	PR00264:	INTERLEUKIN1.		
DR	SMART:	SM00125:	IL1; 1.		
DR	PROSITE:	PS00253:	INTERLEUKIN_1; 1.		
KW	Glycoprotein:	Signal.			
FT	SIGNAL	1	25	BY SIMILARITY.	
FT	CHAIN	26	177	INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN.	
FT	DISULFID	91	141	BY SIMILARITY.	
FT	CARBOHYD	109	109	N-LINKED (GLCNAC..)(POTENTIAL).	
SQ	SEQUENCE	177 AA:	20214 MW; F5BC087F057FEAF CRC64;		
<hr/>					
Query Match 29.5%; Score 241; DB 1; Length 177;					
Best Local Similarity 39.2%; Pred. No. 2.9e-18;					
Matches 60; Conservative 22; Mismatches 57; Indels 14; Gaps 5;					
<hr/>					
QY	2	CSLPMARYIYIKVADOKALYTRDQLLVGPVDNDC-CAEICTLPNRGLDRTKVP--IF 58			
Db	33	CRMOAQRIVDV---NQKTFYLRNNVLGVYLOGPNAKLEERIDVVPLE-----PQLLF 82			
QY	59	LGIQGSRCLACVEETGSPSLQLEDVAIELYKGGEATRTFFQSSSGSAFLAAAWP 118			
Db	83	LGIQNGKLCSUCVKRSDDKKHLGAVNLDTLGKNKEQDKRFTFRSNSGPTTFESASCP 142			
QY	119	GNFLCGPAEPQQPVLUKTESEPS-ARTKFYFEQ 150			
Db	143	GNFLCTALEADQPVSUTNTPDSDISVVTKFYFQE 175			
<hr/>					
RESULT	5				
ID	ILIX_HUMAN				
AC	PI8510;				
DT	01-NOV-1990 (Rel. 16, Created)				
DE	01-NOV-1990 (Rel. 16, Last sequence update)				
DE	20-AUG-2001 (Rel. 40, Last annotation update)				
DE	INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN PRECURSOR (IL-1RA) (ICIL-1RA) (IRAP) (IL-1RN).				
GN	IL1RN OR IL1RA.				
OS	Homo sapiens (Human).				
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
OX	NCBI_TaxId=9606;				
RX	[1]				
RP	SEQUENCE FROM N.A.				
RP	MEDLINE=90220867; PubMed=2139180;				
RA	Cartier D.B., Deibel M.R. Jr., Dunn C.J., Tomich C.S.C., Laborde A.L., Slightom J.I., Berger A.E., Bienkowski M.J., Sun F.F., McEwan R.N., Harris P.K.W., Yem A.W., Waszak G.A., Chosay J.G., Sieu L.C., Hardee M.M., Zurcher-Neely H.A., Reardon I.M., Heinrichson R.L., Truesdell S.E., Shelly J.A., Eessalu T.E., Taylor B.M., Tracey D.E.; "Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein.";				
RL	Nature 344:633-638(1990).				
RP	[2]				
RP	SEQUENCE FROM N.A.				
RP	MEDLINE=90126931; PubMed=2127201.				

RA Eisenberg S.P., Evans R.J., Arend W.P., Verderber E., Brewer M.T.,
RA Hannum C.H., Thompson R.C.;
RT "Primary structure and functional expression from complementary DNA
RT of a human interleukin-1 receptor antagonist.";
RL Nature 343:341-346(1990).
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE-91271363; PubMed=1828896;
RA Eisenberg S.P., Brewer M.T., Verderber E., Heimdal P.,
RA Brandhuber B.J., Thompson R.C.;
RT "Interleukin 1 receptor antagonist is a member of the interleukin 1
RT gene family: evolution of a cytokine control mechanism.";
RL Proc. Natl. Acad. Sci. U.S.A. 88:5232-5236(1991).
RN [4]
RP SEQUENCE FROM N.A.
RX MEDLINE-92338323; PubMed=1385987;
RA Lennard A., Gorman P., Carrier M., Griffiths S., Scotney H.,
RA Sheer D., Solari R.;
RT "Cloning and chromosome mapping of the human interleukin-1 receptor
RT antagonist gene.";
RL Cytokine 4:83-89(1992).
RN [5]
RP SEQUENCE FROM N.A.
RX MEDLINE-97146044; PubMed=8992991;
RA Jenkins J.K., Drong R.F., Shuck M.E., Bienkowski M.J., Slightom J.L.,
RA Arend W.P., Smith M.F. Jr.;
RT "Intracellular IL-1 receptor antagonist promoter: cell type-specific
RT and inducible regulatory regions.";
RL J. Immunol. 158:748-755(1997).
RN [6]
RP SEQUENCE OF 26-45.
RX MEDLINE-90136920; PubMed=2137200;
RA Hannum C.H., Wilcox C.J., Arend W.P., Joslin F.G., Dripps D.J.,
RA Heimdal P.L., Arnes L.G., Sommer A., Eisenberg S.P., Thompson R.C.;
RT "Interleukin-1 receptor antagonist activity of a human interleukin-1
RT inhibitor.";
RL Nature 343:336-340(1990).
RN [7]
RP SEQUENCE OF 26-52.
RX MEDLINE-90354444; PubMed=2143761;
RA Bienkowski M.J., Bessalu T.E., Berger A.E., Truesdell S.E.,
RA Shelly J.A., Laborde A.L., Zurcher-Neely H.A., Reardon I.M.,
RA Heinrikson R.L., Chosay J.G., Tracey D.E.;
RT "Purification and characterization of interleukin 1 receptor level
RT antagonist proteins from FHP-1 cells.";
RL J. Biol. Chem. 265:14503-14511(1990).
RN [8]
RP SEQUENCE FROM N.A. (INTRACELLULAR FORM).
RX MEDLINE-91219436; PubMed=1827201;
RA Haskill S., Martin G., van Le L., Morris J., Peace A., Biglier C.F.,
RA Jaffe G.J., Hammerberg C., Sporn S.A., Fong S., Arend W.P., Ralph P.;
RT "cDNA cloning of an intracellular form of the human interleukin 1
RT receptor antagonist associated with epithelium";
RL Proc. Natl. Acad. Sci. U.S.A. 88:3661-3665(1991).
RN [9]
RP STRUCTURE BY NMR.
RX MEDLINE-92297633; PubMed=1534997;
RA Stockman B.J., Scchill T.A., Roy M., Ulrich E.L., Strakalaitis N.A.,
RA Brunner D.P., Yem A.W., Deibel M.R. Jr.;
RT "Secondary structure and topology of interleukin-1 receptor
RT antagonist protein determined by heteronuclear three-dimensional NMR
RT spectroscopy.";
RL Biochemistry 31:5237-5244(1992).
RN [10]
RP STRUCTURE BY NMR.
RX MEDLINE-94320651; PubMed=8045306;
RA Stockman B.J., Scchill T.A., Strakalaitis N.A., Brunner D.P.,
RA Yem A.W., Deibel M.R. Jr.;
RT "Solution structure of human interleukin-1 receptor antagonist
RT protein.";
RL FEBS Lett. 349:79-83(1994).
RN [11]
RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).

RX MEDLINE-94230368; PubMed=8175703;
RA Vigers G.P.A., Caffes P., Evans R.J., Thompson R.C., Eisenberg S.P.,
RA Brandhuber B.J.;
RT "X-ray structure of interleukin-1 receptor antagonist at 2.0-A
RT resolution.";
RL J. Biol. Chem. 269:12874-12879(1994).
RN [12]
RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS).
RX MEDLINE-95172072; PubMed=7867645;
RA Schreuder H.A., Rondeau J.-M., Tardif C., Soffientini A., Sarubbi E.,
RA Akeson A., Bowlin T.L., Yanofsky S., Barrett R.W.;
RT "Refined crystal structure of the interleukin-1 receptor antagonist.
RT Presence of a disulfide link and a cis-proline.";
RL Eur. J. Biochem. 227:838-847(1995).
RN [13]
RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 32-177 IN COMPLEX WITH IL1R.
RX MEDLINE-97215904; PubMed=9062194;
RA Schreuder H., Tardif C., Trump-Kallmeyer S., Soffientini A.,
RA Sarubbi E., Akeson A., Bowlin T., Yanofsky S., Barrett R.W.;
RT "A new cytokine-receptor binding mode revealed by the crystal
RT structure of the IL-1 receptor with an antagonist.";
RL Nature 386:194-200(1997).
CC -!- FUNCTION: IL-IRA INHIBITS THE ACTIVITY OF IL-1 BY BINDING TO ITS
CC RECEPTOR. IL-IRA HAS NO IL-1 LIKE ACTIVITY.
CC -!- SUBCELLULAR LOCATION: SECRETED OR INTRACELLULAR (THE VARIANT
CC FORM).
CC -!- ALTERNATIVE PRODUCTS: 2 ISOFORMS ARE PRODUCED BY ALTERNATIVE
CC SPLICING.
CC -!- TISSUE SPECIFICITY: THE INTRACELLULAR FORM OF IL-IRA IS
CC PREDOMINANTLY EXPRESSED IN EPITHELIAL CELLS.
CC -!- SIMILARITY: BELONGS TO THE IL-1 FAMILY.
CC WWW="http://www.indsystems.com/cyt_cat/illra.html".
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; M55646; AAA59138.1; -
CC EMBL; M63099; AAB41943.1; -
CC EMBL; X52015; CAA36262.1; -
CC EMBL; X53296; CAA37386.1; -
CC EMBL; X64532; CAA45832.1; -
CC EMBL; U65590; AAB92268.1; -
CC EMBL; U65590; AAB92270.1; -
CC PIR; A30368; A30368.
CC PIR; A37822; A37822.
CC PIR; S08160; S08160.
CC PIR; S08159; S08159.
CC PIR; A40956; A40956.
CC PIR; A39386; A39386.
CC PDB; 1LTN; 30-APR-94.
CC PDB; 2IRT; 15-OCT-94.
CC PDB; 1IRP; 27-FEB-95.
CC PDB; 1ILR; 07-FEB-95.
CC PDB; 1ILT; 01-APR-95.
CC PDB; 1IRA; 17-JUN-98.
CC Aarhus/Ghent-2DPAGE: 7104; IEF.
CC Aarhus/Ghent-2DPAGE: 7105; IEF.
CC MIM; 147679; -
CC InterPro: IPR000975; Interleukin_1.
CC Pfam: PF00340; IL1; 1.
CC PRINTS: PRO0264; INTERLEUKIN1.
CC SMART: SM00125; IL1; 1.
CC PROSITE: PS00253; INTERLEUKIN_1.
CC Glycoprotein; Signal; Alternative splicing; 3D-structure.
CC SIGNAL 1 25
CC CHAIN 26 177 INTERLEUKIN-1 RECEPTOR ANTAGONIST
CC PROTEIN.
CC FT
CC FT

FT	SIGNAL		1	25	BY SIMILARITY.
FT	CHAIN		26	177	INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN.
FT					BY SIMILARITY.
FT	DISULFID		91	141	N-LINKED (GLCNAC..)
FT	CARBOHYD		109	109	P -> L (IN REF. 2).
FT	CONFLICT		19		F -> L (IN REF. 2).
FT	SEQUENCE		177 AA;	20459 MW; 1ABC377FFICF80B CRC64;	
ST					
Query Match				29.1%; Score 238; DB 1; Length 177;	
Best Local Similarity				39.7%; Pred.No.6.le-18;	
Matches				60; Conservative 19; Mismatches 62; Indels 10; Gaps	
QY					
2	CSLPMARYIIKYADOKALYTRDGQLLVGDPVADNC-CAEKICTPLNRGLDRTKVPFLG 160				
DB	:	:	:	:	:
33	KMQAQRIVDW---NQKTFYRNQNLVAGYLQESNTKLQEKIDVVPIE-----PDALFLG 84				
QY	61	IQQSGRLCAVCETEPEGSLOLEDVINIELLYKGGEATRTFTFGSSGSAFRLEAAAMPGW 120			
DB	:	:	:	:	:
85	LHGRRKLCLAVCKGDIEIRPQEAVEANITDSKNKENKRFTFIKSNPGTTSFSASAACPW 144				
QY	121	FLCCGPAPPOQPVOILT-KSEPSARTKEFYEQ 150			
DB		: : : :			
145	FLCTAQADERPVSLTNKPESFMVTKEYLQE 175				
RESULT					
7					
ILIX_BOVIN					
ID	ILIX_BOVIN	STANDARD;	PRT;	174 AA.	
OC	A07482;				
DT	15-DEC-1998 (Rel. 37; Created)				
DT	15-DEC-1998 (Rel. 37; Last sequence update)				
DE	15-JUL-1999 (Rel. 38; Last annotation update)				
DE	INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN PRECURSOR (IL-LRA) (IL-LRn)				
GN	(IRAP.)				
OS	IlLRN.				
OC	Bos taurus (Bovine).				
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
OC	Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoides;				
OX	Bovidae; Bovinae; Bos.				
OX	NCBI_TaxID=9913;				
RN	[1]				
RX	SEQUENCE FROM N.A.				
RX	MEDLINE=98305607; PubMed=9643454;				
RA	Kirisawa K., Fukuda T., Yamanaka H., Hagiwara K., Goto M., Obata Y.,				
RA	Yoshino T., Iwai H.;				
RT	"Enzymatic amplification and expression of bovine interleukin-1				
RT	receptor antagonist cDNA,"				
RL	Vet. Immunol. Immunopathol. 62:197-208(1998).				
CC	-!- FUNCTION: IL-LRA INHIBITS THE ACTIVITY OF IL-1 BY BINDING TO ITS				
CC	RECEPTOR. IL-LRA HAS NO IL-1 LIKE ACTIVITY.				
CC	-!- SIMILARITY: BELONGS TO THE IL-1 FAMILY.				
CC					
CC	This SWISS-PROT entry is copyright. It is produced through a collabor				
CC	between the Swiss Institute of Bioinformatics and the EMBL Outstat				
CC	the European Bioinformatics Institute. There are no restrictions on				
CC	use by non-profit institutions as long as its content is in no				
CC	modified and this statement is not removed. Usage by and for commo				
CC	entities requires a license agreement (See http://www.isb-sib.ch/anno				
CC	or send an email to license@isb-sib.ch).				
CC					
EMBL; AB005148; BAAJ1854.1; -					
DR	InterPro; IPRO00975; Interleukin_1.				
DR	pfam; PF00340; IL1; 1.				
DR	PRINTS; PR00264; INTERLEUKIN1.				
DR	SMART; SMART0125; IL1; 1.				
DR	PROSITE; PS00253; INTERLEUKIN_1; 1.				
KW	Glycoprotein; Signal,				
FT	SIGNAL		1	23	BY SIMILARITY.
FT	CHAIN		24	174	INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN.
FT					BY SIMILARITY.
DISULFID			89	139	N-LINKED (GLCNAC..)
FT	CARBOHYD		107	107	F -> L (IN REF. 2).
FT	SEQUENCE				

```

DR SMART; SMO0125; IL1; 1
KW PROSITE; PS00253; INTERLEUKIN_1; 1
KW Cytokine; Macrophage; Mitogen; Inflammatory response; Pyrogen.
FT PROPEP 1 114 BY SIMILARITY.
FT CHAIN 115 267 INTERLEUKIN-1 BETA.
SQ SEQUENCE 267 AA; 30404 MW; 7F6B92B784D5086F CRC64;

Query Match 16.4%; Score 134.5; DB 1; Length 267;
Best Local Similarity 31.2%; Pred. No. 7.3e-07;
Matches 30; Conservative 20; Mismatches 45; Indels 1; Gaps 1;

QY 54 KVIPLFIQGSGRLACVETEGETPSLQEDVNIEELYKGGEATRTFFQSSGSAFRLE 113
    :::: |::: |::: |::: |::: |::: |::: |::: |::: |::: |::: |
Db 169 KIPVTGLIGKNLYSCVMKDNTPQLQEDID-PKRYPKRDMKRKFVFYKTEIKNRVEF 227

QY 114 AANPGWFLCGPAEPOOPVOLTKSEPSARTKYEE 149
    :|::: |::: |::: |::: |::: |::: |::: |::: |::: |::: |
Db 228 SALYPNMTIISTSOAEOKPVFLNGSKGRDDTDTME 263

RESULT 9
IL1B_SHEEP STANDARD; PRT; 266 AA.
ID IL1B_SHEEP
CD P21621;
DT 01-MAY-1991 (Rel. 18, Created)
DT 01-WAR-1992 (Rel. 21, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE INTERLEUKIN-1 BETA PRECURSOR (IL-1 BETA).
GN IL1B.
OS Ovis aries (Sheep).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Caprinae; Ovis.
OX NCBI_TaxID=9940.
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92119335; PubMed=1840515;
RA Seow H.F., Rothel J.S., David M.J., Wood P.R.;
RT "Nucleotide sequence of ovine macrophage interleukin-1 beta cDNA.";
RL DNA Seq. 1:423-426;(1991).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=91088326; PubMed=2263490;
RA Fiskerstrand C., Sardan D.;
RT "Nucleotide sequence of ovine interleukin-1 beta.";
RL Nucleic Acids Res. 18:7165-7165(1990).
CC -! FUNCTION: PRODUCED BY ACTIVATED MACROPHAGES, IL-1 STIMULATES
CC THYMOCYTE PROLIFERATION BY INDUCING IL-2 RELEASE, B-CELL
CC MATURATION & PROLIFERATION, & FIBROBLAST GROWTH FACTOR ACTIVITY.
CC IL-1 PROTEINS ARE INVOLVED IN THE INFLAMMATORY RESPONSE, BEING
CC IDENTIFIED AS ENDOGENOUS PYROGENS, AND ARE REPORTED TO STIMULATE
CC THE RELEASE OF PROSTAGLANDIN AND COLLAGENASE FROM SYNOVIAL CELLS.
CC -! SUBUNIT: MONOMER.
CC -! DOMAIN: THE SIMILARITY AMONG THE IL-1 PRECURSORS SUGGESTS THAT THE
CC AMINO ENDS OF THESE PROTEINS SPECIFIC AS YET UNDEFINED FUNCTION.
CC -! MISCELLANEOUS: THE LACK OF A SPECIFIC HYDROPHOBIC SEGMENT IN THE
CC PRECURSOR SEQUENCE SUGGESTS THAT IL-1 IS RELEASED BY DAMAGED CELLS
CC OR IS SECRETED BY A MECHANISM DIFFERING FROM THAT USED FOR OTHER
CC SECRETORY PROTEINS.
CC -! SIMILARITY: BELONGS TO THE IL-1 FAMILY.
-----
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
-----
CC EMBL; X54796; CAA38566.1; -.
CC EMBL; X56972; CAA40293.1; -.
CC PIR; S13092; S13092.

```

```

DR PIR: S13810; S13810.
DR PIR: S23010; S23010.
DR HSP: P01584; 411B.
DR InterPro: IPR002348; IL1_HBGF.
DR InterPro: IPR000975; Interleukin_1.
DR InterPro: IPR003502; Interleukin_1_prop.
DR Pfam: PF00340; IL1; 1.
DR Pfam: PF02394; IL1_propep; 1.
DR PRINTS: PR00262; IL1HBGF.
DR PRINTS: PR00264; INTERLEUKIN1.
DR SMART: SM00125; IL1; 1.
DR PROSITE: PS00253; INTERLEUKIN_1.
KW Cytokine; Macrophage; Mitogen; Inflammatory response; Pyrogen.
FT PROPEP 1 113
FT CHAIN 114 266 INTERLEUKIN-1 BETA.
FT CONFLICT 14 14 Y -> C (IN REF. 2).
FT CONFLICT 55 55 Q -> K (IN REF. 2).
FT CONFLICT 64 64 V -> A (IN REF. 2).
FT CONFLICT 145 145 P -> L (IN REF. 2).
SQ SEQUENCE 266 AA; 30717 MW; BDED07B58224AB78 CRC64;

Query Match 16.1%; Score 132; DB 1; Length 266;
Best Local Similarity 25.4%; Pred. No. 1.3e-06;
Matches 34; Conservative 28; Mismatches 44; Indels 28; Gaps 3;

QY 16 DOKALYTRDGLLVDPVADNCCAEKICTLPNRGLDR-----TKYPIELG 60
Db 127 EKSL-----VLDSPCVLKALHLSQENSRVFCMSFVGGERDNKIPVALG 174
QY 61 IGGSRGIACVETEGPSQLQEDVNTIELYKGGEATRTFFQSSGSAFLLEAAAPGW 120
Db 175 IRDKNLYLSCVKGGDTPTLQLEVD-PKVPKRNKREKRVFYKTEIKNTVEFESLYPNW 233
QY 121 FLCGPAEPQOPVOL 134
Db 234 YISTQIEKEPVFL 247

RESULT 10
IL1B_MOUSE STANDARD; PRT: 269 AA.
AC P10749;
DT 01-JUL-1989 (Rel. 11, Created)
DT 01-JUL-1989 (Rel. 11, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE INTERLEUKIN-1 BETA PRECURSOR (IL-1 BETA).
GN IL1B.
OS Mus musculus (Mouse).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxID=10090;
[1]
RN SEQUENCE FROM N.A.
RX MEDLINE=87058957; PubMed=3491144;
RA Gray P.W., Glaister D., Chen E., Goeddel D.V., Pennica D.;
RT "Two interleukin 1 genes in the mouse: cloning and expression of the
RL cDNA for murine interleukin 1 beta.";
RN J. Immunol. 137:3644-3648(1986).
[2]
RN SEQUENCE FROM N.A.
RX MEDLINE=87117546; PubMed=3492706;
RA Telford J.L., Macchia G., Massone A., Carinci V., Palla E., Melli M.;
RT "The murine interleukin 1 beta gene: structure and evolution.";
RL Nucleic Acids Res. 14:9955-9963(1986).
[3]
RN SEQUENCE OF 118-139.
RX MEDLINE=88229074; PubMed=2967326;
RA Huang J.J., Newton R.C., Rutledge S.J., Horuk R., Matthew J.B.,
RA Covington M., Lin Y.;
RT "Characterization of murine IL-1 beta. Isolation, expression, and
RT purification.";
RL J. Immunol. 140:3838-3843(1988).

```

```

RN [4]
RX X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).
MEDLINE=92222792; PubMed=1807351;
RA van Oostrum J., Priestle J.P., Grutter M.G., Schmitz A.;
RT "The structure of murine interleukin-1 beta at 2.8-A resolution.";
RL J. Struct. Biol. 107:189-195(1991).
CC -!- FUNCTION: PRODUCED BY ACTIVATED MACROPHAGES. IL-1 STIMULATES
CC THYMOCYTE PROLIFERATION BY INDUCING IL-2 RELEASE, B-CELL
CC MATURATION & PROLIFERATION, & FIBROBLAST GROWTH FACTOR ACTIVITY.
CC IL-1 PROTEINS ARE INVOLVED IN THE INFLAMMATORY RESPONSE, BEING
CC IDENTIFIED AS ENDOGENOUS PYROGENS, AND ARE REPORTED TO STIMULATE
CC THE RELEASE OF PROSTAGLANDIN AND COLLAGENASE FROM SYNOVIAL CELLS.
CC -!- SUBUNIT: MONOMER.
CC -!- DOMAIN: THE SIMILARITY AMONG THE IL-1 PRECURSORS SUGGESTS THAT THE
CC AMINO ENDS OF THESE PROTEINS SERVE SOME AS YET UNDEFINED FUNCTION.
CC -!- MISCELLANEOUS: THE LACK OF A SPECIFIC HYDROPHOBIC SEGMENT IN THE
CC PRECURSOR SEQUENCE SUGGESTS THAT IL-1 IS RELEASED BY DAMAGED CELLS
CC OR IS SECRETED BY A MECHANISM DIFFERING FROM THAT USED FOR OTHER
CC SECRETORY PROTEINS.
CC -!- SIMILARITY: BELONGS TO THE IL-1 FAMILY.
-----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
-----
DR EMBL: M15131; AAA39276.1; -.
DR EMBL: X04964; CAA28637.1; -.
DR PIR: A24719; A24719.
DR PIR: S13029; S13029.
DR PDB: 811B; 15-OCT-94.
DR PDB: 2M1B; 31-JAN-94.
DR MGD: MGI:96543; 111b.
DR InterPro: IPR002348; IL1_HBGF.
DR InterPro: IPR000975; Interleukin_1.
DR InterPro: IPR003502; Interleukin_1_prop.
DR Pfam: PF02394; IL1; 1.
DR Pfam: PF00340; IL1_propep; 1.
DR PRINTS: PR00262; IL1HBGF.
DR PRINTS: PR00264; INTERLEUKIN1.
DR SMART: SM00125; IL1; 1.
DR PROSITE: PS00253; INTERLEUKIN_1; 1.
KW Cytokine; Macrophage; Mitogen; Inflammatory response; Pyrogen;
KW 3D-structure.
FT PROPEP 1 117
FT CHAIN 118 269 INTERLEUKIN-1 BETA.
FT STRAND 123 129
FT TURN 130 131
FT STRAND 134 137
FT TURN 140 141
FT STRAND 143 146
FT TURN 150 154
FT STRAND 159 163
FT TURN 170 171
FT STRAND 173 179
FT TURN 180 181
FT STRAND 184 191
FT TURN 192 193
FT STRAND 194 201
FT TURN 204 206
FT HELIX 214 216
FT STRAND 217 222
FT STRAND 227 231
FT TURN 235 236
FT STRAND 238 242
FT STRAND 247 248
FT STRAND 250 252
FT STRAND 258 259
FT STRAND 262 266
SQ SEQUENCE 269 AA; 30931 MW; 734FAL7B02ED87EE CRC64;

```

```
Query Match 15.2%; Score 124.5; DB 1; Length 269;
Best Local Similarity 24.4%; Pred. No. 8.3e-06;
Matches 39; Conservative 28; Mismatches 52; Indels 41; Gaps 5;

QY 1 MCSLPMAR-YIIIVADQKALYTRD-----GQ-----LLVGPVADNCC 38
DB 115 VCDVPIQLHRLRDEQKSLVLSLDYELKALHLNGQINQVIFSFFVQGPSND--- 171
QY 39 AEKICTLNRGLDTRKPIPIFGTGGSRCLACVETETEGPSLOLEDVNIIEELKGGEATR 98
DB 172 -----KIPVALGKGNLYLSCVMKDGTPPTLQLESDPKQ-YPKKMKR 215
QY 99 FTFFOSSSGSAFRLEAAAWPGWFLCGPAEPQVPQVLTRES 138
DB 216 FVENKIEVSKVERESAEPFNWYISTQAEHRKPVFLGNNS 255

RESULT 11
IL1B_CEREL
ID IL1B_CEREL STANDARD; PRT; 266 AA.
AC P51745;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE INTERLEUKIN-1 BETA PRECURSOR (IL-1 BETA).
GN IL1B.
OS Cervus elaphus (Red deer).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Cervidae;
OC Cervidae; Cervinae; Cervus.
OX NCBI_TaxID=9860;
RN [1]
RP SEQUENCE FROM N.A.
RA Lockhart E.A.;
RL Submitted E.A.;
CC -!- FUNCTION: PRODUCED BY ACTIVATED MACROPHAGES, IL-1 STIMULATES
CC THYMOCYTE PROLIFERATION BY INDUCING IL-2 RELEASE, B-CELL
CC MATURATION & PROLIFERATION, & FIBROBLAST GROWTH FACTOR ACTIVITY.
CC IL-1 PROTEINS ARE INVOLVED IN THE INFLAMMATORY RESPONSE, BEING
CC IDENTIFIED AS ENDOGENOUS PYROGENS, AND ARE REPORTED TO STIMULATE
CC THE RELEASE OF PROSTAGLANDIN AND COLLAGENASE FROM SYNOVIAL CELLS.
CC -!- SUBUNIT: MONOMER.
CC -!- DOMAIN: THE SIMILARITY AMONG THE IL-1 PRECURSORS SUGGESTS THAT THE
CC AMINO ENDS OF THESE PROTEINS SERVE SOME AS YET UNDEFINED FUNCTION.
CC -!- MISCELLANEOUS: THE LACK OF A SPECIFIC HYDROPHOBIC SEGMENT IN THE
CC PRECURSOR SEQUENCE SUGGESTS THAT IL-1 IS RELEASED BY DAMAGED CELLS
CC OR IS SECRETED BY A MECHANISM DIFFERING FROM THAT USED FOR OTHER
CC SECRETORY PROTEINS.
CC -!- SIMILARITY: BELONGS TO THE IL-1 FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; U20500; AAA62234.1; -
CC HSSP; P01584; IHRB.
CC InterPro; IPR002348; IL1L_HBGF.
CC InterPro; IPR000975; Interleukin_1.
CC InterPro; IPR003502; Interleukin_1_prop.
CC Pfam; PF00340; IL1; 1.
CC Pfam; PF02394; IL1L_propep; 1.
CC PRINTS; PR00262; IL1HBGF.
CC PRINTS; PR00264; INTERLEUKIN1.
CC SMART; SM00125; IL1; 1.
CC PROSITE; PS00253; INTERLEUKIN_1; 1.
CC Cytokine; Macrophage; Mitogen; Inflammatory response; Pyrogen..
CC PROPEP 1 113 BY SIMILARITY.
CC -----

FT CHAIN 114 266 INTERLEUKIN-1 BETA.
SQ SEQUENCE 266 AA; 30629 MW; 4F40B4E6F0D9F060 CRC64;

Query Match 14.6%; Score 119.5; DB 1; Length 266;
Best Local Similarity 29.6%; Pred. No. 2.7e-05;
Matches 24; Conservative 22; Mismatches 34; Indels 1; Gaps 1;

QY 54 KVPFLIGGGSRCLACVETETEGPSLOLEDVNIIEELKGGEATRFTFFOSSSGSAFRLE 113
DB 168 KIPVALGIRDKNQYLSCVKKGDTPLQLEVD-PKYVPRNMEKRFVYKTEIKDVTVEE 226
QY 114 AAAPGWFLCGPAEPQVPQVQL 134
DB 227 SVLYPNWYISTSHPEKPVFL 247

RESULT 12
IL1B_BOVIN
ID IL1B_BOVIN STANDARD; PRT; 266 AA.
AC P09428;
DT 01-MAR-1989 (Rel. 10, Created)
DT 01-MAR-1989 (Rel. 10, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE INTERLEUKIN-1 BETA PRECURSOR (IL-1 BETA).
GN IL1B.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A.
RA Leong S.R.; Flagg G.M.; Lawman M.; Gray P.W.;
RL "The nucleotide sequence for the cDNA of bovine interleukin-1 beta.";
RT Nucleic Acids Res. 10:9054-9054(1988).
RN [2]
RP SEQUENCE FROM N.A.
RA MEDLINE=88318652; Pubmed=3262866;
RA Maliszewski C.R.; Baker P.E.; Schoenborn M.A.; Davis B.S.; Cosman D.;
RA Gillis S.; Cerretti D.P.;
RT "Cloning, sequence and expression of bovine interleukin 1 alpha and
RT interleukin 1 beta complementary DNAs.";
RL Mol. Immunol. 25:429-437(1988).
CC -!- FUNCTION: PRODUCED BY ACTIVATED MACROPHAGES, IL-1 STIMULATES
CC THYMOCYTE PROLIFERATION BY INDUCING IL-2 RELEASE, B-CELL
CC MATURATION & PROLIFERATION, & FIBROBLAST GROWTH FACTOR ACTIVITY.
CC IL-1 PROTEINS ARE INVOLVED IN THE INFLAMMATORY RESPONSE, BEING
CC IDENTIFIED AS ENDOGENOUS PYROGENS, AND ARE REPORTED TO STIMULATE
CC THE RELEASE OF PROSTAGLANDIN AND COLLAGENASE FROM SYNOVIAL CELLS.
CC -!- SUBUNIT: MONOMER.
CC -!- DOMAIN: THE SIMILARITY AMONG THE IL-1 PRECURSORS SUGGESTS THAT THE
CC AMINO ENDS OF THESE PROTEINS SERVE SOME AS YET UNDEFINED FUNCTION.
CC -!- MISCELLANEOUS: THE LACK OF A SPECIFIC HYDROPHOBIC SEGMENT IN THE
CC PRECURSOR SEQUENCE SUGGESTS THAT IL-1 IS RELEASED BY DAMAGED CELLS
CC OR IS SECRETED BY A MECHANISM DIFFERING FROM THAT USED FOR OTHER
CC SECRETORY PROTEINS.
CC -!- SIMILARITY: BELONGS TO THE IL-1 FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; M35589; AAA30585.1; -
CC EMBL; X12498; CAA31018.1; -
CC EMBL; M37211; AAA30584.1; -
CC PIR; J00010; ICB01B.
CC PIR; S01380; S01380.
```



```
DR InterPro: IPR002348; IL1_HGFG.  
DR InterPro: IPR000975; Interleukin_1.  
DR InterPro: IPR003502; Interleukin_1_prop.  
DR Pfam: PF00340; IL1: 1.  
DR Pfam: PF02394; IL1_propep: 1.  
DR PRINTS: PR00262; ILHBGF.  
DR PRINTS: PR00264; INTERLEUKIN_1.  
DR SMART: SM00125; IL1: 1.  
DR PROSITE: PS00253; INTERLEUKIN_1; 1.  
KW Cytokine; Macrophage; Mitogen; Inflammatory response; Pyrogen..  
FT PROPEP      116       BY SIMILARITY.  
FT CHAIN       117       268   INTERLEUKIN-1 BETA.  
SQ SEQUENCE    268 AA;  30644 MW;  109C19EBF69C242D CRC64;  
  
Query Match          13.8%; Score 112.5; DB 1; Length 268;  
Best Local Similarity 23.3%; Pred. No. 0.00015;  
Matches 35; Conservative 31; Mismatches 55; Indels 29; Gaps 5;  
  
Qy  1 MCSLPMARYI-IKYADKALYTRDGQLLVGDVPADVNNCCAEEKICTLPNRGLDR----- 52  
Db  114 VCDVPIRLHCLRDEQKC-----LVLSDP-----CELKALHLNQNISQQVVFSMS 161  
  
Qy  53 -----TKVIPFLIGGSRCACVETEGSPGLEVDNTEELYKGGEATRTFFQS 104  
Db  162 FVOGETSNDKIPVALGLUNLYSCVMKGGTPTQLQESVDPRQ-YPKMKERFRVENKI 220  
  
Qy  105 SSGSAFRLEAAANPGWFLCGPAEQPPVOL 134  
Db     : : : : :  
Db  221 EVKTRVEESAQFPNMVISTQAHRPVFL 250  
  
RESULT 14  
IL1B_CAPHI  
ID IL1B_CAPHI STANDARD; PRT; 266 AA.  
AC P79162;  
DT 15-DEC-1998 (Rel. 37, Created)  
DT 15-DEC-1998 (Rel. 37, Last sequence update)  
DT 30-MAY-2000 (Rel. 39, Last annotation update)  
DE INTERLEUKIN-1 BETA PRECURSOR (IL-1 BETA).  
GN IL1B.  
OC Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;  
OC Bovidae; Caprinae; Capra.  
OX NCBI_TaxID=9925;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Takakura H., Hashimoto O., Mori Y., Tatsumi M.;  
RT "Molecular cloning and expression of caprine IL-1alpha and  
RT IL-1beta".  
RT Submitted (JUN-1995) to the EMBL/GenBank/DDBJ databases.  
CC -! FUNCTION: PRODUCED BY ACTIVATED MACROPHAGES, IL-1 STIMULATES  
CC THYMOCYTE PROLIFERATION BY INDUCING IL-2 RELEASE, B-CELL  
CC MATURATION & PROLIFERATION, & FIBROBLAST GROWTH FACTOR ACTIVITY.  
CC IL-1 PROTEINS ARE INVOLVED IN THE INFLAMMATORY RESPONSE, BEING  
CC IDENTIFIED AS ENDOGENOUS PYOGENS, AND ARE REPORTED TO STIMULATE  
CC THE RELEASE OF PROSTAGLANDIN AND COLLAGENASE FROM SYNOVIAL CELLS  
CC (BY SIMILARITY).  
CC -! SUBUNIT: MONOMER (BY SIMILARITY).  
CC -! DOMAIN: THE SIMILARITY AMONG THE IL-1 PRECURSORS SUGGESTS THAT THE  
CC AMINO ENDS OF THESE PROTEINS SERVE SOME AS YET UNDEFINED FUNCTION.  
CC -! MISCELLANEOUS: THE LACK OF A SPECIFIC HYDROPHOBIC SEGMENT IN THE  
CC PRECURSOR SEQUENCE SUGGESTS THAT IL-1 IS RELEASED BY DAMAGED CELLS  
CC OR IS SECRETED BY A MECHANISM DIFFERING FROM THAT USED FOR OTHER  
CC SECRETORY PROTEINS.  
CC -! SIMILARITY: BELONGS TO THE IL-1 FAMILY.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage bv and for commercial  
CC purposes without prior permission from the copyright holder is prohibited.
```

```
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: D63351; BAA09675.1; --
CC InterPro: IPR002348; IL1_HBGF.
CC InterPro: IPR000975; Interleukin_1.
CC InterPro: IPR003502; Interleukin_1_prop.
CC Pfam: PF00340; IL1; 1.
CC DR PFam: PF02394; IL1_propep; 1.
CC DR PRINTS: PR00262; IL1HBGF.
CC DR PRINTS: PR00264; INTERLEUKIN1.
CC DR SMART: SM00125; IL1; 1.
CC DR PROSITE: PS00253; INTERLEUKIN_1; 1.
CC DR Cytokine; Macrophage; Mitogen; Inflammatory response; Pyrogen.
CC FT PROPEP 1 113 BY SIMILARITY.
CC CHAIN 114 266 INTERLEUKIN-1 BETA.
CC SEQUENCE 266 AA; 30769 MW; 59F7B39BD1D4DDA5 CRC64;

ery Match 13.6%; Score 111; DB 1; Length 266;
Best Local Similarity 23.9%; Pred. No. 0.00021;
Matches 32; Conservative 28; Mismatches 46; Indels 28; Gaps 3;

QY 16 DKALYTRDGLQGVADNCCAECTIPNRGLDR-----TKVPFIPLG 60
DB 127 EQKSL-----VLDSPCVLKALLHLLSQEMSRVWFCMSFVQGEERDNKIPVALG 174
QY 61 IGGSGRCACVETEGPSLOLEDVNTIELYKGGEEATRTFFOSSSGSAFRLFAAAWPGM 120
DB 175 IRDKNLYLSWKKGDPTPLQLEED-PKVIKPNKMKREKRVYKTEINTVEFESVLYPNW 233
QY 121 FLCGPAEPQOPVOL 134
DB 234 YISTSQIEKPVFL 247

RESULT 15
IL1B_RABIT STANDARD; PRT; 268 AA.
AC PI4628;
DT 01-APR-1990 (Rel. 14, Created)
DT 01-APR-1990 (Rel. 14, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE INTERLEUKIN-1 BETA PRECURSOR (IL-1 BETA) (LYMPHOCYTE PROLIFERATION
DE POTENTIATING FACTOR).
GN IL1B.
Oryctolagus cuniculus (Rabbit).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
NCBI_TaxID=9986;
[1]
SEQUENCE FROM N.A.
RX MEDLINE=89176242; PubMed=2784458;
RA Cannon J.G., Clark B.D., Wingfield P., Schmeissner U., Losberger C.,
RA Dinarello C.A., Shaw A.R.;
RT "Rabbit IL-1. Cloning, expression, biologic properties, and
RT transcription during endotoxemia."
RL J. Immunol. 142:2299-2306(1989).
RN [2]
SEQUENCE FROM N.A.
RX MEDLINE=88134238; PubMed=2449207;
RA Mori S., Goto F., Goto K., Ohkawara S., Maeda S., Shimada K.,
RA Yoshinaga M.;
RT "Cloning and sequence analysis of a cDNA for lymphocyte proliferation
RT potentiating factor of rabbit polymorphonuclear leukocytes:
RT identification of rabbit interleukin 1 beta."
RL Biochem. Biophys. Res. Commun. 150:1237-1243(1988).
RN [3]
SEQUENCE FROM N.A.
RX MEDLINE=89315178; PubMed=2787507;
RA Young P.R., Sylvester D.;
RT "Cloning of rabbit interleukin-1 beta: differential evolution of IL-1
RT alpha and IL-1 beta proteins."
```

```
RL Protein Eng. 2:545-551(1989).
CC -1- FUNCTION: PRODUCED BY ACTIVATED MACROPHAGES, IL-1 STIMULATES
CC THYMOCYTE PROLIFERATION BY INDUCING IL-2 RELEASE, B-CELL
CC MATURATION & PROLIFERATION, & FIBROBLAST GROWTH FACTOR ACTIVITY.
CC IL-1 PROTEINS ARE INVOLVED IN THE INFLAMMATORY RESPONSE, BEING
CC IDENTIFIED AS ENDOGENOUS PYROGENS, AND ARE REPORTED TO STIMULATE
CC THE RELEASE OF PROSTAGLANDIN AND COLLAGENASE FROM SYNOVIAL CELLS.
CC -1- SUBUNIT: MONOMER.
CC -1- DOMAIN: THE SIMILARITY AMONG THE IL-1 PRECURSORS SUGGESTS THAT THE
CC AMINO ENDS OF THESE PROTEINS SERVE SOME AS YET UNDEFINED FUNCTION.
CC -1- MISCELLANEOUS: THE LACK OF A SPECIFIC HYDROPHOBIC SEGMENT IN THE
CC PRECURSOR SEQUENCE SUGGESTS THAT IL-1 IS RELEASED BY DAMAGED CELLS
CC OR IS SECRETED BY A MECHANISM DIFFERING FROM THAT USED FOR OTHER
CC SECRETORY PROTEINS.
CC -1- SIMILARITY: BELONGS TO THE IL-1 FAMILY.
CC -----
CC THIS SWISS-PROT entry is copyrighted. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: D21835; BAA04863.1; -.
CC EMBL: M26295; AAA31373.1; -.
CC PIR: A27714; A27714.
CC PIR: JU0082; JU0082.
CC PIR: A30584; A30584.
CC HSSP: P01584; 1H1B.
CC InterPro: IPR002348; IL1_HBGF.
CC InterPro: IPR000975; Interleukin_1.
CC InterPro: IPR003502; Interleukin_1_prop.
CC Pfam: PF00340; IL1; 1.
CC Pfam: PF02394; IL1_propep; 1.
CC PRINTS: PR00262; IL1HBGF.
CC PRINTS: PR00264; INTERLEUKIN1.
CC SMART: SM00125; IL1; 1.
CC PROSITE: PS00253; INTERLEUKIN_1; 1.
CC Cytokine; Macrophage; Mitogen; Inflammatory response; Pyrogen.
KW PROPEP 1 116 INTERLEUKIN-1 BETA.
FT CHAIN 117 268
FT SEQUENCE 268 AA; 30665 MW; 55BF44DD78D1B297 CRC64;
SQ SEQUENCE 268 AA; 30665 MW; 55BF44DD78D1B297 CRC64;

Query Match 13.5%; Score 110.5; DB 1; Length 268;
Best Local Similarity 30.6%; Pred. No. 0.00024;
Matches 26; Conservative 16; Mismatches 42; Indels 1; Gaps 1;

QY 54 KVPFIIGGSGRCACVETEGPSLOLEDVNTIELYKGGEEATRTFFOSSSGSAFRL 113
DB 170 KIPVALGLRGKLYLSCVMKDDKPTLQLESVD-PNRYPKKKMKRKFVFNKTKDKLEFE 228
QY 114 AAAMPGWFLCGPAEPQOPVOLTKES 138
DB 229 SAQFPNMYISTSTQTEYMPVFLGNNS 253

Search completed: May 10, 2002, 13:54:03
Job time: 116 sec
```

Result No.	Query			DB	ID	Description
	Score	Match	Length			
1	991.2	97.2	998	4	US-09-316-081-1	Sequence 1, Appli
2	991.2	97.2	998	4	US-09-316-081-3	Sequence 3, Appli
3	110.8	10.9	1282	4	US-09-417-455-4	Sequence 4, Appli
4	110.8	10.9	1282	4	US-09-348-942-4	Sequence 4, Appli
5	110.8	10.9	2648	4	US-09-417-455-6	Sequence 6, Appli
6	110.8	10.9	2648	4	US-09-348-942-6	Sequence 6, Appli
7	103.4	10.1	1710	3	US-09-000-630C-1	Sequence 1, Appli
8	103.4	10.1	1710	3	US-08-862-730C-1	Sequence 1, Appli
9	97.4	9.5	176373	3	US-08-128-155-17	Sequence 17, Appl
c 10	97	9.5	246240	2	US-08-724-394A-20	Sequence 20, Appl
c 11	97	9.5	246240	2	US-08-724-394A-21	Sequence 21, Appl
c 12	97	9.5	246240	2	US-08-724-394A-22	Sequence 22, Appl
13	95	9.3	462	3	US-08-798-414-1	Sequence 1, Appli
14	95	9.3	462	4	US-09-131-247-1	Sequence 1, Appli
15	95	9.3	474	1	US-08-476-860-9	Sequence 9, Appli
16	95	9.3	474	2	US-08-910-733-9	Sequence 9, Appli
17	95	9.3	474	2	US-08-910-733-9	Sequence 9, Appli
18	95	9.3	514	1	US-08-284-784-9	Sequence 41, Appl
19	95	9.3	514	2	US-08-854-811-41	Sequence 41, Appl
20	95	9.3	531	2	US-08-809-185-1	Sequence 1, Appli
21	95	9.3	534	3	US-09-000-630C-24	Sequence 24, Appl
22	95	9.3	534	3	US-08-862-730C-24	Sequence 24, Appl
23	95	9.3	543	1	US-08-422-655-1	Sequence 1, Appli
24	95	9.3	579	2	US-08-476-860-12	Sequence 12, Appl
25	95	9.3	579	1	US-08-910-733-12	Sequence 12, Appl
26	95	9.3	579	2	US-08-910-884-12	Sequence 12, Appl
27	95	9.3	602	1	US-08-459-811-1	Sequence 1, Appli

Db 478 CCTGCCCTGGCTGCTCTCTGCACACAGCACTGGAGGCCGACCGGCTGTGAGCCTCAACA 537

QY 470 a 470

Db 538 A 538

RESULT 9

US-09-128-155-17/c

; Sequence 17, Application US/09128155

; Patent No. 6117654

; GENERAL INFORMATION:

; APPLICANT: Pan, Yang

; TITLE OF INVENTION: NOVEL MOLECULES OF TANGO-77 RELATED PROTEIN FAMILY

; TITLE REFERENCE: 09404/052001

; CURRENT APPLICATION NUMBER: US/09/128,155

; EARLIER FILING DATE: 1998-08-03

; EARLIER APPLICATION NUMBER: US 60/091,650

; EARLIER FILING DATE: 1998-07-02

; EARLIER APPLICATION NUMBER: US 60/054,646

; EARLIER FILING DATE: 1997-08-04

; NUMBER OF SEQ ID NOS: 18

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 17

; LENGTH: 176373

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (1)...(176373)

; OTHER INFORMATION: n = A,T,C or G

US-09-128-155-17

Query Match 9.5%; Score 97.4; DB 3; Length 176373;
Best Local Similarity 62.1%; Pred. No. 2.9e-19;
Matches 259; Conservative 0; Mismatches 141; Indels 17; Gaps 6;

QY 585 atggttagcagaataatgtcccccgaataatgtccacatctcattcccaagat-ctgtgc 643

Db 160498 ATGATAGGCGAATAATGGCACCACCGGAAATGTCCACATTTCAATCCCGAGCCGTGTGT 160439

644 atatgttaccacacatgtcccaagaggttttgcacatgtgatt-atgttaagatcttga 702

160438 ATATGTTACATGACATACCAAAAGGGACTTTGTCATCTGTGATTAAAGTTAAGCCTCTTTG 160379

QY 703 aatgaagagacaatcctcgtggttatccttgggtcagtttaatacaag-----a 753

Db 160378 AGACGGGAGAGATATCTGGATATTGACGTGAGCCCGATGTAATTTGCAAGCGTTCTTATA 160319

QY 754 aggagcagaagggagagtcagagagagaatggaagataccatgcttcaattttgaag 813

Db 160318 TGTGAAGAGGAAGCAGGAGGTCAGACCAAGCAGTGTGAGAAACCCCAAGCAGCA 160259

QY 814 atggagtaggggcttagcccaacaaatgcaggt-gtttttagaaggtgaaagccaa 872

Db 160258 AGATGGGAGTGGGCACTAGCCAGGAATGCAGGTGGCCTCTGGAAGCTGGAAGGCA 160199

QY 873 ggaaacggattctctcttagagtcctcgggaagaa--cacagctcttgacacatgattt 930

Db 160198 GGAAATTGACTTCCCTTAGAGCCTCCCAAGCAATGCTATCCTGCTGATCTTGTATT 160139

QY 931 cagctcagtagacacccatttcagactcttgacctcgcacacatataaaataaataac 987

Db 160138 TGGCCAGTGAACACATTTCCAGA---CTGACCTCCATAACTGCAAGATAATACATT 160085

RESULT 10

US-08-724-394A-20/c

; Sequence 20, Application US/08724394A

; Patent No. 5872237

; GENERAL INFORMATION:

; APPLICANT: Feder, John N.
; APPLICANT: Kronmal, Gregory S.
; APPLICANT: Lauer, Peter M.
; APPLICANT: Ruddy, David A.
; APPLICANT: Thomas, Winston
; APPLICANT: Tsuchihashi, Zenta
; APPLICANT: Wolff, Roger K.
; TITLE OF INVENTION: Megabase Transcript Map: No. 5872237el
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: TOWNSEND and TOWNSEND and CREW LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/724,394A
; FILING DATE: 01-OCT-1996
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Fitts, Renee A.
; REGISTRATION NUMBER: 35,136
; REFERENCE/DOCKET NUMBER: 017957-000100
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-576-0200
; TELEFAX: 415-576-0300
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 246240 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: not relevant
; TOPOLOGY: not relevant
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..246240
; OTHER INFORMATION: /note= "HLA-H. CONTIG"

US-08-724-394A-20

Query Match 9.5%; Score 97; DB 2; Length 246240;
Best Local Similarity 62.1%; Pred. No. 4.7e-19;
Matches 259; Conservative 0; Mismatches 140; Indels 18; Gaps 6;

QY 585 atggttagcagaataatgtcccccgaataatgtccacatctcattcccaagatctgtgca 644

Db 37190 AGGCTAGCGTGAATGTGTCTCCCAAGATATCCATGCTCTAATCCCGAGAACCTGTAAA 37131

QY 645 tatgttaccatcacatgtcccaagaggttttgcacaaatgtgattatgttaaggaatcttga 704

Db 37130 TATATTACCTTATATGACAAAAGGACCTTACATGTTTAATAA-GTTAAGAAATTTTGAGA 37072

QY 705 tgaagagacaatcctcgtggttatccttgggtc-agttaatacaag-----aagg 756

Db 37071 TGGGCAGATTTTCTGAATTTTGCAGATGGCCCTAGTGTATATCAAGGGTCTCTATAA 37012

QY 757 aggcaggaagaggaatcagagagagaatggaagataccatgctcttaattttgaagatg 816

Db 37011 GAGACAGGCAAGAGATGACAGATAAGAGAAAATACCTTCAAGATGTTACACTGCTGGCTT 36952

QY 817 gagtgaag-----ggccttagcccaacaaatgcaggtgtttttagaaggtgaaagacc 870

Db 36951 TAAGGTGGAGAAAGGCCAAGAGCCAAAATAATGCAGTGGTCTACTACAGCT-GAAAGCAA 36893

QY 871 aagggaacggattctctcttagagtcctcgggaagaaacacagc--tcttgacacatggat 928

Db 36893

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 10, 2002, 13:51:47 ; Search time 24.69 Seconds
(without alignments) 900.502 Million cell updates/sec

Title: US-09-724-583-2
Perfect score: 818
Sequence: 1 MCSLPMARYTIKYADOKAL.....QUTKESEPSARTKEYFEOSW 152

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 473505 seqs, 146272329 residues
Total number of hits satisfying chosen parameters: 473505

```

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                  Maximum Match 10%
                  Listing first 45

```

```
Database :
SPREMBL_17.*
1: sp_archaea.*
2: sp_bacteria.*
3: sp_fungi.*
4: sp_human.*
5: sp_invertebrate.*
6: sp_mammal.*
7: sp_mhc.*
8: sp_organellae.*
9: sp_page.*
10: sp_plant.*
11: sp_rodent.*
12: sp_virus.*
13: sp_vertebrate.*
14: sp_unclassified.*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Sult No.	Query No.	Score	% Match	Length	DB	ID	Description
1	592	72.4	144	4	Q9BYX1	Q9BYX1	homo sapien
2	309	37.8	156	11	Q9J1G2	Q9J1G2	mus musculus
3	307	37.5	155	11	Q9QYV1	Q9QYV1	mus musculus
4	283	34.6	155	4	Q9UBH0	Q9UBH0	homo sapien
5	257.5	31.5	159	11	070207	070207	mus musculus
6	248	30.3	176	6	Q9BEH0	Q9BEH0	canis famill
7	245	30.0	177	6	Q9CMZ4	Q9CMZ4	tursiops tr
8	238.5	29.2	143	4	Q9UPC0	Q9UPC0	homo sapien
9	238.5	29.2	180	6	Q14628	Q14628	homo sapien
10	238	29.1	176	6	Q9GKK2	Q9GKK2	canis famill
11	177.5	21.7	169	4	Q9NZH8	Q9NZH8	homo sapien
12	176	21.5	157	4	Q9UHA5	Q9UHA5	homo sapien
13	172	21.0	181	11	Q9D6Z6	Q9D6Z6	mus musculus
14	169	20.7	158	4	Q9UHA7	Q9UHA7	homo sapien
15	164.5	20.1	72	6	077771	077771	equus cabal
16	156	19.1	178	4	Q9HBF2	Q9HBF2	homo sapien
17	155.5	19.0	192	4	Q9UHA6	Q9UHA6	homo sapien
18	155.5	19.0	218	4	Q9NZH6	Q9NZH6	homo sapien
19	155.5	19.0	218	4	Q9HBF3	Q9HBF3	homo sapien

ALIGNMENTS

```

RESULT 1
ID Q9BYX1 PRELIMINARY: PRT; 144 AA.
AC Q9BYX1;
DT 01-JUN-2001 (TEMBLrel. 17, Created)
DT 01-JUN-2001 (TEMBLrel. 17, Last sequence update)
DT 01-JUN-2001 (TEMBLrel. 17, Last annotation update)
DT 01-JUN-2001 (TEMBLrel. 17, Last annotation update)
DE INTERLEUKIN-1 RECEPTOR ANTAGONIST FKSG75.
GN FKSG75.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
OX NCBI_taxid=9606;
[1]
RN SEQUENCE FROM N.A.
RA Wang Y., Li T., Gong L.;
RT "Identification and characterization of FKSG75, a novel member of the
RT interleukin-1 family.";
RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY026753; AAK01948.1; -.
KW Receptor.
KW SEQUENCE. 144 AA; 15811 MW; 8733B16D6F118B9 CRC64;

Query Match 72.4%; Score 592; DB 4; Length 144;
Best Local Similarity 98.2%; Pred. NO. 8e-55;
Matches 111; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 40 EKICILPNRGLDRTKVPILFGIOGSRCLACVETEEGPSLQLEDVNIELYKGEATRF 99
1111 1111 1111 1111 1111 1111 1111 1111 1111 1111
Db 32 EKICILPNRGLARTKVPILFGIOGSRCLACVETEEGPSLQLEDVNIELYKGEATRF 91
1111 1111 1111 1111 1111 1111 1111 1111 1111 1111
QY 100 TFEOSGSGSAFRLEAAANPWFLCGPAEPQOPVOLTKESEPSARTKFFFEQSW 152
1111 1111 1111 1111 1111 1111 1111 1111 1111 1111
Db 92 TFEOSGSGSAFRLEAAANPWFLCGPAEPQOPVOLTKESEPSARTKFFFEQSW 144
1111 1111 1111 1111 1111 1111 1111 1111 1111 1111

RESULT 2
Q9JIG2
ID Q9JIG2 PRELIMINARY: PRT; 156 AA.
AC Q9JIG2;
DT 01-OCT-2000 (TEMBLrel. 15, Created)

```

DT 01-OCT-2000 (TREMBLrel. 15, Last sequence update)
 DT 01-JUN-2001 (TREMBLrel. 17, Last annotation update)
 DE INTERLEUKIN-1 DELTA (INTERLEUKIN 1 RECEPTOR ANTAGONIST HOMOLOG 1).
 GN IL1HV1
 OS Mus musculus (Mouse)
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Debets R., Timans J.C., Zurawski S., Sana T.R., Bazan F.,
 RA Kastelein R.A.;
 RT "Novel IL-1 ligands IL-1d and IL-1e use IL-1R related protein 2.";
 RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=TONGUE, AND STOMACH;
 MEDLINE=21085660; PubMed=11217851;
 Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
 Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
 Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
 Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
 Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
 Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
 Kuehl P., Lewis S., Matsuo Y., Nikaide I., Pesole G., Quackenbush J.,
 Schram L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
 Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
 Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
 Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
 Gustincich S., Hill D., Hofmann M., Hume D.A., Kamliya M., Lee N.H.,
 Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
 Nordone P., Ringwald M., Rodriguez I., Sakamoto N.,
 Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
 Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
 Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,
 Hayashizaki Y.;
 RT "Functional annotation of a full-length mouse cDNA collection.";
 RL Nature 409:685-690(2001).
 DR EMBL: AF230378; AAF91275.1; -;
 DR EMBL: AK009741; BAB26471.1; -;
 DR EMBL: AK008972; BAB26002.1; -;
 DR MGD: MGI:1859325; Il1hv1.
 DR InterPro: IPR000975; Interleukin_1.
 DR Pfam: PF00340; IL1; 1.
 DR SMART: SM00125; IL1; 1.
 DR PROSITE: PS00253; INTERLEUKIN_1; 1.
 DR SEQUENCE 156 AA; 17136 MW; A4D1EE2F93CF77A7 CRC64;

 Query Match 37.8%; Score 309; DB 11; Length 156;
 Best Local Similarity 45.2%; Pred. No. 6,3e-25;
 Matches 70; Conservative 23; Mismatches 56; Indels 6; Gaps 3;

 QY 1 MCSLPARYIYIKYADQALYTRDQQLYGVDPVADNCC-AEKICTLPNRLDRTKVPFL 59
 Db 1 MWLUSGALCFRMDKALKVLYHNQLLAGLHAERKVEISVVPNRALDASLSPVIL 60
 QY 60 GIQGGSRCLACVETEGESQLQEDVNEELYKGGEATRTFFOSSGSAFRLAAAMP 119
 Db 61 GVQGGSQLSC-GTEKGPILKLEPVNIMELYLGAKESKSTFYRRDMLTSSFESA 119
 QY 120 WFLCGPAEQPQVLTQKSEPSA----RTKFFFEQ 150
 Db 120 WFLCTSPADQPVRLTQIPEDPAWDAPITDFYEQ 154

 RESULT 3
 ID Q9QYI1 PRELIMINARY; PRT: 155 AA.
 AC Q9QYI1;
 DT 01-MAY-2000 (TREMBLrel. 13, Created)
 DE 01-MAY-2000 (TREMBLrel. 13, Last sequence update)
 DE ANTAGONIST HOMOLOG 1 (INTERLEUKIN-1 DELTA).
 GN IL1HV1 OR IL1L1.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=20092888; PubMed=10625660;
 RA Smith D.E., Renshaw B.R., Ketchum R.R., Kubin M., Garka K.E.,
 RA Sims J.E.;
 RT "Four New Members Expand the IL-1 Superfamily.";
 RL J. Biol. Chem. 275:1169-1175(2000).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=99443727; PubMed=10512743;

DE IL-1L1 PROTEIN (INTERLEUKIN-1 HOMOLOG 3).
 GN IL1HV1.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Barton J.L., Nicklin M.J.H.;
 RT "IL-1L1: A Novel Member of the Interleukin-1 Gene Family is Expressed
 in Trophoblasts and Macrophages.";
 RL Submitted (OCT-1999) to the EMBL/GenBank/DBJ databases.
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=20209405; PubMed=10744718;
 RA Kumar S., McDonnell P.C., Lehr R., Tierney L., Tzimas M.N.,
 RA Griswold D.E., Capper E.A., Tai-Singer R., Wells G.I., Doyle M.L.,
 RA Young P.R.;
 RT "Identification and initial characterization of four novel members of
 the interleukin-1 family.";
 RL J. Biol. Chem. 275:10308-10314(2000).
 DR EMBL: AJ250429; CAB59831.1; -;
 DR EMBL: AF200495; AAF69251.1; -;
 DR HSSP: P18510; IL1R.
 DR MGD: MGI:1859325; Il1hv1.
 DR InterPro: IPR000975; Interleukin_1.
 DR Pfam: PF00340; IL1; 1.
 DR SMART: SM00125; IL1; 1.
 DR PROSITE: PS00253; INTERLEUKIN_1; 1.
 DR SEQUENCE 155 AA; 17004 MW; A4B1770F2E12533A CRC64;

 Query Match 37.5%; Score 307; DB 11; Length 155;
 Best Local Similarity 47.8%; Pred. No. 1e-24;
 Matches 66; Conservative 20; Mismatches 46; Indels 6; Gaps 3;

 QY 18 KLYTRDQQLLVDPVADNCC-AEKICTLPNRLDRTKVPFLGIQGGSRCLACVETE 76
 Db 17 KVLVYHNQLLAGLHAERKVEISVVPNRALDASLSPVILGVQGGSQLSC-GTEK 75
 QY 77 PSLQLEDVNEELYKGGEATRTFFOSSGSAFRLAAAMPQVLTQKSPQVOLT 136
 Db 76 PTLKLEPVNIMELYLGAKESKSTFYRRDMLTSSFESAAYPGNFLTSPADQPVRLTQ 135
 QY 137 ESEPSA----RTKFFFEQ 150
 Db 136 IPEDPAWDAPITDFYEQ 153

 RESULT 4
 ID Q9UBH0 PRELIMINARY; PRT: 155 AA.
 AC Q9UBH0;
 DT 01-MAY-2000 (TREMBLrel. 13, Created)
 DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)
 DT 01-JUN-2001 (TREMBLrel. 17, Last annotation update)
 DE FILL DELTA (INTERLEUKIN-1 LIKE PROTEIN 1) (INTERLEUKIN-1 RECEPTOR
 DE ANTAGONIST HOMOLOG 1) (INTERLEUKIN-1 DELTA).
 GN IL1HV1 OR IL1L1.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=20092888; PubMed=10625660;
 RA Smith D.E., Renshaw B.R., Ketchum R.R., Kubin M., Garka K.E.,
 RA Sims J.E.;
 RT "Four New Members Expand the IL-1 Superfamily.";
 RL J. Biol. Chem. 275:1169-1175(2000).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=99443727; PubMed=10512743;


```
Db 85 IHGKGLCLACVKSGDETRQLQLEAVNITLDSKNKQDKRFTTILSDSGPTTSFESAACPGW 144
QY 121 FLCGPAEPQPVOLTKSEPSAR-TKFFFEQ 150
    ||| 1 : ||| 1 : ||| 1 :
Db 145 FLCTALEADRPVSLNRPPEAMVTKFFYQK 175
    ||| 1 : ||| 1 : ||| 1 :

RESULT 7
Q9GMZ4 PRELIMINARY; PRT; 177 AA.
AC Q9GMZ4;
DT 01-MAR-2001 (Tremblrel. 16, Created)
DT 01-MAR-2001 (Tremblrel. 16, Last sequence update)
DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)
DE INTERLEUKIN-1 RECEPTOR ANTAGONIST.
GN IL-1RA.
OS Tursiops truncatus (Atlantic bottle-nosed dolphin);
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
Tursiops.
OX NCBI_TaxID=9739;
RN 1;
RP SEQUENCE FROM N.A.
RA Inoue Y., Itou T., Sakai T.;
RT "Cloning and Sequencing of a Bottle-Nosed Dolphin Interleukin-1
Receptor Antagonist.";
RL Submitted (FBI-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL: AB038268; BABL1806.1;
DR InterPro: IPR000975; Interleukin_1.
DR Pfam: PF00340; IL1; 1.
DR ProDom: PD002536; Interleukin_1; 1.
DR SMART: SM00125; IL1; 1.
DR PROSITE: PS00253; INTERLEUKIN_1; 1.
KW Receptor.
SQ SEQUENCE 177 AA; 19923 MW; 6FD19A06C09B131B CRC64;

Query Match 30.0%; Score 245; DB 6; Length 177;
Best Local Similarity 40.4%; Pred. No. 4;le-18;
Matches 61; Conservative 18; Mismatches 62; Indels 10; Gaps 4;

QY 2 CSLPMARYIYIKYADQKALYTRDGLLVGDPVADNC-CAEKICTLPLNGLDRTKVPFLG 60
    ||| 1 : ||| 1 : ||| 1 : ||| 1 :
Db 33 CEMQAFRLWDV---NOKTFYLRNQLVAGYQGNPKLEEKIDVPIE-----PHAMFLG 84
    ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 :
QY 61 IOGSGRCIACVETEEGPGSLQLEDVNIIEELYKGGEATRTFFFOSSGSAFRLAAAPGW 120
    ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 :
Db 85 IHGKGLCLACVKSGDETRQLQLEAVNITLDSKNKQDKRFTTILSDSGPTTSFESAACPGW 144
    ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 :
QY 121 FLCGPAEPQPVOLTKSEPSAR-TKFFFEQ 150
    ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 :
Db 145 FLCTALEADRPVSLNRPPEAMVTKFFYQK 175
    ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 :

RESULT 8
Q9UPC0 PRELIMINARY; PRT; 143 AA.
AC Q9UPC0;
DT 01-MAY-2000 (Tremblrel. 13, Created)
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)
DE INTERLEUKIN-1 INTRACELLULAR RECEPTOR ANTAGONIST VARIANT (FRAGMENT).
GN IL1RN.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN 1;
RP SEQUENCE FROM N.A.
RA MEDLINE=98183404; PubMed=9514884;
RX Weissbach L., Tran K., Colquhoun S.A., Champilaud M.F., Towle C.A.;
RT "Detection of an interleukin-1 intracellular receptor antagonist mRNA
variant.";
```

```
RL Biochem. Biophys. Res. Commun. 244:91-95(1998).
DR EMBL: AF043143; AAC39672.1; -.
DR HSSP: P18510; IITN.
DR InterPro: IPR000975; Interleukin_1.
DR Pfam: PF00340; IL1; 1.
DR SMART: SM00125; IL1; 1.
DR PROSITE: PS00253; INTERLEUKIN_1; 1.
KW Receptor.
FT NON-TER 143 143
SQ SEQUENCE 143 AA; 16142 MW; 4CAD6784B890905B CRC64;

Query Match 29.2%; Score 238.5; DB 4; Length 143;
Best Local Similarity 40.9%; Pred. No. 1.6e-17;
Matches 56; Conservative 18; Mismatches 56; Indels 7; Gaps 3;

QY 16 DOKALYTRDGLLVGDPVADNC-CAEKICTLPLNGLDRTKVPFLGIGGSRCLACVETE 74
    ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 :
Db 10 NOKTFYLRNQLVAGYQGNPNVLEEKIDVPIE-----PHALFLGHHGKMLSCVKS 64
    ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 :
QY 75 EGPQLQLEDVNIIEELYKGGEATRTFFFOSSGSAFRLAAAPGWFLCGPAEPQPVOL 134
    ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 :
Db 65 DETRLQLEAVNITLDSKNKQDKRFAFIRSDSGPTTSFESAACPGWFLCTAMEADQPVL 124
    ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 :
QY 135 TKESEPSAR-TKFFFEQ 150
    ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 :
Db 125 TNPDEGVMTKFFFOE 141
    ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 : ||| 1 :

RESULT 9
Q14628 PRELIMINARY; PRT; 180 AA.
AC Q14628;
DT 01-NOV-1996 (Tremblrel. 01, Created)
DT 01-NOV-1996 (Tremblrel. 01, Last sequence update)
DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)
DE INTRACELLULAR IL-1 RECEPTOR ANTAGONIST TYPE II.
GN IL-1RN.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN 1;
RP SEQUENCE FROM N.A.
RX MEDLINE=95355865; PubMed=7629520;
RA Muzio M., Polentarutti N., Sironi M., Poli G., De Gioia L.,
Introna M., Mantovani A., Colotta F.;
RT "Cloning and characterization of a new isoform of the interleukin 1
receptor antagonist.";
RL J. Exp. Med. 182:623-628(1995).
RN 1;
RP SEQUENCE FROM N.A.
RX MEDLINE=97146044; PubMed=8992991;
RA Jenkins J.K., Drong R.F., Shuck M.E., Bienkowski M.J., Slightom J.L.,
Arend W.P., Smith M.F. Jr.;
RT "Intracellular IL-1 receptor antagonist promoter: cell type-specific
RT and inducible regulatory regions.";
RL J. Immunol. 158:748-755(1997).
RN 1;
RP SEQUENCE FROM N.A.
RA Slightom J.L.;
RL Submitted (JUL-1996) to the EMBL/GenBank/DBJ databases.
DR EMBL: X84348; CAA39087.1; -.
DR HSSP: P18510; IIRP.
DR InterPro: IPR000975; Interleukin_1.
DR Pfam: PF00340; IL1; 1.
DR SMART: SM00125; IL1; 1.
DR PROSITE: PS00253; INTERLEUKIN_1; 1.
SQ SEQUENCE 180 AA; 19897 MW; 624A1574C2334229 CRC64;

Query Match 29.2%; Score 238.5; DB 4; Length 180;
```



```
Best Local Similarity 40.9%; Pred. No. 2e-17;
Matches 56; Conservative 18; Mismatches 56; Indels 7; Gaps 3;

QY 16 DOKALYTRDGLLVGDPVADNC-CAEIKCTLPNRLDRTKVPFLGIGGSRCLACVETE 74
      :||| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :|
Db 47 NOKTYFLRNQLVAGYLOGPNVNLKLEKTDVVPPIE-----PHALFLGIHGKMKCLSCVKSG 101
      :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :|
QY 75 EGPSIQLEDVNIIEELKYGGEATRTFFQSSGSAFRLEAAWPGWFLCGPAEPPOPVOL 134
      :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
Db 102 DETRLQLEAVNTLDLSENKRQKRAFIIRSDSGPTTSFSAACPGWFLCTAMEADQPVSL 161

QY 135 TKESEPSAR-TKPYFEQ 150
      :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :|
Db 162 TNMPDEGVMTKPYFOE 178

RESULT 10
ID Q9GKK2 PRELIMINARY; PRT; 176 AA.
AC Q9GKK2;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)
DE INTERLEUKIN-1 RECEPTOR ANTAGONIST.
OS Canis familiaris (Dog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
OX NCBI_TaxID=9615;
RN [1]
RP SEQUENCE FROM N.A.
RA Campbell S.E., Nasir L., Argyle D.J., Gault E., Bennett D.;
RT "Canine IL-1 Receptor Antagonist cDNA Sequence.";
RL Submitted (DEC-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF216526; AAG36777.1; -.
DR InterPro; IPR000975; Interleukin_1.
DR Pfam; PF00340; IL1; 1.
DR ProDom; PD002536; Interleukin_1.
DR SMART; SM00125; IL1; 1.
DR PROSITE; PS00253; INTERLEUKIN_1; UNKNOWN_1.
KW Receptor.
SQ SEQUENCE 176 AA; 19938 MW; 8486CA54A254206B CRC64;
```

```
Query Match 29.1%; Score 238; DB 6; Length 176;
Best Local Similarity 39.1%; Pred. No. 2.2e-17;
Matches 59; Conservative 20; Mismatches 62; Indels 10; Gaps 4;

QY 2 CSLPMARYIIKADOKALYTRDGLLVGDPVADNC-CAEIKCTLPNRLDRTKVPFLG 60
      :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :|
33 CRMQAFRIWDV---NOKTFRLRNQLVAGYLOGSNTKLEKLDVWPE-----PHAVFLG 84
      :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :|
61 IQGGSRLCLACVETEEGPSIQLEDVNIIEELKYGGEATRTFFQSSGSAFRLEAAWPGW 120
      :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
85 IHGGKICLACVKSGETRLQLEAVNTLDLSKNKQDKRFTILSDSGPTTSFSAACPGW 144
      :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
QY 121 FLCGPAEPPOPVOLTKESPSAR-TKPYFEQ 150
      :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
Db 145 FLCTALEADRLVSLTNRPPEAMWTKPYFQK 175

RESULT 11
Q9NZH8 PRELIMINARY; PRT; 169 AA.
ID Q9NZH8;
AC Q9NZH8;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)
DE INTERLEUKIN-1 HOMOLOG 1 (INTERLEUKIN-1 EPSILON).
GN IL1E.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
OX NCBI_TaxID=9606;
```

```
RP SEQUENCE FROM N.A.
RX MEDLINE=20209405; PubMed=10744718;
RA Kumar S., McDonnell P.C., Lehr R., Tierney L., Tzimas M.N.,
RA Griswold D.E., Capper E.A., Tal-Singer R., Wells G.I., Doyle M.L.,
RA Young P.R.;
RT "Identification and initial characterization of four novel members of
RT the interleukin-1 family.";
RL J. Biol. Chem. 275:10308-10314(2000).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=AIRWAY EPITHELIAL CELLS INDUCED WITH TNF ALPHA, AND IFN;
RA Debets R., Timans J., Zurawski S., Bazan J.F., Kastelein R.A.;
RT "Novel IL-1 family member IL-1e responds through the orphan IL-1R-
RT related protein 2: response is antagonized by IL-1d.";
RL Submitted (NOV-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF200492; AAF69248.1; -.
DR EMBL; AF206696; AAG35670.1; -.
DR InterPro; IPR000975; Interleukin_1.
DR Pfam; PF00340; IL1; 1.
DR SMART; SM00125; IL1; 1.
SQ SEQUENCE 169 AA; 18721 MW; F00A9243706F4154 CRC64;

Query Match 21.7%; Score 177.5; DB 4; Length 169;
Best Local Similarity 33.6%; Pred. No. 5.2e-11;
Matches 44; Conservative 21; Mismatches 61; Indels 5; Gaps 2;

QY 20 LYTRDGLLVGDPVADNCCAEKI----CTLPNRLDRTKVPFLGIGGSRCLACVETE 75
      :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
Db 34 VWTLOQNLVAVPRSDSVTPVTVAIVITKYKEALEOGRGDPYILGIONPMLCYCEKVG 93
      :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
QY 76 GPSIQLEDVNIIEELKYGGEATRTFFQSSGSAFRLEAAWPGWFLCGPAEPPOPVOLT 135
      :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
Db 94 OPTLQLEKQIMDLYGQPEVPKPELFYRAKTGRTSTLESVAFPDWFIAS-SKRDQPIILT 152
      :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
QY 136 KESEPSARTKF 146
      :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :|
Db 153 SELGKSYNTAF 163

RESULT 12
Q9UHA5 PRELIMINARY; PRT; 157 AA.
ID Q9UHA5;
AC Q9UHA5;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)
DE FIL1 ETA.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20092888; PubMed=10625660;
RA Smith D.E., Renshaw B.R., Ketchum R.R., Kubin M., Garka K.E.,
RA Sims J.E.;
RT "Four New Members Expand the IL-1 Superfamily.";
RL J. Biol. Chem. 275:1169-1175(2000).
DR EMBL; AF201833; AAF25213.1; -.
DR HSSP; P10749; 2M1B.
DR InterPro; IPR000975; Interleukin_1.
DR Pfam; PF00340; IL1; 1.
DR SMART; SM00125; IL1; 1.
DR PROSITE; PS00253; INTERLEUKIN_1; UNKNOWN_1.
SQ SEQUENCE 157 AA; 17702 MW; 7A54F3D7557A3EE3 CRC64;
```

```
Query Match 21.5%; Score 176; DB 4; Length 157;
Best Local Similarity 36.6%; Pred. No. 6.8e-11;
Matches 34; Conservative 16; Mismatches 41; Indels 0; Gaps 0;
```

```
QY 57 IFGLGQGSRLACVETEEGSLQEDVNIIEELYKGBEATRTFTFFOSSGSAFRLAA 116
Db 62 VYLGKGLDGLCFCAEIQGKPTLQLEKRNIMDLVYKKAQKPFLLFFHNKKGSTSVFQSVS 121
QY 117 WPGWFLCGPAEPQPOPVOLTKTESARTFYFE 149
Db 122 YPGWFIATSTWSGQPIFLTKERTGINTNTNYLD 154

RESULT 13
Q9D6Z6 PRELIMINARY; PRT; 183 AA.
AC Q9D6Z6;
DT 01-JUN-2001 (Tremblrel. 17, Created)
DT 01-JUN-2001 (Tremblrel. 17, Last sequence update)
DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)
DE 2310043N20RIK PROTEIN.
CA 2310043N20RIK.
Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=TONGUE;
MEDLINE=21085660; PubMed=11217851;
RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamataka I.,
RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
RA Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,
RA Hayashizaki Y.;
RT "Functional annotation of a full-length mouse cDNA collection.";
RL Nature 409:685-690(2001).
EMBL: AK009787; BAB26505.1; -.
MGI: 1916927; 2310043N20RIK.
InterPro: IPR000975; Interleukin_1.
DR Pfam; PF00340; IL1; 1.
DR ProDom; PD002536; Interleukin_1; 1.
DR SMART; SM00125; IL1; 1.
DR PROSITE; PS00253; INTERLEUKIN_1; UNKNOWN_1.
SQ SEQUENCE 183 AA; 20878 MW; A3ACE339FB96F02F CRC64;

Query Match 21.0%; Score 172; DB 11; Length 183;
Best Local Similarity 29.2%; Pred. No. 2.2e-10;
Matches 40; Conservative 25; Mismatches 68; Indels 4; Gaps 1;

QY 17 OKALYTRDQGLVGDVPADNCCAEKICTLPLNRGLDRTKVP-----IFGLGQGSRLACV 72
Db 44 QQVWVLVTGNTLTAVPASNVKPVILSLIACHDTEFDQVKGNLVFLGINKRNLCFCFCE 103
QY 73 TEEGSLQEDVNIIEELYKGBEATRTFTFFOSSGSAFRLAAAWFLCGPAEPQPOPV 132
Db 104 MEGKPTLQLEKVDIMNLYKKAQKAFLYFHGIEGSTSVFQSVLYPGWFIATSTIERQTI 163
QY 133 QLTKESEPSTARTFYFE 149
Db 164 ILTHORGLVNTNYFE 180
```

```
RESULT 14
Q9UHA7 PRELIMINARY; PRT; 158 AA.
AC Q9UHA7;
DT 01-MAY-2000 (Tremblrel. 13, Created)
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)
DE FIL1 EPSILON.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20092888; PubMed=10625660;
RA Smith D.E., Renshaw B.R., Ketchum R.R., Kubin M., Garka K.E.,
RA Sims J.E.;
RT "Four New Members Expand the IL-1 Superfamily.";
RL J. Biol. Chem. 275:1169-1175(2000).
DR EMBL; AF201831; AAF25211.1; -.
DR HSP; P18510; 1IRA.
DR InterPro; IPR000975; Interleukin_1.
DR Pfam; PF00340; IL1; 1.
DR SMART; SM00125; IL1; 1.
SQ SEQUENCE 158 AA; 17684 MW; 469AC84306B0E280 CRC64;

Query Match 20.7%; Score 169; DB 4; Length 158;
Best Local Similarity 32.0%; Pred. No. 3.8e-10;
Matches 40; Conservative 23; Mismatches 58; Indels 4; Gaps 1;

QY 26 QLLVGDVPADNCCAEKICTLPLNRGLDRTKV----PIFLGQGSRLACVETEEGSLQ 81
Db 28 QTLTAVPRKDRMSPVTIALISCRHVETLEKDRGNPIYLGLNGLNLCAKVGDOPTLQ 87
QY 82 EDVNIIEELYKGBEATRTFTFFOSSGSAFRLAAAWFLCGPAEPQPOPVOLTKSEPS 141
Db 88 KKDMDLNLNQEPKVSFLFHSQSGRSTFVSAPFGWFIASVSEGCPLILQELGKA 147
QY 142 ARTKF 146
Db 148 NITDF 152

RESULT 15
Q77771 PRELIMINARY; PRT; 72 AA.
AC Q77771;
DT 01-NOV-1998 (Tremblrel. 08, Created)
DT 01-NOV-1998 (Tremblrel. 08, Last sequence update)
DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)
DE INTERLEUKIN-1 RECEPTOR ANTAGONIST SECRETORY FORM (FRAGMENT).
GN IL-1RA.
OS Equus caballus (Horse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Perissodactyla; Equidae; Equus.
OX NCBI_TaxID=9796;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=BRED THOROUGHBRED;
RA Dhar A.K., Thompson M.S., Paradis M.R., Alcivar-Warren A.;
RT "Molecular Characterization of Equine Interleukin 1 Receptor Antagonist (IL-1ra) Gene.";
RL Submitted (JUN-1998) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF072476; AAC62237.1; -.
DR HSP; P18510; 1IRA.
DR InterPro; IPR000975; Interleukin_1.
DR Pfam; PF00340; IL1; 1.
DR SMART; SM00125; IL1; 1.
DR PROSITE; PS00253; INTERLEUKIN_1; 1.
FT NON_TER
SQ SEQUENCE 72 AA; 8215 MW; 290CC9B9D4C13D9 CRC64;
```


GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 19, 2002, 07:54:55 ; Search time 270.73 seconds
(without alignments)
6468.632 Million cell updates/sec

Title: US-09-724-583-1
Perfect score: 1020
Sequence: 1 cagggtacgggttcacgga.....acctctaaaaaa 1020

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_032802.*
1: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT.*
2: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT.*
3: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT.*
4: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT.*
5: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT.*
6: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT.*
7: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT.*
8: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT.*
9: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT.*
10: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT.*
11: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT.*
12: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT.*
13: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT.*
14: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT.*
15: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT.*
16: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT.*
17: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT.*
18: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT.*
19: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT.*
20: /SID55/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT.*
21: /SID55/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT.*
22: /SID55/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT.*
23: /SID55/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT.*
24: /SID55/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	1020	100.0	1020	22	Human interleukin-1
2	1016.8	99.7	1020	22	Human interleukin-1 rece
3	991.2	97.2	998	22	Human interleukin-1
4	964.4	94.5	1366	22	Human interleukin-1
5	964.4	94.5	1366	22	Human interleukin-1
6	699.8	68.6	5445	22	Human interleukin-1
7	657.6	64.5	744	22	Human interleukin-1 rece
8	634.8	62.2	827	22	Human IL-1 delta h
9	455.8	44.7	459	22	Human FIL-1 theta

10	412	40.4	483	22	AAF83868	Human interleukin-
11	368.4	36.1	538	22	AAD11158	Mouse FIL-1 theta
12	335.8	32.9	538	22	AAD11147	Human FIL-1 theta
13	328.4	32.2	459	22	AAI70237	Mouse interleukin-
14	328.4	32.2	459	22	AAI70237	Mouse interleukin-
15	204.4	20.0	4388	22	AAI70237	Mouse interleukin-
16	204.4	20.0	4388	22	AAI70237	Mouse interleukin-
17	122.2	12.0	764	22	AAH04444	Human CDNA clone (
18	117.8	11.5	562	22	AAI23955	Human breast cance
19	111.6	10.9	488	20	AAH89431	Mouse interleukin
20	111.6	10.9	488	22	AAI31373	Invention related
21	111.6	10.9	468	22	AAI31373	Murine interleukin
22	111.6	10.9	470	19	AAV71958	Rodent interleukin
23	111.6	10.9	1275	21	AAA09198	Murine IL-1 homolo
24	111.6	10.9	1284	22	AAI70237	Murine IL-1 codi
25	111.6	10.9	1360	21	AAZ50811	Murine TANGO-93 CD
26	110.8	10.9	1385	21	AAI51599	Murine IL-1 recept
27	110.8	10.9	488	20	AAH89432	Human interleukin
28	110.8	10.9	488	21	AAI31597	Human IL-1 recept
29	110.8	10.9	766	21	AAI09193	Human IL-1 homolo
30	110.8	10.9	1025	22	AAI12295	Human interleukin-
31	110.8	10.9	1282	20	AAZ30050	CDNA encoding a hu
32	110.8	10.9	1282	22	AAI31353	Extension of B2HFL
33	110.8	10.9	1323	21	AAZ50812	Human TANGO-93 CDN
34	110.8	10.9	2490	21	AAZ50813	Human TANGO-93 CDN
35	110.8	10.9	2562	22	AAI27921	Human IL-1 codin
36	110.8	10.9	2598	22	AAI27921	Human IL-1 codin
37	110.8	10.9	2647	22	AAI31354	Human PRO4342 CDNA
38	110.8	10.9	2648	20	AAZ30051	Extension of B2HFL
39	108.8	10.7	1183	22	AAI06384	CDNA encoding a hu
40	108.8	10.7	1183	22	AAI29640	Human CDNA SEQ ID
41	108.8	10.7	1183	22	AAI63963	Human endocrine po
42	108.8	10.7	1183	22	AAI31277	Human polynucleoti
43	108.8	10.7	1183	22	AAI31277	Human CDNA encodin
44	105.2	10.3	465	21	AAI34773	CDNA encoding nove
45	105.2	10.3	465	21	AAI09194	Human IL-1 homolog
						Human IL-1 homolog

ALIGNMENTS

RESULT 1
AAI70234
ID AAI70234 standard; cDNA; 1020 BP.
XX AC AAI70234;
XX AC AAI70234;
DT 07-JAN-2002 (first entry)
XX Human interleukin-1 receptor antagonist related protein cDNA.
XX Interleukin-1 receptor antagonist related protein; IL-1ra-R; human;
KW Inhibitor; antiarthritic; antirheumatic; osteopathic;
KW antiinflammatory; neuroprotective; antidiabetic; immunosuppressive;
KW antileptotic; antibacterial; tuberculostatic; anorectic; metabolic;
KW antiviral; hyperglycaemic; nootropic; antiparkinsonian;
KW antidepressant; anticonvulsive; tranquilizer; vulnerary;
KW antiasthmatic; antipsoriatric; dermatological; cytostatic;
KW nephrotropic; antiaemorrhagic; vasotropic; cardiant;
KW antithrombotic; antifertility; ophthalmological;
KW gene therapy; diagnosis; ss.
XX Homo sapiens.
XX Key Location/Qualifiers
XX CDS 64..522
XX FT /*tag= a
XX FT replace(194,T)
XX FT /*tag= b
XX FT replace(215,C)
XX FT /*tag= c
XX WC200142304-A1.


```

FT      variation      /*tag= a
FT      replace(194,C)
FT      /*tag= b
FT      variation      replace(215,A)
FT      /*tag= c
XX      WO200142304-A1.
XX      14-JUN-2001.
XX      04-DEC-2000; 2000WO-US32940.
XX      10-DEC-1999; 99US-170191P.
XX      09-MAR-2000; 2000US-188053P.
XX      04-APR-2000; 2000US-194521P.
XX      10-APR-2000; 2000US-195910P.
XX      28-NOV-2000; 2000US-0170191.
XX      (AMGE-) AMGEN INC.
XX      Saris CM, Giles J, Mu SX, Xia M, Bass MB, Craveiro R;
XX      WPI; 2001-648140/74.
XX      P-PSDB; AAM50218.
XX      Novel interleukin-1 receptor antagonist-related polypeptide, its
XX      fragment, variant useful for treating rheumatoid arthritis, septicemia,
XX      Parkinson's disease, epilepsy, cystic fibrosis, Paget's disease,
XX      uveitis, eczema
XX      Claim 1; Fig 2A-B; 163pp; English.
XX      The present sequence is that of cDNA encoding a novel human
XX      interleukin-1 receptor antagonist-related polypeptide, IL-1ra-R
XX      (see AAM50218), which has interleukin-1 inhibitor activity. The
XX      sequence was derived from cDNA clones obtained by PCR and RACE from
XX      placenta and fetal scalp cDNA libraries. Also isolated was an
XX      IL-1ra-R variant sequence (see AAI70234), which differed from the
XX      present sequence at nucleotide positions 194 and 215 (both altering
XX      the encoded amino acid sequence), and a splice variant (see
XX      AAI70236). The invention provides IL-1ra-R polypeptides and nucleic
XX      acids, as well as selective binding agents, vectors, host cells and
XX      methods for producing the IL-1ra-R polypeptides. It also provides
XX      pharmaceutical compositions and methods for the diagnosis,
XX      treatment, amelioration and/or prevention of diseases, disorders
XX      and conditions associated with IL-1ra-R, such as those involving
XX      immune system dysfunction, infection, weight disorders, neuronal
XX      dysfunction, lung, skin, kidney, bone, vascular system, tumour
XX      cells, reproductive system, and eye. The nucleic acids are useful
XX      in gene therapy, gene mapping, transgenic animal breeding, and as
XX      probes and primers.
XX      Sequence 1020 BP; 287 A; 238 C; 267 G; 228 T; 0 other;

```

```

Query Match      99.7%; Score 1016.8; DB 22; Length 1020;
Best Local Similarity 99.8%; Pred. No. 3.6e-298;
Matches 1018; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      1 caggatcagggttccaggaaactcagatctgcagtgaggaccagacacacactgattgca 60
Db      1 caggatcagggttccaggaaactcagatctgcagtgaggaccagacacacactgattgca 60
QY      61 ggaatgttccctccctccctccctccctccctccctccctccctccctccctccctccct 120
Db      61 ggaatgttccctccctccctccctccctccctccctccctccctccctccctccctccct 120
QY      121 ctatcacacagagatggcagctgctggtggagatcctctgttcagacacactgctgtgca 180
Db      121 ctatcacacagagatggcagctgctggtggagatcctctgttcagacacactgctgtgca 180
QY      181 gagaagatctgcacacttctcaacagagcttgaccgcacacaggtcccccatttctctg 240

```

```

Db      181 gagaagatctgcacacttctcaacagagcttgaccgcacacaggtcccccatttctctg 240
QY      241 gggatccaggaggagcgctgctggcatgtgtgagacagaagaggcccttccta 300
Db      241 gggatccaggaggagcgctgctggcatgtgtgagacagaagaggcccttccta 300
QY      301 cagctggagatgtgaacattgagaaactgtacaagggtggtgaagagggccacacgcttc 360
Db      301 cagctggagatgtgaacattgagaaactgtacaagggtggtgaagagggccacacgcttc 360
QY      361 accttctccagagcagctcaggctccgctccctcaggcttgaggctgctgcctggcctggc 420
Db      361 accttctccagagcagctcaggctccgctccctcaggcttgaggctgctgcctggcctggc 420
QY      421 tggctcctgtgtgcccgcagagcccccagcagctacagctcaccacaaagagagtgag 480
Db      421 tggctcctgtgtgcccgcagagcccccagcagctacagctcaccacaaagagagtgag 480
QY      481 cctcgcgcctgtaccaaagttttaactttgaacagagctggtgaggagacagaaactcgt 540
Db      481 cctcgcgcctgtaccaaagttttaactttgaacagagctggtgaggagacagaaactcgt 540
QY      541 tttagcctgtgccccaaacaaagctcctcctcaggtctatgtaggcagaataa 600
Db      541 tttagcctgtgccccaaacaaagctcctcctcaggtctatgtaggcagaataa 600
QY      601 tgtccccgaaatagtccacatcctaatcccaagatctgtgcatagtttaccatacatg 660
Db      601 tgtccccgaaatagtccacatcctaatcccaagatctgtgcatagtttaccatacatg 660
QY      661 tccaaagagggttttgcataatgtattgttaaggatcttgaatgagagacacactcgt 720
Db      661 tccaaagagggttttgcataatgtattgttaaggatcttgaatgagagacacactcgt 720
QY      721 ggtatcctgtggcctcagtttaatacacaagagagcaggaaggagagtcagagag 780
Db      721 ggtatcctgtggcctcagtttaatacacaagagagcaggaaggagagtcagagag 780
QY      781 agaatggaagatcacctcctcttaattttgaagatgagtgagggtccttgagccaaca 840
Db      781 agaatggaagatcacctcctcttaattttgaagatgagtgagggtccttgagccaaca 840
QY      841 atgcagggtgttttgaagggttgaaaaagccaaagggaacggattcctctagagctccg 900
Db      841 atgcagggtgttttgaagggttgaaaaagccaaagggaacggattcctctagagctccg 900
QY      901 gaaggaaacacagctcttgacacatgatttcaagtcagtgacacccatttcagactctg 960
Db      901 gaaggaaacacagctcttgacacatgatttcaagtcagtgacacccatttcagactctg 960
QY      961 acctccacacactataaaaataataaactgtgttatgtataaactctataaaaaa 1020
Db      961 acctccacacactataaaaataataaactgtgttatgtataaactctataaaaaa 1020

```

```

RESULT 3
AAA89175
ID AAA89175 standard; cDNA; 998 BP.
XX
AC AAA89175;
XX
DT 19-MAR-2001 (first entry)
XX
DE Human interleukin-1 Hy2 cDNA.
XX
KW Interleukin-2 Hy2; IL-1 Hy2; human; interleukin-1 receptor;
KW antagonist; cancer; breast adenocarcinoma; brain tumour; melanoma;
KW myeloma; giant cell tumour of bone; acute myelogenous leukemia;
KW oral epidermoid carcinoma; squamous cell carcinoma; inflammation;
KW antitumour; antiinflammatory; diagnosis; therapy; chromosome 2; ss.
XX
OS Homo sapiens.
XX

```


Db 961 ctataaaataaacttggtattgtataaactct 996

RESULT 4

AAA89176
ID AAA89176 standard; cDNA: 1366 BP.

AC AAA89176;

DT 19-MAR-2001 (first entry)

DE Human interleukin-1 Hy2 cDNA.

KW Interleukin-2 Hy2; IL-1 Hy2; human; interleukin-1 receptor;
KW antagonist; cancer; breast adenocarcinoma; brain tumour; melanoma;
KW myeloma; giant cell tumour of bone; acute myelogenous leukaemia;
KW oral epidermoid carcinoma; squamous cell carcinoma; inflammation;
KW antitumour; antiinflammatory; diagnosis; therapy; chromosome 2; ss.
XX
XX Homo sapiens.

Key Location/Qualifiers
CDS 422..880
/*tag= a

WO200071719-A1.

PN 30-NOV-2000.

PD 22-MAY-2000; 2000WO-US14144.

PR 20-MAY-1999; 99US-0316086.

PR 10-MAR-2000; 2000US-0522964.

XX (HYSE-) HYSEQ INC.

XX Ballinger DG, Ford J, Ho AS, Lin HS, Pace AM;

XX WPI: 2001-016409/02.

XX P-PSDB; AAB19922.

PT New isolated polynucleotide encoding interleukin-1 Hy2 for diagnosing,
PT preventing and treating disorders, such as cancers and inflammatory
PT diseases -

PS Claim 1; Page 145-146; 158pp; English.

XX The present sequence is that of cDNA encoding human interleukin-1
XX Hy2 (IL-1 Hy2, see AAB19922), a novel member of the interleukin-1
XX receptor antagonist family. The sequence was obtained following
XX resequencing of cDNA clone pIL-1Hy2 (see AAB19922), extending the 5'
XX sequence. An alternative IL-1 Hy2 cDNA sequence (see AAB89176),
XX predicted from the IL-1 Hy2 genomic DNA, contains a C to T
XX nucleotide change at position 279, which generates an alternative
XX upstream initiating methionine for open reading frame encoding a
XX 200-amino acid protein (see AAB18824). IL-1 Hy2 polypeptides and
XX polynucleotides are used to treat cancers involving elevated levels
XX of IL-1, such as breast adenocarcinoma, brain tumours, melanoma,
XX giant cell tumours of bone, acute myelogenous leukaemia, oral
XX epidermoid carcinoma or squamous cell carcinoma, and inflammatory
XX disease mediated by interleukin-18 (all claimed). They can also be
XX used to diagnose, prevent or treat shock, thrombosis, acute
XX pancreatitis, arthritis, vasculitis, lupus, immune complex
XX glomerulonephritis, pancreatic cell damage, allograft and xenograft
XX transplantation, graft versus host disease, inflammatory bowel
XX disease, bone degenerative diseases, diabetes and neurodegenerative
XX disorders. The polynucleotides are also useful for the design of
XX hybridization probes and PCR primers, in chromosome and gene
XX mapping, in the recombinant production of IL-1 Hy2 protein, and in
XX the generation of antisense DNA or RNA.

XX Sequence 1366 BP; 334 A; 350 C; 368 G; 314 T; 0 other;

Query Match 94.5%; Score 964.4; DB 22; Length 1366;
Best Local Similarity 99.4%; Pred. No. 3.4e-282;
Matches 968; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 33 cagtaagagacagacacacacactgattgcaggaatgtgttccctcccatggaagatacta 92
DB 391 cagcaggagacagacacacacactgattgcaggaatgtgttccctcccatggaagatacta 450
QY 93 cataataaatatgcagacacagagcgtctctacacagagatggccagctgctggtggg 152
DB 451 cataataaatatgcagacacagagcgtctctacacagagacgagcagctgctggtggg 510
QY 153 aatctctgtgcagacacactgctgtgcagagagatctgcacacttctctaacagagcctt 212
DB 511 agatccctgtgcagacacactgctgtgcagagagatctgcacacttctctaacagagcctt 570
QY 213 gaccgcacacaggtcccccattttctctggggtccagggagggagcgcgtgctggcatg 272
DB 571 gaccgcacacaggtcccccattttctctggggtccagggagggagcgcgtgctggcatg 630
QY 273 tgtgcagacagagagggccttccctacagctggagatgtgaacattgaggaactgta 332
DB 631 tgtgcagacagagagggccttccctacagctggagatgtgaacattgaggaactgta 690
QY 333 caaaggtgtgaagagccacacgcttccaccttctccagagcagctcaggtccgcctt 392
DB 691 caaaggtgtgaagagccacacgcttccaccttctccagagcagctcaggtccgcctt 750
QY 393 caggcttgagcgtgctgctgctgctgctgctgctgctgctgctgctgctgctgctgct 452
DB 751 caggcttgagcgtgctgctgctgctgctgctgctgctgctgctgctgctgctgctgct 810
QY 453 gccagtcagctcaccagagagagtgagccctcagccctcagccctcagccctcagccctc 512
DB 811 gccagtcagctcaccagagagtgagccctcagccctcagccctcagccctcagccctc 870
QY 513 gagctgtgtagggagacaggaactcgcttttagcctgtgctgctgctgctgctgctgctgct 572
DB 871 gagctgtgtagggagacaggaactcgcttttagcctgtgctgctgctgctgctgctgctgct 930
QY 573 tgcctcagggctctgtaggcagaaataatgtccccccgaataatgtccccccgaataatgt 632
DB 931 tgcctcagggctctgtaggcagaaataatgtccccccgaataatgtccccccgaataatgt 990
QY 633 aagatctgcatatgttaccatacatgtccaaagaggttttgcaaatgtgattatgta 692
DB 991 aagatctgcatatgttaccatacatgtccaaagaggttttgcaaatgtgattatgta 1050
QY 693 aggatcttgaatagggagacaaatccctgggttattcttctgtggcctcagtttaatacacaag 752
DB 1051 aggatcttgaatagggagacaaatccctgggttattcttctgtggcctcagtttaatacacaag 1110
QY 753 aaggagcaggaaggag 812
DB 1111 aaggagcaggaaggag 1170
QY 813 gatgagtagggggccttgagcacaacaaatcaggtgttttttagaaggtgggaaagccaa 872
DB 1171 gatgagtagggggccttgagcacaacaaatcaggtgttttttagaaggtgggaaagccaa 1230
QY 873 ggggaacgattctctctagatgctccgggaaggaacacagctcttgacacatggatttca 932
DB 1231 ggggaacgattctctctagatgctccgggaaggaacacagctcttgacacatggatttca 1290
QY 933 gctcagtgacacacacattcagactctcagctcagctcagctcagctcagctcagctcagct 992
DB 1291 gctcagtgacacacacattcagactctcagctcagctcagctcagctcagctcagctcagct 1350
QY 993 tattgtaaacctct 1006
DB 1351 tattgtaaacctct 1364

XX	Sequence	344 A	349 C	368 G	315 T	0 other
QY	Query Match	94.5%	Score 964.4	DB 22	Length 1366	
SQ	Best Local Similarity	99.4%	Prod. No. 3.4e-282			
	Matches 968	Conservative	Mismatches 6	Indels 0	Gaps 0	
QY	33	cagtgagacacacaccactgattgcaggaatgtgttccctcccatcggcagaacta	92			
DB	391	cagtgagacacacaccactgattgcaggaatgtgttccctcccatcggcagaacta	450			
QY	93	cataataatatgcagacacagaaggtctctatacacaagagatgacagctgctgtgag	152			
DB	451	cataataatatgcagacacagaaggtctctatacacaagagatgacagctgctgtgag	510			
QY	153	agatcctgtttgcagacaaactgtgtgcagagaagatgtgcacacttctcaacagagctt	212			
DB	511	agatcctgtttgcagacaaactgtgtgcagagaagatgtgcacacttctcaacagagctt	570			
QY	213	gaacgcacacaaaggtcccattttctctggggtccagagagggagcgtgctggcgtg	272			
DB	571	gaacgcacacaaaggtcccattttctctggggtccagagagggagcgtgctggcgtg	630			
QY	273	tgtgagacacagaagggccttccctacagctggagagatgtgaacattcaggaactgt	332			
DB	631	tgtgagacacagaagggccttccctacagctggagagatgtgaacattcaggaactgt	690			
QY	333	caaaagtgtgaagagggcacacgcttcaccttcttcagagcagctcaggtccgcctt	392			
DB	691	caaaagtgtgaagagggcacacgcttcaccttcttcagagcagctcaggtccgcctt	750			
QY	393	caggcttgagctgtcgtgcctgcgtgcttctgtgtggccggcagagcccaaga	452			
DB	751	caggcttgagctgtcgtgcctgcgtgcttctgtgtggccggcagagcccaaga	810			
QY	453	gccagtacagctcaccagaagagtgagccctcagccgtaccacagtttactttgaaca	512			
DB	811	gccagtacagctcaccagaagagtgagccctcagccgtaccacagtttactttgaaca	870			
QY	513	gagcttgtaggagacaggaactcgttttagccttgtgcccacaaacacagctcatcc	572			
DB	871	gagcttgtaggagacaggaactcgttttagccttgtgcccacaaacacagctcatcc	930			
QY	573	tgctcaggtctatgtagacagaataatgtcccccgaataatgtccacatctcaatccc	632			
DB	931	tgctcaggtctatgtagacagaataatgtcccccgaataatgtccacatctcaatccc	990			
QY	633	aagatctgtcatatgtttaccatacatgtccaaagaggttttgcaaatgtatatttta	692			
DB	991	aagatctgtcatatgtttaccatacatgtccaaagaggttttgcaaatgtatatttta	1050			
QY	693	aggatctgaaatgaggagacaatcctgggttatctctgttgggtcagtttaatacacaag	752			
DB	1051	aggatctgaaatgaggagacaatcctgggttatctctgttgggtcagtttaatacacaag	1110			
QY	753	aaggagcaggaagggagagtgcagagagaatggaagataccatgcttcaatttgaa	812			
DB	1111	aaggagcaggaagggagagtgcagagagaatggaagataccatgcttcaatttgaa	1170			
QY	813	gatggagtggggccttgagccacaataatgcaggtgttttttagaaggtggaagaagccaa	872			
DB	1171	gatggagtggggccttgagccacaataatgcaggtgttttttagaaggtggaagaagccaa	1230			
QY	873	ggacacagatctctctagagctcgcgaaggaacacagctcttgacacatggatttcca	932			
DB	1231	ggacacagatctctctctagagctcgcgaaggaacacagctcttgacacatggatttcca	1290			
QY	933	gctcagtgacacccaatttcagacttctgcacttccaaactataaaataaactttgt	992			
DB	1291	gctcagtgacacccaatttcagacttctgcacttccaaactataaaataaactttgt	1350			
QY	993	tatttgaacacctct	1006			

Db 1351 tattgttaaacctct 1364
|||||
RESULT 6
ID AAA89177
AC AAA89177 standard; DNA: 5445 BP.
XX AAA89177;
DT 19-MAR-2001 (first entry)
XX Human interleukin-1 Hy2 gene.
XX Interleukin-2 Hy2; IL-1 Hy2; human; interleukin-1 receptor;
KW antagonist; cancer; breast adenocarcinoma; brain tumour; melanoma;
KW myeloma; giant cell tumour of bone; acute myelogenous leukaemia;
KW oral epidermoid carcinoma; squamous cell carcinoma; inflammation;
KW antitumour; antinflammatory; diagnosis; therapy; chromosome 2; ds.
XX Homo sapiens.
OS
Key Location/Qualifiers
CDS 2188..4961
FT /*tag= a
FT /note = "contains introns"
FT exon 1911..2363
FT /*tag= b
FT /number = 1
FT intron 2364..3924
FT /*tag= c
FT /number = 1
FT exon 3925..4011
FT /*tag= d
FT /number = 2
FT intron 4012..4318
FT /*tag= e
FT /number = 2
FT exon 4320..4447
FT /*tag= f
FT /number = 3
FT intron 4448..4747
FT /*tag= g
FT /number = 3
FT exon 4749..5445
FT /*tag= h
FT /number = 4
PN WO200071791-A1.
30-NOV-2000.
PF 22-MAY-2000; 2000WO-US14144.
XX
PR 20-MAY-1999; 99US-0316086.
PR 10-MAR-2000; 2000US-0522964.
XX
PA (HYSE-) HYSEQ INC.
XX
XX Ballinger DG, Ford J, Ho AS, Lin HS, Pace AM;
PI WPI; 2001-016409/02.
DR P-PSDB; AAB19924.
DR
XX New isolated polynucleotide encoding interleukin-1 Hy2 for diagnosing,
PT preventing and treating disorders, such as cancers and inflammatory
PT diseases -
PT
XX Example 8; Page 146-149; 158pp; English.
PS
XX The present sequence is that of human genomic DNA encoding
CC interleukin-1 Hy2 (IL-1 Hy2, see AAB19924), a novel member
CC of the interleukin-1 receptor antagonist family. The DNA was

CC obtained by screening a commercial human BAC library with IL-1 Hy2
CC cDNA. Exons were predicted using GenScan software. The predicted
CC cDNA (see AAA89178) based on this genomic sequence contains thymidine
CC at nucleotide 279, whereas IL-1 Hy2 cDNA obtained by PCR
CC amplification (see AAA89176) contains cytosine at this position. The
CC change in nucleotides extends the IL-1 Hy2 open reading frame in the
CC 5' direction, resulting in a 200-amino acid polypeptide, whereas the
CC amplified cDNA encodes a 152-amino acid polypeptide (see AAB19922).
CC IL-1 Hy2 polypeptides and polynucleotides are used to treat cancers
CC involving elevated levels of IL-1, such as breast adenocarcinoma,
CC brain tumours, melanoma, giant cell tumours of bone, acute
CC myelogenous leukaemia, oral epidermoid carcinoma or squamous cell
CC carcinoma, and inflammatory disease mediated by interleukin-18 (all
CC claimed). They can also be used to diagnose, prevent or treat
CC shock, thrombosis, acute pancreatitis, arthritis, vasculitis,
CC lupus, immune complex glomerulonephritis, pancreatic cell damage,
CC allograft and xenograft transplantation, graft versus host disease,
CC inflammatory bowel disease, bone degenerative diseases, diabetes
CC and neurodegenerative disorders. The polynucleotides are also
CC useful for the design of hybridization probes and PCR primers, in
CC chromosome and gene mapping, in the recombinant production of
CC IL-1 Hy2 protein, and in the generation of antisense DNA or RNA.
XX
XX Sequence 5445 BP; 1365 A; 1382 C; 1246 G; 1452 T; 0 other;
SQ
Query Match 68.6%; Score 699.8; DB 22; Length 5445;
Best Local Similarity 99.0%; Pred. No. 1.6e-201;
Matches 704; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
QY 296 ccctacagctggagatgtgaacattgaggaactgtacaaaggtggtgaagagccacac 335
Db |||||
QY 4735 cctgtcccccacagatgtgaacattgaggaactgtacaaaggtggtgaagagccacac 4794
QY 356 gcttcacctcttccagagcagctcagctccgcttcaggctgagctgctcctggc 415
Db |||||
QY 4795 gcttcacctcttccagagcagctcagctccgcttcaggctgagctgctcctggc 4854
QY 416 ctggctggttctctgtgtgcccgcagagcccccagccagtcagctaccagagaga 475
Db |||||
QY 4855 ctggctggttctctgtgtgcccgcagagcccccagccagtcagctaccagagaga 4914
QY 476 gtgagccctcagcccgaccagtttactttgaaacagagctggtagggagacaggaac 535
Db |||||
QY 4915 gtgagccctcagcccgaccagtttactttgaaacagagctggtagggagacaggaac 4974
QY 536 tgcgttttagcttgcgcccaacacacagctcctcctcaggggtctatggttaggcag 595
Db |||||
QY 4975 tgcgttttagcttgcgcccaacacacagctcctcctcaggggtctatggttaggcag 5034
QY 596 aataatgtcccccgaataatgtccacatccttaacccaagatctgtgcatatgttaccat 655
Db |||||
QY 5035 aataatgtcccccgaataatgtccacatccttaacccaagatctgtgcatatgttaccat 5094
QY 656 acatgtccaaagaggttttgcacaaatgatttgcacaaatgatttgcacaaatgatttgcacaa 715
Db |||||
QY 5095 acatgtccaaagaggttttgcacaaatgatttgcacaaatgatttgcacaaatgatttgcacaa 5154
QY 716 tctgtggttatccttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc 775
Db |||||
QY 5155 tctgtggttatccttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc 5214
QY 776 gagagagaatgaagataccatgcttcttaattttgaagatgagtgagtgagtgagtgagtgagtgag 835
Db |||||
QY 5215 gagagagaatgaagataccatgcttcttaattttgaagatgagtgagtgagtgagtgagtgagtgag 5274
QY 836 acaaatgcaggtgttttttagaaggtggaagacccagggagacgattctcctctagatt 895
Db |||||
QY 5275 acaaatgcaggtgttttttagaaggtggaagacccagggagacgattctcctctagatt 5334
QY 896 ctccgaagaagaacacagcttgcacacatgatttcagctcagtcagtcagtcagtcagtcagtcagtc 955
Db |||||
QY 5335 ctccgaagaagaacacagcttgcacacatgatttcagctcagtcagtcagtcagtcagtcagtcagtc 5394

QY 956 ttctgacctcacactataaaataaactgtgtgtattgtaaacctct 1006
 Db |||||||||||||||||||||||||||||||||||||||||||||||||

Db 5395 ttctgacctcacactataaaataaactgtgtgtattgtaaacctct 5445

RESULT 7

AAI70236
 ID AAI70236 standard; cDNA; 744 BP.

AC AAI70236;

XX 07-JAN-2002 (first entry)

DE Interleukin-1 receptor antagonist related protein splice variant.

XX Interleukin-1 receptor antagonist related protein; IL-1ra-R; human;
 KW inhibitor; antiarthritic; antirheumatic; osteopathic;
 KW antiinflammatory; neuroprotective; antidiabetic; immunosuppressive;
 KW antileprotic; antibacterial; tuberculostatic; anorectic; metabolic;
 KW antiviral; hyperglycaemic; nootropic; antiparkinsonian;
 KW antidepressant; anticonvulsive; tranquilizer; cytostatic;
 KW antasthmatic; antihemorrhagic; dermatological; vasotropic;
 KW nephrotropic; antihemorrhagic; vasotropic; cardiac;
 KW antiatherosclerotic; antifertility; ophthalmological;
 KW gene therapy; diagnosis; ss.

XX Homo sapiens.

XX Key Location/Qualifiers
 PH CDS 58..573
 FT /*tag= a

XX WO200142304-A1.

XX 14-JUN-2001.

XX 04-DEC-2000; 2000WO-US32940.

XX 10-DEC-1999; 99US-170191P.

XX 09-MAR-2000; 2000US-188053P.

XX 04-APR-2000; 2000US-194521P.

XX 10-APR-2000; 2000US-195910P.

XX 28-NOV-2000; 2000US-0170191.

XX (AMGE-) AMGEN INC.

PA Saris CM, Giles J, Mu SX, Xia M, Bass MB, Craveiro R;

DR WPI; 2001-648140/74.

DR P-PSDB; AAM50219.

XX Novel interleukin-1 receptor antagonist-related polypeptide, its
 PT fragment, variant useful for treating rheumatoid arthritis, septicemia,
 PT Parkinson's disease, epilepsy, cystic fibrosis, Paget's disease,
 PT uveitis, eczema

XX Claim 1; Fig 3; 163pp; English.

XX The present sequence is that of cDNA encoding a splice variant (see
 CC AAM50219) of human interleukin-1 receptor antagonist-related
 CC polypeptide IL-1ra-R, a novel protein that has interleukin-1
 CC inhibitor activity. The sequence was obtained from a human
 CC placenta cDNA library by PCR amplification. The splice variant
 CC may arise from splicing (or a fusion) of the first 2 exons of
 CC the upstream IL-1 Omega gene onto the second exon of the IL-1ra-R
 CC gene. The invention provides IL-1ra-R polypeptides and nucleic
 CC acids, as well as selective binding agents, vectors, host cells
 CC and methods for producing the IL-1ra-R polypeptides. It also
 CC provides pharmaceutical compositions and methods for the diagnosis,
 CC treatment, amelioration and/or prevention of diseases, disorders
 CC and conditions associated with IL-1ra-R, such as those involving
 CC immune system dysfunction, infection, weight disorders, neuronal

CC dysfunction, lung, skin, kidney, bone, vascular system, tumour
 CC cells, reproductive system, and eye. The nucleic acids are useful
 CC in gene therapy, gene mapping, transgenic animal breeding, and as
 CC probes and primers.

XX Sequence 744 BP; 183 A; 194 C; 205 G; 162 T; 0 other;

Query Match 64.5%; Score 657.6; DB 22; Length 744;
 Best Local Similarity 99.4%; Pred. No. 3.6e-189;
 Matches 660; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 30 ctgcagtgaggaccagacacacactgattgcaggaaatgtttccctcccatggcacaata 89

Db 81 ctctccctggggaccagacacacactgattgcaggaaatgtttccctcccatggcacaata 140

QY 90 ctacataataaataatgcagaccagaaggtctctacacaagaagatgccagctgctggt 149

Db 141 ctacataataaataatgcagaccagaaggtctctacacaagaagatgccagctgctggt 200

QY 150 gggagatccctgttcagacaactctgtgcagagaagatctgcacacttcctaaacagg 209

Db 201 gggagatccctgttcagacaactctgtgcagagaagatctgcacacttcctaaacagg 260

QY 210 ctggaccgcacacaaggtcccccatttctctggggatccaggaggagcgctgcctggc 269

Db 261 ctggaccgcacacaaggtcccccatttctctggggatccaggaggagcgctgcctggc 320

QY 270 atgtgtggagacagagaaggggccttccctacagctggaggatgtgaacattgaggaa 329

Db 321 atgtgtggagacagagaaggggccttccctacagctggaggatgtgaacattgaggaa 380

QY 330 gtacaaagtggtgaaggagccacacgcttccacttctccagagcagctcaggtccgc 389

Db 381 gtacaaagtggtgaaggagccacacgcttccacttctccagagcagctcaggtccgc 440

QY 390 cttcaggcttgaggctgctgctgctgctgctgctgctgctgctgctgctgctgctgct 449

Db 441 cttcaggcttgaggctgctgctgctgctgctgctgctgctgctgctgctgctgctgct 500

QY 450 gcagccagtacagctccacagaaggagagtgagccctcagccctacacagtttacttga 509

Db 501 gcagccagtacagctccacagaaggagagtgagccctcagccctacacagtttacttga 560

QY 510 acagagctgtgaggagacagagaactgcgttttagcctgtgcccccaaaccaagctca 569

Db 561 acagagctgtgaggagacagagaactgcgttttagcctgtgcccccaaaccaagctca 620

QY 570 tctgtctcagggtctatggtgagcagaataatgtcccccgaaatatgtccacatcctaat 629

Db 621 tctgtctcagggtctatggtgagcagaataatgtcccccgaaatatgtccacatcctaat 680

QY 630 cccaagatctgtcatatgttaccacacatgtccaaagaggttttgcaaatgtgattatg 689

Db 681 cccaagatctgtcatatgttaccacacatgttccaaagaggttttgcaaatgtgattatg 740

QY 690 ttaa 693

Db 741 ttaa 744

RESULT 8

ABA08991

ID ABA08991 standard; cDNA; 827 BP.

AC ABA08991;

XX 11-JAN-2002 (first entry)

DE Human IL-1 delta homologue-encoding cDNA, SEQ ID NO:767.

XX Human; cytokine; cell proliferation; cell differentiation; growth factor;
 KW haematopoiesis regulation; tissue growth; immunomodulator; activin;

KW	inhibit; chemotaxis; chemokinesis; thrombolysis; oncogenesis;
KW	proliferation; metastasis; cancer; tumour; haematopoietic disorder;
KW	myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;
KW	chronic inflammatory condition; proliferative retinopathy;
KW	atherosclerosis; coronary heart disease; arterial ischaemia;
KW	bone disorder; osteoporosis; vascular growth disorder;
KW	tissue regeneration; wound healing; infection; immune disorder;
KW	cell culture; drug screening; gene therapy; antiinflammatory;
KW	cellulitic; antiarthritic; haemostatic; antiarteriosclerotic;
KW	cytostatic; osteopathic; vasotropic; cardiac; virucide; antibacterial;
KW	antifungal; vulnery; antiulcer; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO200157188-A2.
XX	
PD	09-AUG-2001.
XX	
PP	05-FEB-2001; 2001WO-US03800.
XX	
PP	
XX	03-FEB-2000; 2000US-0496914.
PR	27-APR-2000; 2000US-0560875.
XX	
PA	(HYSE-) HYSEQ INC.
XX	
PI	Tang YT, Liu C, Drmanac RT;
DR	WPI; 2001-457740/49.
DR	P-PSDB; ABB11747.
DR	
PT	Human proteins and DNA encoding sequences useful for preventing,
PT	treating or ameliorating a medical condition in a mammalian subject
PT	e.g. arthritis and cancer
XX	
PS	Claim 1; Page 686; 1963pp; English.
XX	
CC	Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and
CC	sequences ABA08225-ABA09574 represent nucleic acids encoding them. The
CC	invention also relates to vectors and recombinant host cells comprising a
CC	nucleotide of the invention, methods of producing the novel polypeptides,
CC	antibodies against the polypeptides, methods of detecting the nucleotides
CC	or polypeptides in a sample, and methods of identifying compounds which
CC	bind to polypeptides of the invention. Although novel, many of the
CC	polypeptides of the invention have homology to known proteins, thereby
CC	giving an insight into their probable biological activities, and hence
CC	potential therapeutic applications. The polypeptides of the invention may
CC	have various activities, including cytokine, cell proliferation or cell
CC	differentiation activities; stem cell growth factor activity;
CC	haematopoietic regulatory activity; tissue growth activity;
CC	immunomodulatory activity; activin- or inhibin-related activities;
CC	chemotactic or chemokinetic activities; haemostatic, thrombotic or
CC	thrombolytic activities; receptor or ligand activities; or may be
CC	involved in oncogenesis, cancer cell proliferation or metastasis.
CC	depending on their biological activities, polypeptides and nucleotides of
CC	the invention are useful for preventing, treating or ameliorating medical
CC	conditions, e.g., by protein or gene therapy. Such conditions include
CC	cancers, haematopoietic disorders (e.g., myeloid or lymphoid cell
CC	disorders), chronic inflammatory conditions (e.g., asthma or arthritis),
CC	proliferative retinopathy, atherosclerosis, coronary heart disease,
CC	arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal
CC	vascular growth. Polypeptides involved with tissue regeneration and
CC	repair (or nucleic acids encoding them) may be used to promote wound
CC	healing (e.g., of burns, incisions and ulcers), while those with
CC	immunomodulatory activities may be used in the treatment of viral,
CC	bacterial and fungal infections in addition to immune disorders.
CC	Polypeptides with growth factor activity may be used in cell cultures to
CC	promote cell growth. For example, such polypeptides may be used to
CC	manipulate stem cells in culture to give rise to neuroepithelial cells
CC	that can be used to augment or replace cells damaged by illness,
CC	autoimmune disease or accidental damage. The polypeptides and nucleotides
CC	may also be used in the diagnosis of the above conditions, and in drug
CC	screening techniques. The present sequence represents a cDNA encoding a
CC	novel human polypeptide of the invention.

DE Human FIL-1 theta full-length DNA..

XX Interleukin-1 family ligand; FIL-1 theta; IL-1; glaucoma; leukaemia;

XX insulin dependent diabetes mellitus; lymphoma; microbial infection;

KW ectodermal dysplasia; wrinkly skin syndrome; antisense therapy;

KW tibial muscular dystrophy; inflammation; gene therapy; human; ds.

XX Homo sapiens.

XX Key Location/Qualifiers

FT 1..459

FT /*tag= a

FT /product= "Human FIL-1 theta full-length protein"

FT replace (131, T)

FT /*tag= b

FT /note= "This polymorphism results in an amino

FT acid change from Thr to Ile at position 44"

FT variation

FT replace (131..132, TC)

FT /*tag= b

FT /note= "This polymorphism results in an amino

FT acid change from Thr to Ile at position 44"

FT variation

FT replace (152, C)

FT /*tag= b

FT /note= "This polymorphism results in an amino

FT acid change from Asp to Ala at position 51"

XX W0200155211-A2.

XX 02-AUG-2001.

XX 25-JAN-2001; 2001WO-US02514.

XX 27-JAN-2000; 2000US-0178389.

XX 11-APR-2000; 2000US-0195962.

XX (IMMV) IMMUNEX CORP.

XX Sims JE;

XX WPI: 2001-457718/49.

XX P-PSDB; AAE05840.

XX Isolated FIL-1 theta polypeptide to induce or inhibit the induction of

XX fever and to stimulate the immune system for the treatment of microbial

XX infections -

XX Claim 1; Page 5; 65pp; English.

XX The invention relates to interleukin-1 (IL-1) family ligand designated

XX as FIL-1 theta polypeptides and nucleic acid molecules encoding such

XX polypeptides. Fil-1 theta DNA is used to identify glaucoma, insulin

XX dependent diabetes mellitus, ectodermal dysplasia, T-cell leukaemia/

XX lymphoma, wrinkly skin syndrome and tibial muscular dystrophy. Fil-1

XX theta polypeptides are used to activate and/or inhibit the activation

XX of vascular endothelial cells and lymphocytes; the induction of local

XX tissue destruction and fever; the stimulation of macrophages and

XX vascular endothelial cells to produce IL-6 and the induction of

XX prostaglandins. They are also used to treat inflammation and microbial

XX infections. FIL-1 theta DNA is useful in antisense therapy and gene

XX therapy. The present sequence is a DNA encoding human FIL-1 theta

XX full-length protein.

XX Sequence 459 BP; 109 A; 124 C; 132 G; 94 T; 0 other;

XX

Query Match 44.7%; Score 455.8; DB 22; Length 459;

Best Local Similarity 99.6%; Pred. No. 5.2e-128;

Matches 457; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 64 atgtgttcctccctcccaagatgactacataataataatgcagaccagaagctcta 123

DB 1 atgtgttcctccctcccaagatgactacataataataatgcagaccagaagctcta 60

QY 124 tacacaagagatgcccagctgctggtgggaagatcctgttgcagacaaactgctgtgcagag 183

DB 61 tacacaagatgcccagctgctggtgggaagatcctgttgcagacaaactgctgtgcagag 120

QY 184 aagatctgcacacttctaacagagcttgagccgaccaaaggtcccatcttctctggg 243

DB 121 aagatctgcacacttctaacagagcttgagccgaccaaaggtcccatcttctctggg 180

QY 244 atccagagagagagccgctccctgcctgctgtgtgagacagagagggcctccctacag 303

DB 181 atccagagagagagccgctccctgcctgctgtgtgagacagagagggcctccctacag 240

QY 304 ctggagatgtgaacttgaggaaactgtacaaggtggtgaagagggccacacgcttccac 363

DB 241 ctggagatgtgaacttgaggaaactgtacaaggtggtgaagagggccacacgcttccac 300

QY 364 ttcttcagagcagctcaggtccgccttcaggtctgaggtgctgctgctgctgctgctg 423

DB 301 ttcttcagagcagctcaggtccgccttcaggtctgaggtgctgctgctgctgctgctg 360

QY 424 ttctgtgtgcccgcagagcccccagcagcagctacagctcaccagaagagagtgagccc 483

DB 361 ttctgtgtgcccgcagagcccccagcagcagctacagctcactaagagagtgagccc 420

QY 484 tcagcccgtagcagaagtttactttactttgaacagagctggtag 522

DB 421 tcagcccgtagcagaagtttactttactttgaacagagctggtag 459

RESULT 10

AAF83868

ID AAF83868 standard; cDNA; 483 BP.

XX

AC AAF83868;

XX

DT 06-AUG-2001 (first entry)

XX

DE Human interleukin-1 receptor antagonist (NOVINTRA A) encoding cDNA.

XX NOVX; transmembrane protein; NOVTRAN; neuromedin peptide; NOVNEUR;

XX gonadotropin-like protein; NOVCON; interleukin-1; NOVINTRA; human;

XX cytostatic; neuroprotective; reproductive; antiinflammatory; cancer;

XX antibacterial; cerebroprotective; antidiabetic; antiarthritic;

XX antiasthmatic; antiallergic; ss.

XX Homo sapiens.

XX

XX Key Location/Qualifiers

FT CDS 3..467

FT /*tag= a

FT /product= "NOVINTRA A"

XX

XX W0200140291-A2.

XX

XX 07-JUN-2001.

XX

XX 06-DEC-2000; 2000WO-US33029.

XX

XX 06-DEC-1999; 99US-0169056.

XX 09-DEC-1999; 99US-0169866.

XX 09-DEC-1999; 99US-0169886.

XX 10-DEC-1999; 99US-0170252.

XX 12-JAN-2000; 2000US-0175740.

XX 05-DEC-2000; 2000US-0170252.

XX

XX (CURA-) CURAGEN CORP.

XX

XX Burgess CE, Prayaga SK, Shimkets RA, Rastelli L, Zerhusen BD;

XX Mezes PS;

XX

XX WPI: 2001-374790/39.

XX P-PSDB; AAB84999.

XX

PT Novel isolated human transmembrane, neuromedin peptide
PT gonadotropin-like protein and interleukin-1 receptor antagonist
PT proteins, useful for treating cancer, immune response disorder,
PT metabolic function disorders
PS Claim 8; Fig 9A; 138pp; English.
XX
XX The invention provides novel polypeptides (NOVX) selected from human
CC transmembrane protein (NOVTRAN), neuromedin peptide (NOVNEUR),
CC gonadotropin-like protein (NOVGON) and two interleukin-1 receptor
CC antagonist proteins (NOVINTRA A and B). The invention also provides
CC methods in which a NOVX polypeptide, polynucleotide and antibody are
CC used in the detection, prevention and treatment of a broad range of
CC pathological states. NOVTRAN can be used to treat a cell signaling
CC disorder such as cancer, immune response disorder, hematopoietic
CC disorder, neurodegenerative disorder. NOVNEUR can be used to treat
CC endocrine disorder, muscle disorder, neurologic disorder, cancers of
CC central nervous system, breast, colon, ovary, kidney, prostate and
CC thyroid. NOVGON can be used to treat reproductive development disorder,
CC metabolic function disorder and melanoma. NOVINTRA A and B can be used
CC to treat bone metabolism or structure disorder, inflammatory response
CC disorder, immune regulation disorder, septic shock, stroke, diabetes,
CC arthritis and cancer. The present sequence represents a cDNA encoding
CC the NOVINTRA A polypeptide.
XX
XX
SQ Sequence 483 BP; 114 A; 134 C; 138 G; 97 T; 0 other;

Query Match 40.4%; Score 412; DB 22; Length 483;
Best Local Similarity 93.5%; Pred. No. 1,le-114;
Matches 449; Conservative 0; Mismatches 10; Indels 21; Gaps 1;

Qy 80 tggcagagatcactacaataataatgacagaccagagagctctatcacaaagagatgccc 139
Db 4 tgtcactactgtttcagaataatgacagaccagagagctctatcacaaagagatgccc 63

Qy 140 agctgctgtgtggagatcctgttcagacaaactgctgcagagaaagatctgcacacttc 199
Db 64 agctgctgtgtggagatcctgttcagacaaactgctgcagagaaagatctgcacacttc 123

Qy 200 ctacagagagcttgagccagcagcaaggtcccatcttctgtggatccagagagagccc 259
Db 124 ctacagagagcttgagccagcagcaaggtcccatcttctgtggatccagagagagccc 183

Qy 260 gctgctgcatgtgtgagacagaaagagggccctccctcacagctgg----- 307
Db 184 gctgctgcatgtgtgagacagaaagagggccctccctcacagctggagccatccact 243

Qy 308 -----aggatgtgaacttgaggaactgtacaagggtgtgaagagggccacacgct 358
Db 244 tgcgccccacagagatgtgaacttgaggaactgtacaagggtgtgaagagggccacacgct 303

Qy 359 tcactcttccagagagctcagctccgcttcagcttcagcttcagcttcgctgctgctg 418
Db 304 tcactcttccagagagctcagctccgcttcagcttcagcttcgctgctgctgctg 363

Qy 419 gctggttctgtgtggcccgagagagccagcagcagcagcagcagcagcagcagcag 478
Db 364 gctggttctgtgtggcccgagagagccagcagcagcagcagcagcagcagcagcag 423

Qy 479 agcctcagccgctaccagtttactttgaacagagctgtgagagagagagagagagc 538
Db 424 agcctcagccgctaccagtttactttgaacagagctgtgagagagagagagagagc 483

RESULT 11
AADI1158
ID AADI11158 standard; DNA; 538 BP.
XX
XX
XX AADI1158;
XX
XX
DT 24-SEP-2001 (first entry)
XX

DE Mouse FIL-1 theta DNA.
XX
KW Interleukin-1 family ligand; FIL-1 theta; IL-1; glaucoma; leukaemia;
KW insulin dependent diabetes mellitus; lymphoma; microbial infection;
KW ectodermal dysplasia; wrinkly skin syndrome; antisense therapy;
KW tibial muscular dystrophy; inflammation; gene therapy; mouse; ds.
OS
XX Mus musculus.
XX
FH Key Location/Qualifiers
FT CDS 29..487
FT /tag= a
FT /product= "Mouse FIL-1 theta protein"
PN WO200155211-A2.
XX
XX 02-AUG-2001.
XX
XX 25-JAN-2001; 2001WO-US02514.
XX
XX 27-JAN-2000; 2000US-0178389.
XX
XX 11-APR-2000; 2000US-0195962.
XX
XX (IMMV) IMMUNEX CORP.
XX
XX
XX Sims JE;
XX
XX WPI; 2001-457718/49.
XX
XX P-PSDB; AAE05841.
XX
XX Isolated FIL-1 theta polypeptide to induce or inhibit the induction of
XX fever and to stimulate the immune system for the treatment of microbial
XX infections -
XX
XX
XX Claim 1; Page 5-6; 65pp; English.
XX
XX The invention relates to interleukin-1 (IL-1) family ligand designated
XX as FIL-1 theta polypeptides and nucleic acid molecules encoding such
XX polypeptides. Fil-1 theta DNA is used to identify glaucoma, insulin
XX dependent diabetes mellitus, ectodermal dysplasia, T-cell leukaemia/
XX lymphoma, wrinkly skin syndrome and tibial muscular dystrophy. Fil-1
XX theta polypeptides are used to activate and/or inhibit the activation
XX of vascular endothelial cells and lymphocytes; the induction of local
XX tissue destruction and fever; the stimulation of macrophages and
XX vascular endothelial cells to produce IL-6 and the induction of
XX prostaglandins. They are also used to treat inflammation and microbial
XX infections. FIL-1 theta DNA is useful in antisense therapy and gene
XX therapy. The present sequence is a DNA encoding mouse FIL-1 theta
XX protein.
SQ Sequence 538 BP; 132 A; 148 C; 140 G; 118 T; 0 other;

Query Match 36.1%; Score 368.4; DB 22; Length 538;
Best Local Similarity 80.3%; Pred. No. 2e-101;
Matches 432; Conservative 0; Mismatches 106; Indels 0; Gaps 0;

Qy 36 tgaagacagacagacacactgattcaggaatgtgttccctcccatggcgaagatactacat 95
Db 1 tgaagacagacacactcccaactcaggaatgtgttccctcccatggcgaagatactacat 60

Qy 96 aatataatgcagacagagctctatcacaaagagatggccagctgctggtggaga 155
Db 61 aatcaagatgcacatacaaaaggctttgtacacacggaatggccagctgctggtggaga 120

Qy 156 tctctttcacacacactgctgtgcagagagatctgcacacttccctaaagagcttga 215
Db 121 ccttgaltcagacaattatagtcagagagaggtctgtatcttccctaaacaggagctaga 180

Qy 216 ccgcacacaggtcccccatttctctggggatccagggagagagccgctgctgagctgct 275
Db 181 ccgctccaaaggtcccccatttctctggggatccagggagagaggttctgctgctgctg 240

```
QY 276 ggagacagagaggggcttccctacagctggagatgtgaacattgaggaactgtacaa 335
Db 241 aaagacaaagagagggaccctctcctcgagctggagatgtgaacatcgaggacattacaa 300
QY 336 agtgtgtgaagagggcaccagcttcccttccagagcagctccagctccgcttcag 395
Db 301 gggagtgaaacaaacccgttccaccttttccagagaagcttgggatctgcttcag 360
QY 396 gcttgaggctgctgctgctgctggttctctgtgtggtcccgagagcccccagcc 455
Db 361 gcttgaggctgctgctgctgctggttctctgtgtggtcccgagagcccccagcc 420
QY 456 agtacagctccaccagagagtgagccctcagccctgacagcttcttactttgaaacagag 515
Db 421 agtgagctccaccagagagtgagccctcagccctcagccctgacagcttcttactttgagatgag 480
QY 516 ctggtgagagagacagaaactgctttagccttctgcccacaaacaaagctcactct 573
Db 481 tcggtgaagagacataagctgggctcgtctgtggtgcccacagctctgagatctctt 538

RESULT 12
AADI1147
ID AADI1147 standard; DNA; 339 BP.
AC AADI1147;
XX
XX 24-SEP-2001 (first entry)
DE Human FIL-1 theta DNA.
KW Interleukin-1 family ligand; FIL-1 theta; IL-1; glaucoma; leukaemia;
KW insulin dependent diabetes mellitus; lymphoma; microbial infection;
KW ectodermal dysplasia; wrinkly skin syndrome; antisense therapy;
KW tibial muscular dystrophy; inflammation; gene therapy; human; ds.
XX
OS Homo sapiens.
FH Key Location/Qualifiers
FT CDS 1..339
FT /tag= a
FT /product= "Human FIL-1 theta protein"
FT /note= "CDS does not include start codon"
FT /partial
XX
XX WO200155211-A2.
XX
XX 02-AUG-2001.
XX
XX 25-JAN-2001; 2001WO-US02514.
XX
XX 27-JAN-2000; 2000US-0178389.
XX
XX 11-APR-2000; 2000US-0195962.
XX
XX (IMMUNEX ) IMMUNEX CORP.
XX
XX Sims JE;
XX
XX WPI: 2001-457718/49.
XX
XX P-PSDB; AAE05639.
XX
XX isolated FIL-1 theta polypeptide to induce or inhibit the induction of
XX fever and to stimulate the immune system for the treatment of microbial
XX infections -
XX
XX Claim 1; Page 4; 65pp; English.
XX
XX The invention relates to interleukin-1 (IL-1) family ligand designated
XX as FIL-1 theta polypeptides and nucleic acid molecules encoding such
XX polypeptides. FIL-1 theta DNA is used to identify glaucoma, insulin
XX dependent diabetes mellitus, ectodermal dysplasia, T-cell leukaemia/
XX lymphoma, wrinkly skin syndrome and tibial muscular dystrophy. FIL-1
XX theta polypeptides are used to activate and/or inhibit the activation
```

```
CC of vascular endothelial cells and lymphocytes; the induction of local
CC tissue destruction and fever; the stimulation of macrophages and
CC vascular endothelial cells to produce IL-6 and the induction of
CC prostaglandins. They are also used to treat inflammation and microbial
CC infections. FIL-1 theta DNA is useful in antisense therapy and gene
CC therapy. The present sequence is a DNA encoding human FIL-1 theta
CC protein.
XX
XX Sequence 339 BP; 73 A; 96 C; 102 G; 68 T; 0 other;
SQ
Query Match 32.9%; Score 335.8; DB 22; Length 339;
Best Local Similarity 99.4%; Pred. No. 1.2e-91;
Matches 337; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 184 agatctgcacactctcaacagagcttggacgcacacaggtcccccatttctctgggg 243
Db 1 agatctgcatactctcaacagagcttggccgcacacaggtcccccatttctctgggg 60
QY 244 atccaggagggagccgctgctggtcatgtgtggagacagagaagggtcttccctacag 303
Db 61 atccaggagggagccgctgctggtcatgtgtggagacagagaagggtcttccctacag 120
QY 304 ctggagagatgtgaacattgaggaactgtacaaggtgtgaagggccacagcgttcacc 363
Db 121 ctggagagatgtgaacattgaggaactgtacaaggtgtgaagggccacagcgttcacc 180
QY 364 ttcttcagagcagctcagctccgcttcagcttgaagctcagctcagctcagctcagct 423
Db 181 ttcttcagagcagctcagctccgcttcagcttgaagctcagctcagctcagctcagct 240
QY 424 ttctgtgtgcccggcagagcccccagcagccagctacagctcaccagagagtgagccc 483
Db 241 ttctgtgtgcccggcagagcccccagcagccagctacagctcaccagagagtgagccc 300
QY 484 tsagcccgctaccagattttactttgacagagctggttag 522
Db 301 tsagcccgctaccagattttactttgacagagctggttag 339

RESULT 13
AAI70237
ID AAI70237 standard; cDNA; 459 BP.
XX
XX AAI70237;
XX
XX 07-JAN-2002 (first entry)
XX
XX Mouse interleukin-1 receptor antagonist related protein cDNA.
XX
XX Interleukin-1 receptor antagonist related protein; IL-lra-R; mouse;
XX inhibitor; antiarthritic; antirheumatic; osteopathic;
XX antiinflammatory; neuroprotective; antidiabetic; immunosuppressive;
XX antileptotic; antibacterial; tuberculostatic; anorectic; metabolic;
XX antiviral; hyperglycaemic; nootropic; antiparkinsonian;
XX antidepressant; anticonvulsive; tranquilizer; vulnerary;
XX antiasthmatic; antipsoriatic; dermatological; cytostatic;
XX nephrotropic; antihemorrhagic; vasotropic; cardiant;
XX antiatherosclerotic; antiinfertility; ophthalmological;
XX gene therapy; diagnosis; ss.
XX
XX Mus musculus.
XX
XX WO200142304-A1.
XX
XX 14-JUN-2001.
XX
XX 04-DEC-2000; 2000WO-US32940.
XX
XX 10-DEC-1999; 99US-170191P.
XX
XX 09-MAR-2000; 2000US-188053P.
XX
XX 04-APR-2000; 2000US-194521P.
XX
XX 10-APR-2000; 2000US-195910P.
```


PR 28-NOV-2000; 2000US-0170191.
 XX (AMGE-) AMGEN INC.
 XX Saris CM, Giles J, Mu SX, Xia M, Bass MB, Craveiro R;
 PI
 XX WPI: 2001-648140/74.
 DR P-PSDB; AAM50220.
 XX
 PT Novel interleukin-1 receptor antagonist-related polypeptide, its
 fragment, variant useful for treating rheumatoid arthritis, septicemia,
 PT Parkinson's disease, epilepsy, cystic fibrosis, Paget's disease,
 PT uveitis, eczema
 XX
 PS Claim 1; Fig 7; 163pp; English.
 XX
 CC The present sequence is that of the coding region of cDNA encoding a
 CC novel murine interleukin-1 receptor antagonist-related polypeptide,
 CC IL-1ra-R (see AAM50220), which has interleukin-1 inhibitor activity.
 CC The cDNA was obtained from a day 7 mouse embryo cDNA library. The
 CC mouse IL-1ra-R gene sequence was also determined (see AAI70238).
 CC The invention provides mouse and human IL-1ra-R polypeptides and
 CC nucleic acids, as well as selective binding agents, vectors, host
 CC cells and methods for producing the IL-1ra-R polypeptides. It also
 CC provides pharmaceutical compositions and methods for the diagnosis,
 CC treatment, amelioration and/or prevention of diseases, disorders,
 CC and conditions associated with IL-1ra-R, such as those involving
 CC immune system dysfunction, infection, weight disorders, neuronal
 CC dysfunction, lung, skin, kidney, bone, vascular system, tumour
 CC cells, reproductive system, and eye. The nucleic acids are useful
 CC in gene therapy, gene mapping, transgenic animal breeding, and as
 CC probes and primers.
 XX
 SQ Sequence 459 BP; 113 A; 125 C; 119 G; 102 T; 0 other;

Query Match 32.2%; Score 328.4; DB 22; Length 459;
 Best Local Similarity 82.3%; Pred. No. 2.5e-89;
 Matches 377; Conservative 0; Mismatches 81; Indels 0; Gaps 0;

Qy 64 atgtgtctccctccatggaagataactacataataataatcagacagagctcta 123
 Db 1 atgtgtctccctccatggaagataactacataataataatcagacagagctcta 60
 Qy 124 tacacagagatggcagctgctgtgagagatcctgttgcagacactgctgcagag 183
 Db 61 tacacagagatggcagctgctgtgagagatcctgttgcagacactgctgcagag 120
 Qy 184 aagatctgcacacttccataacagagctgtgagacccagacaggtccctctctgggg 243
 121 aaggtctgtatcttccataacagagctgtgagacccagacaggtccctctctgggg 180
 Qy 244 atccagggagggagcgcgtgctgtgagagatggtgagacagagagggccttcctcag 303
 Db 181 atcagggagggagcgcgtgctgtgagagatggtgagacagagagggccttcctcag 240
 Qy 304 ctgagagatgtgaacatgaggactgtacaaagggtgtgagagggccacagccttcacc 363
 Db 241 ctgagagatgtgaacatgaggactgtacaaagggtgtgagagggccacagccttcacc 300
 Qy 364 ttcttcagagcagctcaggtccgcttcaggttgcaggtgaggtgctgctgctgctg 423
 Db 301 ttcttcagagcagctcaggtcgccttcaggttgcaggtgaggtgctgctgctgctg 360
 Qy 424 ttctctgtgtgcccagcagacccacagcagcagctacagctcaccagagagagtgagcc 483
 Db 361 ttctctgtgtgcccagcagcagcagcagcagctacagctcaccagagagagtgagcc 420
 Qy 484 tcagccgctgacaaagttttactttgaaacagagctgta 521
 Db 421 tccaccactactgaattacttactgtgagatgagtcgta 458

RESULT 14
 AAA89180
 ID AAA89180 standard; cDNA; 459 BP.
 XX
 AC AAA89180;
 XX
 DT 19-MAR-2001 (first entry)
 XX
 DE Mouse interleukin-1 Hy2 cDNA.
 XX
 KW Interleukin-2 Hy2; IL-1 Hy2; mouse; interleukin-1 receptor;
 KW antagonist; cancer; breast adenocarcinoma; brain tumour; melanoma;
 KW myeloma; giant cell tumour of bone; acute myelogenous leukaemia;
 KW oral epidermoid carcinoma; squamous cell carcinoma; inflammation;
 KW antitumour; antiinflammatory; diagnosis; therapy; ss.
 XX
 OS Mus sp.
 XX
 PN WC200071719-Al.
 XX
 PD 30-NOV-2000.
 XX
 PF 22-MAY-2000; 2000WO-US14144.
 XX
 PR 20-MAY-1999; 990US-0316086.
 PR 10-MAR-2000; 2000US-0522964.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Ballinger DG, Ford J, Ho AS, Lin HS, Pace AM;
 XX
 DR WPI: 2001-016409/02.
 DR P-PSDB; AAB19925.
 XX
 PT New isolated polynucleotide encoding interleukin-1 Hy2 for diagnosing,
 PT preventing and treating disorders, such as cancers and inflammatory
 PT diseases -
 XX
 PS Example 9; Page 152; 158pp; English.
 XX
 CC The present sequence is that of mouse cDNA encoding interleukin-1 Hy2
 CC (IL-1 Hy2; see AAB19925), a novel member of the interleukin-1 receptor
 CC antagonist family. The sequence is predicted from isolated IL-1 Hy2
 CC genomic DNA (see AAB19925). The predicted mouse and human (see
 CC AAB19922) IL-1 Hy2 polypeptides share 81.7% homology. The murine
 CC genomic DNA can be used to generate transgenic animals which overexpress
 CC IL-1 Hy2 protein or have the IL-2 Hy2 gene knocked out. Human
 CC IL-1 Hy2 polypeptides and polynucleotides are used to treat cancers
 CC involving elevated levels of IL-1, such as breast adenocarcinoma,
 CC brain tumours, melanoma, giant cell tumours of bone, acute
 CC myelogenous leukaemia, oral epidermoid carcinoma or squamous cell
 CC carcinoma, and inflammatory disease mediated by interleukin-18 (all
 CC claimed).
 XX
 SQ Sequence 459 BP; 113 A; 125 C; 119 G; 102 T; 0 other;

Query Match 32.2%; Score 328.4; DB 22; Length 459;
 Best Local Similarity 82.3%; Pred. No. 2.5e-89;
 Matches 377; Conservative 0; Mismatches 81; Indels 0; Gaps 0;

Qy 64 atgtgtctccctccatggaagataactacataataataatcagacagagctcta 123
 Db 1 atgtgtctccctccatggaagataactacataataataatcagacagagctcta 60
 Qy 124 tacacagagatggcagctgctgtgagagatcctgttgcagacactgctgcagag 183
 Db 61 tacacagagatggcagctgctgtgagagatcctgttgcagacactgctgcagag 120
 Qy 184 aagatctgcacacttccataacagagctgtgagacccagacaggtccctctctgggg 243
 Db 121 aaggtctgtatcttccataacagagctgtgagacccagacaggtccctctctgggg 180

